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Abstract
I have investigated the potential role of Toll-Like Receptors (TLRs) in mediat-
ing adipose inflammation in obesity. TLRs are a family of pattern recognition
receptors that play a key role in host defence and are also implicated in chronic
inflammatory disorders. The finding that TLR4-deficient mice are protected
against obesity-induced diabetes led me to hypothesise that TLR expression
on adipocytes could play a role in obesity-induced adipose inflammation and
metabolic dysfunction.
The first chapter investigates the expression and function of TLRs in in vitro
differentiated human subcutaneous adipocytes. I found that stimulation with
ligands for TLR2, TLR3 and TLR4 but not the other TLRs, induces the
expression of pro-inflammatory cytokines. I also explored the use of the TLR
adapter molecules MyD88, Mal and TRIF by different TLRs.
The second chapter examines whether TLR activation in adipocytes has an
effect on glucose uptake. I established a 3H-2-deoxy-D-glucose (2DOG) uptake
assay which led to an interesting yet unexpected observation: Stimulation with
TLR3 and TLR4 ligands led to a decrease in insulin-stimulated glucose uptake
but at the same time, insulin-independent glucose uptake was increased. I
showed that these observations are at least partly due to altered expression of
different glucose transporter (GLUT) isoforms. As the effects were seen only
after prolonged TLR stimulation, I speculated that this was mediated via a
secondary secreted factor.
The third chapter is based on a cytokine and adipokine array, which I per-
formed to identify cytokines that may be responsible for the effects described
in Chapter 2. The secretion of several cytokines/chemokines with diverse pro-
inflammatory functions was observed following stimulation with TLR3 and
TLR4 ligands. The contribution of some of these factors to altered glucose
handling was investigated. Whilst a contribution for ENA-78 was ruled out, I
present evidence that IL-1 can contribute to this.
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Chapter 1
Introduction
The worldwide prevalence of obesity has dramatically increased over the past two decades.
In 2008, the WHO estimated that at least 500 million adults were obese (defined by a
body mass index (BMI) > 30 kg/m2). The WHO expects that this number will rise to
more than 700 million obese people by 2015 [1], almost 10% of the world’s population.
Strategies combating this pandemic wave have not been effective so far and unless drastic
action is taken, the life expectancy in industrialised countries is expected to fall for the
first time ever due to obesity-related diseases [2].
It is recognised that a raised BMI is closely associated with metabolic dysfunction such
as type 2 diabetes mellitus (T2DM) [3]. According to the international diabetes federation
(IDF) [4], there will be some 438 million people with diabetes in 2030. Yet there is only
little knowledge of the mechanisms that link increased fat mass to ill health. My work
tries to elucidate one of these links, namely, how obesity induces insulin resistance, which
is an underlying factor of T2DM.
Due to the prevalent epidemic, the physiological effect of obesity has been investi-
gated intensively in recent years. It has been shown that obesity is associated with a
state of mild chronic inflammation, manifested by changes such as an increased level of
circulating inflammatory markers including interleukin-6 (IL-6) [5] and C-reactive protein
(CRP) [6]. This obesity-induced inflammation, which is now commonly referred to as
’metainflammation’ (metabolically triggered inflammation) [7], is thought to play a cen-
tral role in obesity-associated insulin-resistance and T2DM. Although the initial trigger
of this obesity-associated inflammation has not yet been identified, adipose tissue has
been shown to directly contribute to the pro-inflammatory milieu in obesity by secreting
various factors, including cytokines. Thus, adipose tissue is no longer regarded as a pas-
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sive fat store but rather as a highly dynamic endocrine organ. It has been observed that
adipose tissue expansion increases the production of cytokines, and many of these have
been implicated in insulin resistance. Furthermore, adipose tissue expansion has been
shown to promote the progressive infiltration of immune cells such as macrophages [8, 9]
and T cells [10, 11]. Finally, toll-like receptors (TLRs), currently the most investigated
receptors of the innate immune system, appear to be a crucial link between inflammation
and insulin resistance in obesity: Whilst TLR2- and TLR4-deficient mice are reportedly
protected from obesity-induced insulin resistance and T2DM [12, 13], the situation in
TLR5-deficient mice is paradoxically reversed [14]. Thus, the immune system seems to be
closely linked to the metabolic changes in obesity. The investigation of this interaction
has become the new field of immunometabolism in which this thesis is set.
In the next few sections I will introduce the background to areas relevant to my thesis,
focusing on the molecular basis of insulin metabolism in health and disease.
1.1 The pathophysiology of obesity
1.1.1 The worldwide obesity epidemic
Obesity is a chronic metabolic disease that has reached epidemic dimensions worldwide
[15]. According to the WHO [1], obesity is defined as abnormal or excessive fat accumu-
lation that may impair health. It is commonly measured by the BMI, a simple index that
is defined as the ratio of the weight over the height squared of a person. A BMI between
25 kg/m2 and 30 kg/m2 defines people as overweight, whereas a value greater than 30
kg/m2 indicates obesity. Table 1.1 shows a selection of the estimated percentage of adults
with a BMI > 25 of different countries around the world. The data was obtained from
the global BMI database by the WHO [16].
As Table 1.1 illustrates, obesity is no longer a problem of high-income Western coun-
tries, as it is becoming increasingly common in developing countries as well. In the past
20 years, the rates of obesity have tripled in developing countries, in particular in urban
settings [17]. Countries of the Middle East, the Pacific Islands, China and Southeast Asia
are currently facing the greatest threat [17]. Moreover, a particularly worrisome fact is
that childhood obesity is increasing with alarming rates around the world: 43 million
children under the age of 5 years (35 million in developing countries) were estimated to
be overweight and obese in 2010 [18]. This trend is expected to rise to 60 million by 2020,
which would mean that 9% of all preschool children will be overweight or obese [18].
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Table 1.1: Percentage of overweight and obese adults
Country BMI ≥ 25 (%) Geographic location
American Samoa 93.5 Pacific Ocean
Kiribati 81.5 Pacific Ocean
French Polynesia 73.7 Pacific Ocean
Saudi Arabia 72.5 Middle East
Panama 67.4 Central America
USA 66.9 North America
Germany 66.5 Europe
Egypt 66.0 Middle East
Kuwait 64.2 Middle East
Bosnia-Herzegovina 62.9 Europe
New Zealand 62.7 Pacific Ocean
Israel 61.9 Middle East
United Kingdom 61.0 Europe
Switzerland 37.3 Europe
China 18.9 Asia
Source: World Health Organisation (WHO)
Global database on body mass index, January 2011
Like many other medical conditions, obesity is the result of an interplay between ge-
netic and environmental factors. The two most common environmental factors associated
with obesity are diet and physical activity. In most cases, obesity is the natural con-
sequence of excessive caloric intake combined with a sedentary lifestyle [1]. This is a
particular problem in the developing world, where the traditional diet is replaced with
energy-dense, cheap ”Western food” that is high in fat and sugars but low in fibres and
complex carbohydrates [17]. As reviewed by Keith et al. [19], other suggested putative
factors that may contribute to obesity include sleep deprivation, endocrine disruption
(i.e. environmental pollutants that interfere with lipid metabolism), increased exposure
to central heating, decreased smoking rates, increased consumption of medications that
cause weight gain (i.e. atypical antipsychotics), as well as ageing.
Recent studies imply that the intestinal bacteria in obese humans and mice may differ
from those in lean subjects. In 2004, it was found that germ-free mice on a chow or sugar
and fat-rich Western diet gain less weight than conventionally raised mice [20, 21]. This
finding promoted the analysis of the composition of the gut microbiota in human and
mouse. As examined by Eckburg et al. [22], the majority of the gut microbiota in human
and mouse is formed by members of the Bacteroidetes and Firmicutes phyla. Analysis of
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the microbiota of obese human and genetically obese mice revealed a significant reduction
in the abundance of Bacteroidetes, in parallel with a proportional increase in Firmicutes
(compared to lean subjects) [23, 24]. However, it still needs to be investigated whether
this imbalance in the gut microbiota in obesity is a cause or a consequence of increased
fat mass [25].
In addition to environmental factors, genetic factors also play an important role in
the pathogenesis of obesity. A twin study has shown that the heritability for BMI and
total body fat lies between 0.58 - 0.63 [26]. At present, over 100 genes are suspected
to influence obesity [27]. The currently most discussed genetic factors are the FTO (fat
mass and obesity-associated gene) gene [28] and variants near the MC4R (melanocortin-
4 receptor) gene [29]. The FTO gene was identified in a study of 38,759 Europeans.
Adults who are homozygous for the FTO risk allele weighed about 3 kilograms more
when compared to those without the risk allele [28].
1.1.2 Obesity causes disease
The WHO recognises overweight and obesity as a serious problem, as an increased BMI
is a major risk factor for several, partly life-threatening diseases [1]. This includes cardio-
vascular disease [30], T2DM [3], non-alcoholic fatty liver disease [31], atherosclerosis [32],
rheumatoid arthritis (RA) [33] and some forms of cancer [34]. Furthermore, some studies
have also shown that obesity may be a trigger for asthma [35] or Alzheimer’s disease [36].
As already mentioned, the particular focus of this thesis is the link between obesity and
T2DM.
1.1.3 Diabetes mellitus
Diabetes mellitus is defined as a syndrome of chronic hyperglycaemia due to relative
insulin deficiency, resistance, or both [37]. Therefore, insulin (which is discussed in section
1.2.1) plays the key role in all forms of diabetes. It is commonly distinguished between
three major forms of diabetes: type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus
(T2DM) and gestational diabetes mellitus (GDM), which is a varying degree of glucose
intolerance during pregnancy [4].
24
INTRODUCTION
< >
M
A
P 
2.
2 
 
Pr
ev
al
en
ce
* 
(%
) e
st
im
at
es
 o
f d
ia
be
te
s 
(2
0-
79
 y
ea
rs
), 
20
30
* 
co
m
pa
ra
tiv
e 
pr
ev
al
en
ce
ID
F 
D
ia
be
te
s A
tla
s, 
4t
h  e
d.
 ©
 In
te
rn
at
io
na
l D
ia
be
te
s 
Fe
de
ra
tio
n,
 2
00
9
F
ig
u
re
1.
1:
E
st
im
a
te
d
p
re
v
a
le
n
ce
o
f
d
ia
b
e
te
s
in
2
0
3
0
.
A
cc
or
d
in
g
to
th
e
in
te
rn
at
io
n
al
d
ia
b
et
es
fe
d
er
at
io
n
(I
D
F
)
[4
],
ap
p
ro
x
im
at
el
y
43
8
m
il
li
on
p
eo
p
le
,
or
7.
8%
of
th
e
ad
u
lt
p
op
u
la
ti
on
,
w
il
l
h
av
e
d
ia
b
et
es
b
y
20
30
[4
].
T
h
e
la
rg
es
t
in
cr
ea
se
s
is
ex
p
ec
te
d
to
ta
ke
p
la
ce
in
d
ev
el
op
in
g
co
u
n
tr
ie
s.
25
CHAPTER 1
Due to the obesity pandemic, the prevalence of diabetes is increasing rapidly in every
part of the world. The IDF estimates that 285 million people were suffering from diabetes
in 2010 [4]. This number is expected to rise to 438 million people by 2030 (Figure 1.1).
Like obesity, diabetes is no longer seen as a disease of aﬄuent countries. As illustrated in
Table 1.2, 70% of the current cases of diabetes occur in low- and middle income countries
[4]. India is currently leading the top 10 table with more cases of diabetes than any other
nation in the world [38].
The majority of people that are diagnosed with diabetes suffer from T2DM, often as a
consequence of increased fat mass. However, the data presented in Figure 1.1 and Table
1.2 do not distinguish between T1DM and T2DM. Although T1DM is far less common
than T2DM, its prevalence is increasing as well [39]. In contrast to T2DM, T1DM is
a chronic autoimmune disease characterised by selective destruction of pancreatic islets.
The highest rates of T1DM in the world are occurring in Finland and other Scandinavian
countries, as well as Scotland [40]. There appears to be a North to South gradient in
Europe, with the great exception of the island of Sardinia (Italy), which after Finland has
the second highest rate of T1DM worldwide. As with other diseases, T1DM is thought to
be caused by a combination of genetic susceptibility and environmental triggers (reviewed
in [41] and [42]).
While T1DM affects mainly young adults of Caucasian background, T2DM affects
people worldwide and is associated with rapid cultural and social changes, ageing pop-
ulations, increasing urbanisation, dietary changes, and reduced physical activity [4]. In
the UK, people of South Asian, African and Caribbean background have a 2 - 3 times
higher risk of T2DM than white Europeans [43]. Although T1DM and T2DM repre-
sent two distinct diseases from the epidemiological point of view, their clinical distinction
can sometimes be difficult. Hybrid forms are increasingly recognised, and patients with
immune-mediated T1DM may also be overweight and insulin resistant.
The gradual progression of T2DM is caused by insulin resistance (see section 1.1.5)
and β cell dysfunction. Thus, although insulin resistance may be the key primary defect
in the progression of this disease, T2DM cannot occur without an impairment of insulin
secretion. The pre-diabetic state is characterised by hyperinsulinemia. This is because
pancreatic β cells initially manage to compensate for insulin resistance by upregulating
insulin production (Figure 1.2).
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Table 1.2: Top 10 of current and predicted estimation of people with diabetes
(20 - 79 years)
2010 2030
Country/Territory Millions Country/Territory Millions
1 India 50.8 1 India 87.0
2 China 43.2 2 China 62.6
3 USA 26.8 3 USA 36.0
4 Russian Federation 9.6 4 Pakistan 13.8
5 Brazil 7.6 5 Brazil 12.7
6 Germany 7.5 6 Indonesia 12.0
7 Pakistan 7.1 7 Mexico 11.9
8 Japan 7.1 8 Bangladesh 10.4
9 Indonesia 7.0 9 Russian Federation 10.3
10 Mexico 6.8 10 Egypt 8.6
Source: International Diabetes Federation (IDF), Diabetes Atlas, 4th edition (2009)
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Figure 1.2: Insulin resistance and β cell failure lead to the gradual progression
of T2DM. Pancreatic β cells initially manage to compensate for insulin resistance by
up-regulating the production of insulin, leading to a state of hyperinsulinemia. At some
point, however, β cells fail to secrete sufficient amounts of insulin, leading to a combination
of hyperglycemia and hypoinsulinemia. This figure is modified from Type 2 Diabetes
BASICS, International Diabetes Center (IDC), Minneapolis, 2000.
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Relative insulin deficiency leads to an increase in glucose production from the liver (due
to inadequate suppression of gluconeogenesis) and reduced glucose uptake by peripheral
tissues. Hyperglycaemia is toxic to β cells (in vitro), a phenomenon known as glucotoxicity
[44, 45]. At some point, β cells fail to secrete sufficient amounts of insulin. The disease
progresses to the next stage which is characterised by a combination of hyperglycaemia
and hypoinsulinemia. A fasting blood glucose of 7 mM or more finally indicates diabetes.
Over time, hyperglycaemia can lead to serious disorders such as macrovascular disease
(including atherosclerosis and foot amputations) and microvascular damage (including
retinopathy, nephropathy and neuropathy) [46].
1.1.4 The metabolic syndrome
People at risk for T2DM normally feature characteristics of the metabolic syndrome, which
is a cluster of several metabolic abnormalities [47]. There are currently two major defini-
tions for the metabolic syndrome which are presented in Table 1.3. Both definitions are
very similar: Generally, the IDF criteria use slightly lower cut-off values for waist circum-
ference (close to values of people with a BMI of 25 kg/m2) and lower fasting blood glucose
concentrations than the National Cholesterol Education Program-Adult Treatment Panel
III (NCEP-ATPIII). Therefore, the common factors that define the metabolic syndrome
are: abdominal obesity, dyslipidemia, hypertension, hyperglycaemia and a prothrombotic
state.
Table 1.3: Classification systems for metabolic syndrome
Risk factor NCEP-ATPIII IDF
Waist circumference
Men > 102 cm > 94 cm
Women > 88 cm > 80 cm
Triglycerides > 150 mg/dL (1.7 mmol/L) > 150 mg/dL (1.7 mmol/L)
HDL cholesterol
Men < 40 mg/dL (1.03 mmol/L) < 40 mg/dL (1.03 mmol/L)
Women < 50 mg/dL (1.29 mmol/L) < 50 mg/dL (1.29 mmol/L)
Blood pressure ≥ 130/≥ 85 mmHg ≥ 130/≥ 85 mmHg
Fasting glucose > 110 mg/dL (6.1 mmol/L) > 100 mg/dL (5.6 mmol/L)
Abbreviations: International diabetes federation (IDF)
National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII)
This table is modified after [37].
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The purpose of this classification system is to identify individuals at high risk for
T2DM and cardiovascular disease. In addition to the factors described in Table 1.3,
the IDF consensus group recommended additional criteria that should be part of future
research of the metabolic syndrome, including a pro-inflammatory state [48], which is
characterised by elevated levels of CRP, tumour necrosis factor α (TNFα) and IL-6, and
decreased levels of adiponectin. The importance of incorporating these markers will be
discussed in section 1.5.
As shown in Table 1.3, the waist circumference, rather than the BMI, is a central
aspect of the metabolic syndrome. However, there is no scientific rationale behind the
cut-offs. Because different definitions of conflicting and incomplete diagnostic criteria
are currently used for the assessment of the metabolic syndrome, some researchers have
started to question its necessity [49]. In their view, insulin resistance (discussed next in
section 1.1.5) simply is the key risk factor for diabetes and cardiovascular disease.
1.1.5 Insulin resistance
Insulin resistance is a state of decreased responsiveness of target tissues to normal cir-
culating levels of insulin [50]. It is considered as the key event and link between obesity
and T2DM. As already mentioned, insulin resistance does not automatically lead to the
onset of T2DM. As long as the β cells of the pancreas can compensate for the increased
demand of insulin, the individuals are not diabetic. However, about one-third of obese,
insulin-resistant individuals develop chronic hyperglycaemia and T2DM at some point
[46].
Various factors have been proposed to cause insulin resistance. Some leading can-
didates are discussed here, including oxidative stress and hypoxia [51, 52], endoplasmic
reticulum (ER) stress [53], visceral adiposity [54] and lipid mediators [55]. It should be
emphasised that all factors described here are potentially associated with inflammation
[53, 54, 55, 56]. Thus, inflammation seems to be a central player in mediating insulin
resistance by linking all these factors together. As the role of inflammation in insulin
resistance is at the centre of this thesis, this is discussed separately in section 1.5.
Oxidative stress / Hypoxia. Insulin resistance has been associated with the gener-
ation of reactive oxygen species (ROS), which can be induced by oxidative stress and
hypoxia [51, 52]. Hypoxia may in turn occur in obese adipose as it has been suggested
that white adipose tissue is poorly oxygenated in the obese [57]. Cell culture models have
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shown that ROS can decrease insulin sensitivity by reducing insulin-stimulated glucose
uptake in adipocytes and muscle cells or by impairing glucose-induced insulin secretion in
pancreatic β cells [52, 58, 59]. Furthermore, oxidative stress has recently been shown to
be induced in the liver and adipose tissue of mice consuming a high fat diet (HFD), inter-
estingly even before the onset of insulin resistance [60]. It is therefore thought that ROS
production may be an initial key event triggering HFD-induced insulin resistance. The
concept of ROS-induced insulin resistance has gained further support through a few clin-
ical trials, which have demonstrated that treatment with antioxidants such as vitamin E,
vitamin C, or glutathione may transiently improve insulin sensitivity in insulin-resistant
individuals [51, 61]. In vitro studies and animal models have also shown that the antiox-
idant α-lipoic acid can improve insulin sensitivity [58, 62].
ER stress. In 2004, O¨zcan et al. [63] discovered an association between insulin resis-
tance and the ER which is a principal site for protein folding and trafficking [53]. When
the ER becomes stressed due to the accumulation of newly synthesized unfolded proteins,
the unfolded protein response is activated. This is a cellular stress response that leads
to a halt in protein translation and activation of signalling pathways that promote pro-
duction of molecular chaperones (proteins that assists the non-covalent folding of other
proteins). In addition to proteins, the ER is also sensitive to nutrients and can therefore
integrate pathways that are central to metabolic pathways [53]. O¨zcan et al. have found
that chronic nutrient overload in obesity causes ER stress in metabolically sensitive tis-
sues such as adipose and liver tissues. This may in turn lead to insulin resistance via
mechanisms discussed below in section 1.2.4. Hence, the ER might be an important link
between obesity and insulin resistance.
Visceral adiposity. Many studies have indicated that visceral adiposity may be one
of the key players in mediating insulin resistance [64]. Computer tomography scans and
magnet resonance imaging have made it possible to precisely measure specific adipose
tissue depots of an individual (i.e. the amount of visceral and subcutaneous adipose)
and compare it to the degree of insulin resistance. This has led to the finding that the
amount of visceral adipose tissue significantly correlates with insulin resistance, T2DM,
and cardiovascular events [65, 66]. However, this finding has also been challenged by
several studies. Some have reported that abdominal subcutaneous adipose and not vis-
ceral adipose independently correlates with insulin resistance [67], whereas others have
suggested that they were both equally correlated [68].
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Lipid mediators. Adipocyte-derived free fatty acids (FFAs) have long been suspected
to be key culprits in the induction of insulin resistance in T2DM [69, 70]. The link between
increased levels of circulating FFAs and insulin resistance might involve accumulation of
triglycerides and fatty acid-derived metabolites (e.g. ceramides) in muscle, liver and
pancreas [71]. Furthermore, FFAs suppress glucose uptake by muscle and adipose, whilst
inducing hepatic gluconeogenesis [72, 73]. This is thought to promote lipid burning as
a fuel source in most tissues, whereas carbohydrates are saved for neurons and immune
cells, which depend on glucose as an energy source. Almost 50 years ago, Randle et al.
[74] have shown that FFAs compete with glucose for substrate oxidation in isolated rat
heart muscle and diaphragms. They therefore postulated that increased fat oxidation
might cause insulin resistance associated with diabetes and obesity. Others have followed
to investigate the mechanisms by which FFAs induce insulin resistance. This has led to
several findings showing that high concentrations of FFAs promote insulin resistance by
causing defects in the insulin signalling cascade [75]. This is discussed in more detail in
section 1.2.4. As lipolysis in adipocytes is suppressed by insulin, insulin resistance from
any cause can lead to elevated levels of FFAs, which in turn promotes insulin resistance
as part of a vicious cycle. Lastly, prolonged exposure of pancreatic β cells to FFAs leads
to lipotoxicity-induced cell apoptosis [76].
1.2 Insulin signalling and glucose handling
One of the best-documented metabolic actions of insulin is the stimulation of glucose
uptake into muscle and adipose which are the main sites responsible for dietary glucose
uptake [77]. This is mediated by a complex, highly integrated network which not only
controls glucose uptake but also other functions including cell growth, differentiation and
protein synthesis [78]. In general, insulin can signal via one of the following three path-
ways: 1.) the phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway,
which mediates most of the metabolic actions of insulin; 2.) the Ras-mitogen-activated
protein kinase (MAPK) pathway, which regulates gene expression and cooperates with
the PI3K pathway to control cell growth and differentiation; and 3.) the CAP-Cbl path-
way, which has been only poorly investigated but may mediate insulin-stimulated glucose
uptake in addition to the PI3K pathway [79]. The PI3K-Akt/PKB pathway appears to
be central for insulin-stimulated glucose uptake in muscle and adipose and is described
in section 1.2.3. Activation of this pathway ultimately results in the translocation of
the intracellular glucose transporter GLUT4 to the plasma membrane (see section 1.2.2).
The failure of insulin to stimulate glucose uptake into skeletal muscle and adipose, and
31
CHAPTER 1
therefore to trigger GLUT4 translocation, is recognised as one of the first defects in the
development of insulin resistance and T2DM [80].
1.2.1 Insulin
Insulin is a peptide hormone produced by the β cells of the islets of Langerhans in the
pancreas [81]. Apart from its role in cell growth and protein synthesis, it is a major
regulator of glucose metabolism whose function in the fasting and postprandial states
differ: In the fasting state, its main function is to regulate glucose release by the liver. In
the postprandial state, it inhibits hepatic glucose production and additionally stimulates
glucose uptake into fat and muscle [37]. Thus, although insulin does not stimulate glu-
cose uptake into the liver, it inhibits glycogenolysis and gluconeogenesis, and stimulates
glycogen synthesis, therefore regulating fasting glucose levels. In addition to its role in
glucose homoeostasis, insulin also plays a major role in lipid metabolism by inhibiting
lipolysis and stimulating triglyceride synthesis in adipose tissue.
Human insulin contains 51 amino acids distributed in two peptide chains, the A- and
B-chain, which are linked to each other by two disulphide bonds. Although insulin is
active as a monomer, it assembles to dimers during its biosynthesis and storage and, in
the presence of zinc, to hexamers [82]. Initially, insulin is synthesized as a single chain
proinsulin molecule in which the C-peptide is located between the A and B chains [83].
When trafficking through the Golgi, proinsulin is thought to be cleaved by the proprotein
convertases PC2 and PC1/PC3 [84], leading to the excision of the C-peptide. The C-
peptide remains in the secretory granule of the β cell and is co-secreted with mature
insulin in response to glucose [85]. Secretion of insulin is induced via a mechanism in which
glucose, entering the β cell via the glucose transporter GLUT2, is metabolised thereby
leading to the generation of adenosine-5’-triphosphate (ATP). The rise in intracellular
ATP closes potassium channels within the plasma membrane which predisposes the cell
to depolarisation and allows calcium ions to enter the cell. The subsequent rise in calcium
finally triggers the exocytosis of the insulin- and C-peptide-containing secretory granules
[37].
1.2.2 Glucose transporter molecules
Cell membranes are not permeable to glucose because it is a polar molecule. Therefore, in
order to take up glucose, they are equipped with specialised glucose transporters belong-
ing to two different families of proteins, the sodium-(Na+-) driven sugar co-transporters
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(SGLTs) and glucose transporters (GLUTs). SGLTs are required by cells of the small
intestine and kidneys for absorption and re-absorption of glucose against its concentra-
tion gradient. As the name indicates, SGLT-mediated glucose transport is dependent
on a Na+-electrochemical gradient which is provided by the Na+-K+ ATPase pump [86].
GLUT proteins, on the other hand, are Na+-independent sugar transporters. They play
an important role for maintenance of glucose homoeostasis by facilitating the passive
diffusion of glucose across the plasma membrane. 14 GLUT isoforms, summarised in Ta-
ble 1.4, have been identified in humans. These isoforms are grouped into three different
classes based on their sequence homology [87]. Class I represents the well characterised
”classical” transporters which bind to 2-deoxy-D-glucose (2DOG) and cytochalasin B [88],
a cell-permeable mycotoxin which also blocks the polymerisation of actin and therefore
inhibits cell movement. Class II family members are characterised by their ability to
transport fructose but not 2DOG, whereas class III family differ in their predicted struc-
ture from the other two members of this family [87]. As it has so far not been possible
to crystallise any of the GLUT proteins, the predicted structures of all members of the
GLUT protein family are based on the initial hydropathy plot for GLUT1 [89]. Each
isoform is predicted to consist of 12 α-helical transmembrane domains along with amino-
and carboxy-terminal domains that face into the cytosol. In addition, they all contain an
extracellular N-linked oligosaccharide [90]. In class I and II family members, the N-linked
glycosylation site is located in the first exofacial loop between transmembrane helices 1
and 2 (Figure 1.3). In contrast, class III family members contain a shorter extracellular
loop 1 and harbour the glycosylation site within the larger loop 9 [87].
The expression of different GLUT isoforms allows the fine-tuning of glucose transport
into individual tissues. Each isoform has its own characteristic kinetics, substrate speci-
ficity and tissue-restricted expression, and therefore different expression patterns of the
GLUT isoforms ensure a high degree of specificity in the control of glucose uptake. For in-
stance, the isoform GLUT1 is ubiquitously expressed and accounts for insulin-independent
glucose uptake, whilst GLUT4 expression is restricted to heart, skeletal muscle and adi-
pose tissue [91].
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Table 1.4: The 14 members of the GLUT (SLC2A) protein family
Tissue Functional
Isoform Class localisation properties References
GLUT1 I ubiquitous glucose transport [89]
GLUT2 I liver, intestine, bidirectional [92]
kidney, pancreas glucose transport [93]
GLUT3 I brain glucose transport [93]
GLUT4 I adipose tissue insulin-dependent [94]
I muscle, heart glucose transport [95]
GLUT5 II intestine, kidney fructose transport [96]
testis, adipose tissue [97]
GLUT6 III brain, spleen glucose transport [98]
GLUT7 II intestine, colon fructose transport, [99]
glucose transport [100]
GLUT8 III testis, brain glucose transport [101]
GLUT9 II liver, kidney fructose/uric acid transport [102]
GLUT10 III liver, pancreas ascorbate transport [103]
GLUT11 II various tissues fructose/glucose transport [104]
GLUT12 III adipose, muscle glucose transport [105]
GLUT13 III brain Myoinositol transport [106]
GLUT14 I testis n.d. [107]
Abbreviations: Glucose transporter (GLUT), not determined (n.d.), solute carrier 2 A (SLC2A)
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Figure 1.3: Sequence and topology of human GLUT1. The sequence of the hu-
man GLUT1 glucose transporter is illustrated by the single-letter amino acid code. The
12 predicted transmembrane helices and the soluble linker domains are numbered. This
model is also representative for other members of class I and II glucose transporters (e.g.
GLUT4). The N-linked glycosylation site at asparagine45 is indicated by CHO. The posi-
tively charged residues (arginine and lysine) and the negatively charged residues (aspartate
and glutamate) are circled and squared, respectively. This Figure was originally published
in the Journal of Biological Chemistry. M. Sato, R. Hresko and M. Mueckler. Testing the
charge difference hypothesis for the assembly of a eucaryotic multispanning membrane
protein. J Biol Chem. 1998; 273:25203-8. c©the American Society for Biochemistry and
Molecular Biology.
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GLUT4 is unique in its ability to respond to insulin and therefore plays a central role in
controlling whole body glucose homoeostasis [108]. It was originally discovered in a screen
of monoclonal antibodies that were raised against intracellular vesicles isolated from rat
adipocytes in a search for novel insulin-responsive proteins. One antibody recognised a
highly insulin-responsive protein that was expressed only in muscle and adipose tissue
and had the predicted size and biochemical properties of known glucose transporters [94].
It has to be mentioned that despite the high expression of GLUT4 in muscle and adipose,
these tissues also express a selective cohort of other transporters. Additional glucose
transporters that have been reported to be expressed in adipocytes include GLUT1 [109],
GLUT10 [110], GLUT11-B/C [104] and GLUT12 [105].
In contrast to other GLUT isoforms, which are localised in the plasma membrane,
GLUT4 continuously cycles through several membrane systems within the cell. In the
absence of insulin, the majority of GLUT4 accumulates in specialised sequestration com-
partments and perhaps also in other intracellular membranes such as the trans-Golgi
network [108], which is due to very slow exocytosis rates of GLUT4. It is estimated that
in unstimulated cells, approximately 3-10% of GLUT4 is located at the cell surface and
> 90% is residing in intracellular compartments [111], whereas the plasma membrane
contains almost exclusively the GLUT1 isoform [109]. However, insulin stimulation of
glucose uptake leads to a rapid increase in GLUT4 translocation to the plasma membrane
by elevating the exocytic rate of GLUT4 and slightly reducing its endocytic rate [112].
Within 10 minutes, the level of surface GLUT4 increases 2 - 3-fold in human adipocytes
and more than 10-fold in rodent adipocytes [111], whereas the distribution of the GLUT1
isoform barely changes in response to insulin. Thus, the increase in GLUT4 exocytosis to
the plasma membrane is finally responsible for an increased uptake of glucose from the
interstitial fluid.
1.2.3 Insulin signalling via the PI3K-Akt pathway
Much research on the metabolic action of insulin has focussed on the PI3K-Akt pathway
illustrated in Figure 1.4. This pathway is induced upon insulin binding to the insulin
receptor, which belongs to a subfamily of receptor tyrosine (Tyr) kinases that includes
the insulin-like growth factor (IGF)-1-receptor [113]. The insulin receptor is a tetrameric
protein consisting of two extracellular α-subunits and two intracellular β-subunits. Func-
tionally, the receptor behaves like a classical allosteric enzyme in which the α-subunit
inhibits the Tyr-kinase activity of the β-subunit [78]. Insulin binding to the α-subunits
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Figure 1.4: Insulin-stimulated glucose uptake via the PI3K-Akt/PKB pathway. In-
sulin binding to the extracellular α subunits of the insulin receptor (IR) activates the intra-
cellular tyrosine kinase domain of the β subunit. The activated insulin receptor kinase then
phosphorylates targets such as the insulin receptor substrate 1 (IRS-1) at specific Tyrosine (Y)
residues. These phosphorylated residues act as a docking site for the p85 regulatory subunit of
the phosphatidylinositol 3-kinase (PI3K) which catalyses the formation of phosphatidylinositol
(3,4,5)-triphosphate (PIP3). This creates a lipid-based signalling platform that attracts pleck-
strin homology (PH) domain-containing signalling molecules including the 3-phosphoinositide-
dependent protein kinase 1 (PDK1) and Akt2. The colocalization of PDK1 and Akt2 allows
Akt2 to become activated by PDK1. Akt2 eventually leads to the translocation of vesicles con-
taining the glucose transporter GLUT4 to the plasma membrane. The PH domain of IRS-1
allows for binding to membrane phospholipids and the phosphotyrosine-binding (PTB) domain
binds to phosphorylated Y residues at the IR. Serine (S) phosphorylation of IRS-1 via c-Jun
NH2-terminal kinase (JNK), IκB kinase (IKK), protein kinase C (PKC), mitogen-activated pro-
tein kinase (MAPK), mammalian target of rapamycin (mTOR) or S6 kinase 1 (S6K1) generally
inhibits its function.
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induces a conformational change in the β-subunits resulting in activation and transpho-
sphorylation of the β subunits. Once activated, the β subunit activates downstream
effector molecules such as the PI3K via specific adapter proteins, of which insulin recep-
tor substrate 1 (IRS-1) appears to be central for insulin-stimulated glucose transport in
muscle and adipose [114].
IRS-1 therefore plays an important role in bridging the insulin receptor and PI3K
via direct binding and functions as an important control switch in mediating insulin
action (section 1.2.4). It contains a pleckstrin-homology (PH) domain, allowing it to
bind to membrane phospholipids as well as a phosphotyrosine-binding (PTB) domain,
which mediates its binding to specific Tyr-phosphorylated residues in the insulin receptor
[115]. Additionally, IRS-1 contains over 20 Tyr phosphorylation residues that serve as
docking sites for downstream effectors (reviewed in [77]). After phosphorylation by the
insulin receptor, these docking sites bind to Src-homology-2-domain-containing molecules
such as the p85 regulatory subunit of PI3K which is an important downstream effector
of IRS-1 [116]. Following insulin stimulation, PI3K binds to Tyr-phosphorylated IRS
proteins and catalyses the formation of the lipid second messenger phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), thereby creating a lipid-based signalling platform that at-
tracts downstream PH domain-containing signalling molecules. Of particular interest is
the recruitment of Akt and the phosphoinositide-dependent kinase 1 (PDK1). Association
with PIP3 at the membrane brings these proteins into proximity and facilitates activation
of Akt by PDK1 through phosphorylation of threonine (Thr) 308 and Serine (Ser) 473
[117]. Three major isoforms of Akt have been identified, and although all isoforms are ac-
tivated in response to insulin, only Akt2 is thought to play a role in glucose uptake [118].
By activating various downstream effectors, activation of Akt2 is thought to induce the
translocation of GLUT4 to the plasma membrane and therefore to an increased uptake of
glucose from the blood. However, the exact pathway by which Akt2 leads to the GLUT4
translocation remains elusive.
In addition to its downstream effects, Akt has been proposed as a positive regulator
of IRS-1 function. By phosphorylating Ser residues within the PTB domain of IRS-1, it
protects IRS-1 from Tyr phosphatases and enables it to maintain its Tyr-phosphorylated,
active conformation [119]. Ser phosphorylation of IRS proteins by other insulin-stimulated
Ser kinases, in contrast, serves as a negative-feedback control mechanism that inhibits
further Tyr phosphorylation of IRS proteins (see section 1.2.4).
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Monogenic and tissue-specific murine knockout studies of components of the signalling
cascade have yielded some valuable insights into the complexity of insulin signalling (Ta-
ble 1.5). Of interest, IRS-1-deficient mice develop mild insulin resistance but do not
develop diabetes because of compensatory β cell hyperplasia and insulin secretion [120].
In contrast to IRS-1-deficient mice, IRS-2-deficient mice develop peripheral insulin resis-
tance early on as a result of hepatic insulin resistance and diabetes develops at the age
of 10 weeks in these mice [121]. Epidemiological studies, however, have shown that IRS-1
polymorphism is associated with insulin resistance and diabetes in humans, whereas no
consistent association between IRS-2 and diabetes has been documented [122].
1.2.4 Negative regulation of insulin-induced glucose uptake as
a molecular cause of insulin resistance
As discussed in section 1.1.5, insulin resistance can be caused by several factors including
hypoxia, FFAs and ER stress. On the molecular level, these factors have been shown to
inhibit insulin signalling at many critical signalling nodes, for instance through suppres-
sion of the synthesis of signalling components (e.g. decreased expression of the insulin
receptor, IRS-1 or Akt) or through interference with phosphorylation events in the sig-
nalling cascade (e.g. inhibiting phosphorylation of the insulin receptor, IRS-1 or Akt).
The latter has been demonstrated in a study with 3T3-L1 and human adipocytes where it
was shown that hypoxia promotes insulin resistance by preventing insulin-induced insulin
receptor and IRS-1 Tyr phosphorylation [52]. Similarly, it has been observed that in-
creased plasma levels of FFAs cause a significant reduction in IRS-1 Tyr phosphorylation
in skeletal muscle in rats [75]. Finally, ER stress impairs insulin action by promoting
inhibitory IRS-1 Ser phosphorylation [63]. Hence, IRS-1 function is generally inhibited
by Ser phosphorylation and over 70 potential Ser phosphorylation sites of IRS-1 have so
far been identified [78].
Many studies are currently focusing on the identification of IRS Ser kinases which may
counterproductively become activated in obesity, and therefore inhibit IRS-1 function,
leading to insulin resistance. It is becoming increasingly clear that these kinases either
belong to the insulin signalling cascade as part of a negative-feedback mechanism (e.g.
PKCζ [137], MAPK [138]) or that they belong to other pathways induced by ER stress,
hypoxia or inflammation (e.g. JNK [63], PKCθ [139] or IKKβ [140]). Of note, the
mammalian target of rapamycin (mTOR) and its downstream effector S6 kinase 1, which
both cause IRS-1 Ser phosphorylation, can be activated as part of the insulin signalling
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Table 1.5: Mice phenotypes with deletion of components of the insulin signalling
pathway
Gene knockout Tissue Phenotype
Insr total Severe diabetes (ketoacidosis);
postnatal death at 3-7 days [123]
adipose Low fat mass; normal glucose tolerance [124]
muscle High fat mass; normal glucose tolerance [125]
liver Decreased hepatic function; impaired glucose tolerance;
hyperinsulinemia [126]
β cell Loss of glucose-stimulated insulin secretion;
impaired glucose tolerance;
decreased β cell growth in adults [127]
brain Increased appetite; increased fat and leptin;
mild insulin resistance [128]
Igf1r total Growth retardation;
normal glucose homoeostasis [129]
Irs1 total Insulin resistance/impaired glucose tolerance;
IGF resistance/growth retardation [130];
no diabetes because of β cell hyperplasia [120]
Irs2 total Severe insulin resistance, β hypoplasia;
early development of T2DM [121]
Irs3 total Normal growth & glucose tolerance [131]
Irs4 total Normal growth & glucose tolerance [131]
Cbl total Low fat mass; improved insulin sensitivity [132]
Akt2 total Insulin resistance in muscle & liver [133]
Slc2a4 total Cardiac hypertrophy; low fat mass;
mild insulin resistance, no diabetes [134]
adipose Glucose intolerance; hyperinsulinaemia; secondary
insulin resistance in muscle & liver [135]
muscle Glucose intolerance; insulin resistance [136]
Gene names: v-akt murine thymoma viral oncogene homolog 2 (Akt2 ), casitas B-lineage lymphoma
(Cbl), insulin-like growth factor I receptor (Igf1r), insulin receptor (Insr), insulin receptor substrate
(Irs), solute carrier family 2 (facilitated glucose transporter), member 4 (Slc2a4 ). This table has been
modified and updated from [71].
40
INTRODUCTION
cascade but also by nutrients such as amino acids [141]. Tremblay et al. [141] have shown
that IRS-1 Ser phosphorylation in the liver of S6 kinase 1-deficient mice consuming a HFD
is reduced compared to wild-type mice. Furthermore, infusion of amino acids in humans
leads to the concomitant activation of S6 kinase 1, IRS-1 Ser phosphorylation and reduced
IRS-1 function, causing insulin resistance in skeletal muscle [141]. This has led to the idea
that the aberrant inhibition of IRS-1 by S6 kinase 1 through chronic overnutrition may
be a causative factor in the induction of insulin resistance in obesity.
In addition to Ser phosphorylation of IRS-1, other important factors responsible for
insulin resistance are defects in the GLUT4 translocation machinery or reduced expression
of GLUT4. Of interest, adipocytes isolated from obese subjects and those with T2DM
have a marked reduction in the intracellular pool of GLUT4 protein, whereas normal
concentrations of GLUT4 are found in the muscle of these patients [142]. As shown in
Table 1.5, global depletion of GLUT4 in mice results in mild insulin resistance, however
without the onset of diabetes. In contrast, tissue-specific depletion of GLUT4 in muscle
and adipose causes severe insulin resistance [135, 136]. Intriguingly, adipocyte-specific
depletion of GLUT4 has been found to not only cause insulin resistance in adipose tissue
but also in muscle and liver [135], therefore indicating that adipose tissue is an important
coordinator of the body’s response to insulin. Remarkably, adipose-specific overexpression
of GLUT4 in insulin-resistant, muscle-specific GLUT4-deficient mice has been shown to
reverse insulin resistance and diabetes in these mice [143]. Hence, adipose-selective down-
regulation of GLUT4 which is observed in human obesity and T2DM seems to contribute
to insulin resistance and diabetes on the whole organism level [135].
1.3 Pattern recognition receptors (PRRs)
The immune system of a mammal is divided into two major branches: adaptive and
innate immunity. In the pre-TLR era, the innate immune system was regarded as a
simple, non-specific barrier for pathogens. For this reason it was long neglected by im-
munologists, who focused mainly on the adaptive branch of the innate immune system
(i.e. the investigation of T and B lymphocytes). Nonetheless, in 1989 the immunologist
Charles Janeway formulated his landmark hypothesis by which he predicted the existence
of so-called pattern recognition receptors (PRRs) which would permit cells of the innate
immune system to respond to conserved molecules made by microbes but not by the host
[144]. He named these microbe-specific molecules ”pathogen-associated molecular pat-
terns” (PAMPs). The subsequent ground-breaking discovery of TLRs in the mid-1990s
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by Medzhitov et al. [145] and other groups validated Janeway’s hypothesis and led to
the realisation that innate immunity is far more diverse than initially assumed. After the
discovery of TLRs, different classes of cytosolic PRRs were identified, including RIG-I-
like receptors (RLRs) and proteins of the nucleotide-binding domain, leucine-rich repeat
containing (NLR) family (section 1.3.1).
In addition to Janeway’s hypothesis, a growing body of literature suggests that PRRs
are not only expressed by cells of the innate immune system, but also by non-immune
cells including fibroblasts [146], endothelial cells [147] and hepatocytes [148]. Moreover, it
is increasingly recognised that non-pathogenic microbes can also synthesise many of the
molecules that stimulate PRRs [149]. Thus, the term PAMP may be increasingly replaced
by the term ”microbe-associated molecular pattern” (MAMP) in the future [150]. MAMP-
induced PRR signalling leads to antigen-presenting cell activation which may in turn
activate the adaptive immune system. Moreover, it has also been shown that PRRs can
recognise endogenous molecules released from damaged cells, so-called ”damage-associated
molecular patterns” (DAMPs). DAMPs can include intracellular proteins such as heat-
shock proteins [151] or extracellular matrix proteins such as hyaluronan fragments [152]
that are generated during tissue injury. Additionally, non-protein molecules including
ATP [153] or uric acid [154] are also recognised as DAMPs.
1.3.1 The family of nucleotide-binding domain, leucine-rich re-
peat containing (NLR) proteins
The NLR family consists of more than 20 protein members. Several of these proteins
are involved in the detection of DAMPs and MAMPs, although the precise mechanisms
by which this detection is mediated remain a major challenge in the field. In the lit-
erature, the acronym ”NLR” is still often used for ”NOD-like receptor”. However, this
terminology is now officially outdated. Since 2008, NLRs stands for ”Nucleotide-binding
domain, Leucine-Rich Repeat containing” proteins, which refers to the centrally located
nucleotide-binding domain (NBD or NACHT) of these proteins which is commonly flanked
by a C-terminal domain containing leucine-rich repeats (LRRs) (see the gene nomencla-
ture homepage of the human genome organization, [155]). The N-terminal region of the
two major protein subfamilies NLRC and NLRP contains either a caspase recruitment
domain (CARD) or a pyrin domain (PYD), respectively. The LRR domain of NLRs
is believed to function in ligand sensing, whereas the CARD and PYD domains seem
to mediate homotypic protein-protein interactions for downstream signalling [156]. The
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NBD/NACHT domain, which is the only domain common to all NLR family members,
enables activation of the signalling complex via ATP-dependent oligomerisation (Figure
1.5).
Stimulation of NLRs can trigger a number of signalling cascades, including the nuclear
factor-κB (NF-κB) pathway [157], autophagy [158] or cell death [159]. Furthermore,
many MAMPs and DAMPs that are sensed through NLR-dependent pathways result in
the activation of the inflammasome, namely the NLRP1 [160], NLRP3 [161] or NLRC4
inflammasome [162]. The inflammasome, first described by Martinon et al. [160], is a
large (∼ 700 kDa) multiprotein complex involved in production of cytokines such as IL-
1β. Since IL-1β is a highly potent inflammatory stimuli (a major endogenous pyrogen
[163]), its activity is tightly regulated through several control steps in its expression,
maturation and secretion. Pro-inflammatory signalling via TLRs, the TNF receptor or
the IL-1 receptor (IL-1R) induce expression of the inactive IL-1β proform, but cytokine
maturation and release are controlled by the inflammasome [164]. Thus, a central step
in IL-1β production is the processing of inactive pro-IL-1β into the bioactive IL-1β. In
monocytes and macrophages, this processing is mediated by the cysteine protease caspase-
1, which was initially called IL-1 converting enzyme [165]. Caspase-1, in its turn, is
also initially produced as an inactive pro-caspase-1. Its autocatalytic action depends on
changes in the 3D-conformation of the inflammasome [160]. Inflammasomes are assembled
by various self-oligomerising scaffold proteins and many of the involved proteins are still
poorly characterised.
The NLRP3 inflammasome, also known as NALP3 inflammasome, is currently the
most fully characterised inflammasome. As shown in Figure 1.5, it consists of the NLRP3
scaffold, the apoptosis-associated speck-like protein containing a CARD (ASC) adapter,
and caspase-1. Tschopp and Schroder [166] have proposed that NLRP3 is auto-repressed
due to an internal interaction between the NACHT domain and LRRs, and this is removed
in the presence of PAMPs or DAMPs, although the precise requirement for activation
remains a matter of debate. Nonetheless, NLRP3 is thought to oligomerise via homotypic
interactions between NACHT domains upon activation, leading to recruitment of ASC and
pro-caspase 1. Finally, pro-caspase 1 clustering enables its autocleavage and activation
and the activated caspase-1 then cleaves pro-IL-1β into mature IL-1β. Whereas most
cytokines traffic through the Golgi complex to be secreted, biologically active IL-1β is
thought to be secreted through an unconventional, poorly defined mechanism following
its cleavage [167].
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Figure 1.5: Processing of IL-1β by the NLRP3 inflammasome. IL-1β is initially
produced as an 31 kDa inactive precursor. Processing of pro-IL-1β into the 17 kDa bioac-
tive IL-1β form is mediated by the cysteine protease caspase-1. Caspase-1 is in turn regu-
lated by the NLRP3 inflammasome, which assembles in the presence of microbe-associated
molecular patterns (MAMPs) or damage-associated molecular patterns (DAMPs) from en-
dogenous danger signals. Stimulation leads to oligomerisation of NLRP3 and recruitment
of apoptosis-associated speck-like protein containing a CARD (ASC), an adapter protein
containing a N-terminal pyrin domain (PYD) and a C-terminal caspase recruitment do-
main (CARD). The PYD of ASC interacts with the PYD of NLRP3 whereas the CARD
recruits pro-caspase-1 through CARD-CARD interactions. This results is caspase-1 auto-
activation and finally to IL-1β processing. This figure is adapted from [166].
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1.3.2 Toll-like receptors (TLRs)
TLRs are the best-characterised signal-generating components among PRRs. Research
on TLRs has grown at an exponential rate over the last few years and TLR signalling
has been extensively studied in knockout mice and cell lines. TLRs are an evolutionary
conserved family of type I transmembrane proteins composed of three major domains: The
N-terminal ectodomain consists of LRRs and serves for ligand recognition [168]. This is
followed by a transmembrane region which links the ectodomain to the intracellular Toll-
interleukin 1 (IL-1) receptor (TIR) domain [169]. The third domain, the TIR domain,
is highly conserved among species and is essential for downstream signal transduction.
Signalling through this domain activates intracellular pathways that culminate in the
induction of inflammatory cytokines, chemokines, interferons (IFNs) and upregulation of
co-stimulatory molecules.
To date 10 functional TLRs have been identified in human (Table 1.6) and 12 func-
tional TLRs are known in mice [170]. TLR1 - TLR9 are conserved in both species. The
murine Tlr10 gene does not lead to a functional protein because of a retrovirus insertion
whereas TLR11 - TLR13 have been lost from the human genome. In the past few years,
non-mammalian TLRs have been increasingly identified and a genome-wide analysis of
the purple sea urchin Strongylocentrotus purpuratus detected a remarkably high number
of 222 different TLR-like genes [171]. Besides being expressed by a great range of species,
TLRs are reportedly also expressed in a wide variety of different cell types: from immune
cells of the innate and adapative immune system to non-immune cells including fibrob-
lasts [172], epithelial cells [173], Schwann cells [174], hepatocytes [175] and pancreatic β
cells [176]. In Drosophila, where the first Toll protein was identified, the fat body is the
primary organ responsible for the humoral defense by secreting a battery of antimicrobial
peptides in response to infections [177] and also serves as energy storage. Interestingly,
it has been found that adipose tissue can also express functional TLRs, underlining the
potential role of adipose in inflammation [178].
Based on their location, TLRs can be divided into two different groups: The first
group (TLRs 1, 2, 4, 5, and 6) are found at the plasma membrane on the cell surface.
The second group (TLRs 3, 7, and 9) are intracellular and are thought to signal from
endosomes. Since TLR2, TLR3 and TLR4 are of particular interest for this thesis, they
will be considered in more detail below.
45
CHAPTER 1
Table 1.6: TLR ligands
Receptor Ligand Origin References
TLR1/TLR2 Lipoproteins/lipopeptides Gram-negative bacteria, [179]
and Mycoplasma [179]
TLR2/TLR6 Peptidoglycan Gram-positive bacteria [180]
Lipoteichoic acid Gram-positve bacteria [180], [181]
Zymosan Fungi [182]
Heat-shock protein 60 Endogenous [151]
Heat-shock protein 70 Endogenous [183]
Gp96 Endogenous [184]
Pam3CSK4 Synthetic [185]
MALP-2 Synthetic [186]
TLR3 Double-stranded RNA Viruses [187]
Poly(I:C) Synthetic [187]
mRNA Endogenous [188]
TLR4 LPS Gram-negative bacteria [189]
Taxol Plants [190]
Fusion protein Respiratory syncytial virus [191]
Heat-shock protein 60 Endogenous [151]
Chlamydia pneumoniae [192]
Heat-shock protein 70 Endogenous [183]
Gp96 Endogenous [184]
Fibronectin Endogenous [193]
Heparan sulfate Endogenous [194]
Fibrinogen Endogenous [195]
SFA Endogenous [196]
Tenascin-C Endogenous [197]
TLR5 Flagellin Bacteria [198]
TLR7 Single-stranded RNA Viruses [199]
Small nuclear RNA Endogenous [200]
TLR8 Single-stranded RNA Viruses [199]
Small nuclear RNA Endogenous [200]
TLR9 CpG-containing DNA Bacteria and viruses [201]
Chromatin-Ig complexes Endogenous [202]
TLR10 Not defined Uropathogenic bacteria [203]
Abbreviations: Lipopolysaccharide (LPS), polyinosinic-polycytidylic acid [poly(I:C)],
Macrophage-activating lipopeptide-2 (MALP-2), Pam3CysSerLys4 (Pam3CSK4), saturated fatty acids
(SFAs)
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TLR2 senses various components from bacteria, mycoplasma, fungi and also endoge-
nous ligands. TLR2 recognises its ligands by forming a heterodimer with either TLR1
or TLR6 [204]. The resulting TLR1/TLR2 and TLR2/TLR6 heterodimers recognise
distinct ligands. Triacyl lipopeptides (e.g. synthetic Pam3CSK4) are recognised by
TLR1/TLR2 heterodimers, whereas diacyl lipopeptides (e.g. synthetic MALP-2) are
recognised by TLR2/TLR6 heterodimers. Studies have found that the TLR1/TLR2
and the TLR2/TLR6 heterodimers share an ’m’-shaped structure [205], [206]. In the
TLR1/TLR2 heterodimer complex, two of the three lipid chains of Pam3CSK4 interact
with TLR2, whereas the third chain is inserted into a hydrophic channel in TLR1 [205].
It is thought that the formation of the TLR1/TLR2 heterodimer brings the intracellular
TIR domains close to each other to promote dimerisation and initiate signalling. Stimula-
tion with TLR2 ligands commonly induces the production of pro-inflammatory cytokines,
but not type I IFNs, in human macrophages and dendritic cells.
In contrast, TLR3 belongs to a set of intracellular TLRs (including TLR7, TLR8 and
TLR9) that recognise viral and bacterial nucleic acids as well as endogenous nucleic acids
[204]. Activation of these TLRs leads to production of type I IFNs and pro-inflammatory
cytokines (although the latter are not produced by human macrophages and dendritic
cells in response to TLR3 as reported by Lundberg et al. [207]). TLR3 is located in the
endolysosome, where it responds to dsRNA [187]. dsRNA is a molecular pattern associ-
ated with viral infection since it is produced by most viruses at some point during their
replication. It has been demonstrated that TLR3 can also be activated by polyinosinic
polycytidylic acid [poly(I:C)], a synthetic analog of dsRNA [187]. Moreover, poly(I:C)
has been shown to be a potent pyrogen in rodents, apparently through an IL-1-dependent
mechanism [208]. The structure of TLR3 ectodomain has been demonstrated in a study
by Choe et al. [209], where it was shown that the human TLR3 ectodomain forms a
large horseshoe shape that contacts with a neighbouring horseshoe, thereby forming a
homodimer of two horseshoes.
Lipopolysaccharide (LPS), the notorious cause of septic shock, is a major compo-
nent of the outer membrane of gram-negative bacteria. When TLR4-mutant mice (e.g.
C3H/HeJ mice) were found to be resistant to LPS-induced sepsis this was the first proof
that TLR4 was the long-sought receptor for LPS [189]. TLR4 is unique in that an associ-
ation with the myeloid differentiation factor 2 (MD-2) on the cell surface is required, and
together they serve as the main LPS-binding component [210]. The crystal structure of
the TLR4/MD-2/LPS complex has recently been determined [211]. This has revealed that
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two complexes of TLR4/MD-2/LPS interact symmetrically to form an ’m’-shaped TLR4
homodimer. Five of the six lipid chains of LPS thereby bind the hydrophobic pocket of
MD-2, whereas the remaining lipid chain associates with TLR4. Further to TLR4 and
MD-2, additional proteins such as the LPS-binding protein (LBP) and CD14 also assist in
LPS-binding. LBP is a soluble plasma protein which binds LPS [212], whereas CD14 is a
glycosylphosphatidylinositol-linked, LRR-containing protein that binds LBP and delivers
the LPS/LBP complex to the TLR4/MD-2 complex [170]. In addition to LPS, TLR4 has
been shown to respond to several other ligands, including plant-derived compounds such
as taxol [190], respiratory syncytial virus fusion proteins [191] or endogenous saturated
FFAs [196].
In addition to responding to different ligands, individual TLRs also induce different
biological responses. It has to be mentioned that most of the knowledge on TLR sig-
nalling is based on studies with cell lines and knockout mice and this sometimes differs
from what is found in primary human cells [213]. Nonetheless, stimulation of TLR3 and
TLR4 commonly leads to generation of type I IFN and inflammatory cytokines, whereas
cell surface TLR1/TLR2, TLR2/TLR6 and TLR5 appear to be mainly involved in the
induction of pro-inflammatory cytokines. This difference in cell signalling is made possible
by TIR domain-containing adapter molecules (Figure 1.6).
Five different TLR adapter molecules have so far been identified. These are MyD88
(myeloid differentiation primary-response protein 88) [214], Mal (MyD88-adapter-like
protein), also known as TIRAP (TIR-domain containing adapter protein) [215], TRIF
(TIR domain containing adapter-inducing interferon β), also known as TICAM-1 (TIR-
containing adapter molecule-1) [216], TRAM (Trif-related adapter molecule), also known
as TICAM-2 (TIR-domain containing adapter molecule-2) [217], and SARM (sterile α
and HEAT-armadillo motifs) [218]. TLR adapters are responsible for the specificity of a
TLR response as well as species- and cell-type-specific differences. With the exception of
SARM, which inhibits TRIF-mediated signalling, all adapters induce an intracellular sig-
nalling cascade, ultimately resulting in the activation of the transcription factors NF-κB
and interferon-regulatory factors (IRFs) which leads to production of pro-inflammatory
cytokines and type I IFN (see Figure 1.6).
MyD88, the first identified member of the TIR family, is used by all TLRs except
TLR3 and leads to activation of the NF-κB pathway as well as the MAPK pathway [170].
In addition to its C-terminal TIR domain, it also contains an N-terminal death domain
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Figure 1.6: Overview of TLR signalling. TLR adapters are responsible for the speci-
ficity of a TLR response as well as species- and cell-type-specific differences. With the
exception of SARM, which inhibits TRIF-mediated signalling, all adapters induce an in-
tracellular signalling cascade, ultimately resulting in the activation of the transcription
factors NF-κB and IRFs which leads to production of pro-inflammatory cytokines as
well as type I IFN. Abbreviations: Mal (MyD88-adapter-like protein), MyD88 (myeloid
differentiation primary-response protein 88), IFN (interferon), IRF (interferon regula-
tory factor), NF-κB (nuclear factor κ B), SARM (sterile α and HEAT-armadillo mo-
tifs), TRIF (TIR domain containing adapter-inducing interferon β), TRAM (Trif-related
adapter molecule).
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which plays an important role in downstream signalling (section 1.3.3). On the other
hand, TRIF seems to be only used by TLR3 and TLR4 and induces alternative pathways
that trigger the activation of IRF3 and NF-κB, therefore leading to production of type I
IFN alongside with inflammatory cytokines (section 1.3.4). Two other adapters, TRAM
and TIRAP, are thought to function as sorting adapters that recruit TRIF to TLR4 and
MyD88 to TLR2 and TLR4, respectively [219]. For this reason, TLR signalling pathways
are generally divided into MyD88-dependent and TRIF-dependent pathways (described
below in section 1.3.3 and 1.3.4).
Notably, TLR4 appears to be the only TLR that uses all the four adapters MyD88,
Mal, TRIF and TRAM, which allows for activation of both the MyD88- and TRIF-
dependent pathway. The first step in TLR4 signalling takes place at the cell surface,
where TLR4 initially recruits Mal, thereby facilitating the recruitment of MyD88 [220].
This triggers the initial activation of the NF-κB and MAPK pathway. Kagan et al. [219]
have proposed that the next step involves dynamin-dependent endocytosis of TLR4, which
then travels to an early endosome, where it forms a signalling complex with TRAM and
TRIF to initiate the TRIF-dependent pathway. TRIF-dependent signalling leads to IRF3
activation as well as the late-phase activation of NF-κB and MAPK. Thus, stimulation
of TLR4 leads to early and late activation of NF-κB due to the initial activation of the
MyD88-dependent pathway followed by later activation of the TRIF-dependent pathway
(see Figure 3.14 on page 135).
1.3.3 MyD88-dependent TLR signalling
The adapter MyD88 is recruited to TLR2 or TLR4 through homotypic interactions via
TIR domains. The death domain of MyD88 is known to interact with the IL-1R-associated
kinases IRAK1, IRAK2, IRAK4 and IRAK-M, which also contain a N-terminal death do-
main as well as a C-terminal Ser/Thr kinase or kinase-like domain [221]. IRAK4 is known
as the master IRAK member and TLR signalling is strongly impaired in its absence [170].
According to a recent study on TLR2 signalling by Kawagoe et al. [222], IRAK1 and
IRAK2 function redundantly downstream of IRAK4 during early TLR activation, whereas
IRAK2 is activated again at later time points. Upon activation, IRAKs dissociate from
MyD88 and interact with tumour-necrosis factor-receptor-associated factor 6 (TRAF6),
an E3 ubiquitin ligase which catalyses the synthesis of polyubiquitin chains [170]. The
polyubiquitin chains are thought to activate transforming growth factor-β-activated pro-
tein kinase 1 (TAK1) [223], a member of the MAPK family that is essential for activation
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of the MAPK and NF-κB pathway [224] (see Figure 1.7).
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) plays a pivotal
role in regulating inflammation and is composed of dimers belonging to the Rel family
of DNA-binding transcription factors. The most abundant and best characterised form
is the p50/p65 heterodimer which plays a more elaborate role than other factors in reg-
ulating gene expression [225]. In unstimulated cells, NF-κB dimers are sequestered in
the cytoplasm by IκB (nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor) isoforms which mask a nuclear localisation signal [226]. The isoform IκBα
has been shown to form a complex with the p50/p65 heterodimer and therefore inhibits
its translocation into the nucleus [227]. Upon stimulation, TLR-induced signalling via
TAK1 causes phosphorylation of the IκB kinase (IKK) complex, which consists of the
two catalytic subunits IKKα and IKKβ as well as the regulatory subunit NF-κB essen-
tial modulator (NEMO, also known as IKKγ) [170]. The activated IKK complex then
phosphorylates IκBα, which results in its polyubiquitination and subsequent degradation
by the proteasome [228]. As a consequence, the nuclear localisation signals of p50 and
p65 are unmasked, and the dimers are translocated into the nucleus where they activate
the transcription of NF-κB responsive genes encoding pro-inflammatory cytokines and
chemokines (e.g. IL-6, IL-8, MCP-1) [226]. It has to be mentioned that in addition to
induction of inflammatory genes, NF-κB also leads to upregulation of a variety of other
genes, including immunoreceptors, cell adhesion molecules, acute phase proteins as well
as proliferation and survival factors. It is therefore no surprise that dysregulation of the
NF-κB response is seen as a cause for cancer and several inflammatory and autoimmune
disorders such as RA. Moreover, a growing body of literature implicates dysregulation of
the NF-κB pathway in metabolic disease including T2DM (discussed in section 1.5.2).
In addition to the NF-κB pathway, TAK1 also activates the MAPK pathway which
leads to phosphorylation and activation of members of the activator protein 1 (AP-1)
family of transcription factors and regulates multiple processes including apoptosis, pro-
liferation and differentiation. MAPK activation is also responsible for post-transcriptional
induction of inflammatory proteins by pathways that increase mRNA stability and transla-
tion. MAPKs are part of a phosphorelay system composed of three sequentially activated
kinases, and, like their substrates, MAPKs are regulated by phosphorylation. According
to their hierarchy, these kinases are termed MAPK kinase kinase (e.g. TAK1), MAPK
kinase and MAPK. The currently best described MAPKs are the extracellular signalreg-
ulated kinase (ERK), c-Jun NH2-terminal kinase (JNK) and p38 [229].
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Figure 1.7: Signalling via TRIF and MyD88 modulates the TLR response. TLR4 stim-
ulation leads to recruitment of MyD88 and TRIF via the sorting adapters Mal and TRAM. The
MyD88-dependent pathway recruits the IL-1R-associated kinases IRAK1, IRAK2 and IRAK4
and tumour-necrosis factor-receptor-associated factor 6 (TRAF6), which activates the trans-
forming growth factor-βactivated protein kinase 1 (TAK1). TAK1 simultaneously activates the
mitogen-activated protein kinase (MAPK) pathway and the IκB kinase (IKK) complex. The
IKK complex consists of IKKα, IKKβ and NF-κB essential modulator (NEMO) and cataly-
ses the phosphorylation of IκB, causing its degradation. The NF-κB p50/p65 heterodimer is
released into the nucleus where it induces the transcription of a range of pro-inflammatory cy-
tokines. The TRIF-dependent pathway, which is also used by TLR3, leads to activation of IKK
and TANK-binding kinase-1 (TBK1) via TRAF3, resulting in phosphorylation and dimerisa-
tion of interferon regulatory factor 3 (IRF3) which is critical for induction of type I interferon
(IFN) transcription. Similar to TLR4, TLR3 causes MAPK and NF-κB activation although this
cascade is TRIF- and not MyD88-dependent.
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1.3.4 TRIF-dependent TLR signalling
TLR3 and TLR4 stimulation also leads to recruitment of TRIF which is critical for the
induction of IFN and IFN-related genes [230]. As illustrated in Figure 1.7, two important
proteins involved in TRIF-mediated signalling are TRAF3 and TRAF6. TRAF6 recruit-
ment in the TRIF-dependent pathway appears to be similar to the MyD88 pathway, and
its activation also results in induction of the NF-κB and MAPK pathway via TAK1 [170].
Importantly, signalling via TRIF also leads to recruitment of the non-canonical IKK ho-
mologs IKK and TANK-binding kinase-1 (TBK1) which are essential for IRF3 activation
[231]. Activation of IRF3 requires phosphorylation of its C-terminal Ser/Thr-rich portions
and upon phosphorylation, IRF3 forms a homodimer and translocates into the nucleus
where it regulates the transcription of the type I IFN genes. TRAF3 is thought to func-
tion as a crucial link between TRIF and TBK1, and cells lacking TRAF3 are defective for
production of type I IFN [232]. According to a study by Tseng et al. [233], differences in
the ubiquitination of TRAF3 are the key to the selective production of type I IFN versus
pro-inflammatory cytokines. TRIF-mediated signalling reportedly triggers TRAF3 ubiq-
uitination linked to the lysine at position 63 which appears to be essential for activation
of IRF3 and the IFN response. In contrast, MyD88-dependent signalling through TRAF6
results in ubiquitination linked to the lysine at position 48, resulting in degradation of
TRAF3 and subsequent activation of the MAPK and NF-κB pathway. Hence, although
TRAF3 is incorporated into both MyD88- and TRIF-assembled signalling, its function is
regulated in different ways by alternative ubiquitination modes.
Besides TLR3 and TLR4, other TLRs that lead to production of type I IFN are TLR7,
TLR8 and TLR9. However, whilst TLR3 and TLR4 utilise the TRIF-dependent pathway,
signal propagation via these TLRs occurs via MyD88 and the transcription factor IRF7.
1.4 Adipose tissue biology
1.4.1 Adipose as a highly heterogeneous tissue
Adipose tissue is a highly heterogeneous tissue that consists not only of adipocytes, but
also of stromal vascular (SV) cells such as preadipocytes, endothelial cells, smooth muscle
cells, fibroblasts, leukocytes and macrophages [234]. In addition to containing different cell
types, adipose tissue is also extremely diverse in terms of its location and its biochemistry.
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Unlike many other organs, adipose tissue is composed of different depots found at
various locations in the body. It is now common to distinguish between visceral and sub-
cutaneous adipose. Subcutaneous adipose is found underneath the skin, whereas visceral
adipose is located in the abdomen surrounding vital organs. As mentioned in section
1.1.5, epidemiological studies demonstrated that the subgroup of patients with visceral
obesity is particularly prone to develop cardiovascular disease, stroke and T2DM [65, 66].
Furthermore, ectopic triglyceride deposition has the potential to infiltrate the liver and
other organs even in lean individuals.
In addition to depot-specific differences, adipose tissue is also classified according to its
biochemical properties. In mammals, it is possible to distinguish between white adipose
tissue (WAT) and brown adipose tissue (BAT) (see Table 1.7). Although these two types
of tissues have completely different functions, they are found within the same depots, i.e.
subcutaneous and visceral adipose. However, when we generally talk of adipose tissue, this
normally refers to WAT. WAT is the predominant type in adult humans specialised in lipid
storage, whilst BAT is abundant in newborns and hibernating mammals where it helps
to dissipate chemical energy through the production of heat [235]. BAT has been shown
to contain a high density of mitochondria which express a unique H+ transporter called
uncoupling protein 1 (UCP-1) [236]. UCP-1 functions to dissipate the proton gradient
that is normally used to drive the synthesis of cellular ATP [237]. As a consequence, the
energy in the mitochondrial electrochemical gradient is released in the form of heat. Until
recently (2007), it was a generally accepted dogma that BAT was primarily limited to
newborns in humans. However, radiologic studies in adults to trace tumour metastasis
have suggested that there are areas of adipose tissue with high 18F-deoxyglucose uptake
which are assumed to represent BAT. Nedergaard et al. [238] therefore believe that
a significant fraction of adults possess active BAT and that this may be of metabolic
significance for human physiology and become a target in combating obesity. But why
are two different tissues with different physiological roles contained within the same organ?
A possible explanation was recently provided by S. Cinti [239] with his hypothesis of trans-
differentiation. Based on the observation that cold acclimatisation induces the appearance
in WAT of cells with an intermediate morphology between white and brown adipocytes,
he proposed that brown and white adipocytes may reversibly convert into each other
depending on which function is required.
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Table 1.7: Differences between brown and white adipose tissue
Characteristic Brown adipose tissue White adipose tissue
Function Thermogenesis [237] Lipid storage
No Production of leptin [240] Production of adipokines (e.g. leptin)
Morphology Multilocular cells [241] Unilocular cells [241]
Mitochondria [236] Triglycerides
Key enzymes UCP-1 [236, 237] Lipoprotein lipases, FA synthetase [242]
Found in Newborns [243] Adults
After 2007: Adults [238]
Abbreviations: fatty acid (FA), uncoupling protein 1 (UCP-1)
1.4.2 Adipogenesis
Adipogenesis is the development of fat cells from their precursor cells which are called
preadipocytes [244]. This process is controlled by a tightly regulated cascade of tran-
scription factors acting at different time points during differentiation [245]. Experiments
with cultured cell lines (especially the murine 3T3-L1 cell line) have provided most of the
understanding about the process and led to identification of some of the key transcription
factors of adipogenesis: CCAAT enhancer binding proteins (C/EBPs) and peroxisome
proliferator-activated receptor-γ (PPARγ).
C/EBPs are a family of the basic leucine zipper class of transcription factors. Three
of the six known members (termed C/EBPα to C/EBPζ) have been found to play an
important role in adipogenesis. After treatment of preadipocytes with inducers of differ-
entiation, an early and transient rise in C/EBPβ and C/EBPδ mRNA and protein levels
is observed [246, 247, 248]. Later in the differentiation process, C/EBPα is induced,
slightly prior to induction of genes characteristic of terminally differentiated adipocytes
(e.g. ADIPOQ, FABP4, GLUT4 ).
PPARγ is a lipid-activated member of the PPAR subfamily of nuclear hormone recep-
tors [249]. It is induced during the differentiation of preadipocytes into adipocytes and is
highly expressed in both WAT and BAT [250]. In the literature, PPARγ is often referred
to as the ’master regulator of adipogenesis’ as it is obligate for adipocyte differentiation
[251] and in many cases sufficient to convert non-adipose cells to adipocyte-like cells [252].
It has to be mentioned that the biologically relevant endogenous ligand of PPARγ still
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remains elusive. Although a study in 3T3-L1 adipocytes has found a putative endogenous
PPARγ ligand that is transiently produced during adipogenesis [253], efforts to purify it
biochemically have proven problematic. Nonetheless, several studies have shown that lipid
metabolites (e.g. polyunsaturated fatty acids, prostanoids) are ligands for PPARγ [253].
In addition to fatty acids, PPARγ is also a high affinity receptor for the thiazolidinediones
(TZDs) class of anti-diabetic drugs [244]. TZDs lead to increased insulin sensitivity by
increasing the storage capacity of fatty acids in the adipocytes and thereby a decrease in
the amount of circulating fatty acids.
Cell culture studies have demonstrated that treatment of preadipocytes with the
glucocorticoid dexamethasone, insulin and a cAMP phosphodiesterase inhibitor induces
C/EBP-β and -δ [254]. These two transcription factors then induce PPARγ expression
[255]. Upon ligand activation, PPARγ induces many target genes involved in lipogenesis
and adipogenesis, and it also turns on the expression of C/EBPα. C/EBPα feeds back on
PPARγ as a positive feedback loop to maintain the differentiation state. Once the differ-
entiation programme has been switched on, the cell expresses genes that are characteristic
of mature adipocytes and undergoes morphological changes through lipid accumulation.
1.4.3 Adipose tissue function
Adipose tissue has long been considered as a inert storage depot for triglycerides unworthy
of attention. However, the emergence of the obesity epidemic at the end of last century
caused a surge in interest in adipose and fuelled research into adipose function. This has
led to the realisation that adipose is not inert and is, instead, an endocrine organ which
produces multiple factors known as adipokines (see section 1.4.4).
Traditionally, adipose tissue has been defined as the major sites for insulation, me-
chanical support and storage of excess calories. During times of increased food intake
and/or decreased energy expenditure, excess energy is stored in the form of triglycerides
by the action of lipogenic enzymes. In times of fasting or when glucose is rare, the triglyc-
erides reserves can be used to provide fuel for energy generation. This is catalysed by
lipolytic enzymes that break down triglycerides into glycerol and fatty acids. The fatty
acids are then transported to the liver and muscle for fatty acid oxidation. In contrast
to carbohydrates, fatty acids contain more energy per unit mass and can be stored an-
hydrously, whereas glycogen must be stored in association with water which decreases its
efficiency [256].
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In addition to the factors named above, it is believed that adipose tissue is also a
crucial integrator of glucose homoeostasis [256] (see also discussion on GLUT4 in section
1.2.4). One way by which it affects global glucose handling is by serving as a lipid sink.
This idea has emerged from the observation that animals and humans with lipodystrophy
(i.e. underdeveloped adipose tissue) have ectopic lipid deposition in the liver, muscles,
and β cells [257]. Ectopic lipid deposition in non-adipose tissues is thought to lead to
insulin resistance and decreased insulin secretion [256]. Thus, the ability to store lipids
in a manner that is not toxic to the cell or the organism as a whole might be one of the
most critical functions of the adipocyte.
Early studies on glucose disposal after a meal have shown that adipose tissue may only
account for 10-15% of total disposal, whereas most of the glucose is taken up by skeletal
muscle [258]. This made it first difficult to accept studies such as those performed by
Abel et al. [135], where it was demonstrated that adipose-selective depletion of GLUT4
impairs insulin action in muscle and liver, thereby supporting the idea that adipose tissue
plays a key role in whole body glucose homoeostasis. Nonetheless, it was also known that
alterations in adiposity have profound implications for glucose homoeostasis as obesity
and lipodystrophy are both associated with insulin resistance and hyperglycaemia. As
mentioned previously (section 1.4.2), the use of TZDs has proven to be very successful
in improving insulin sensitivity, despite the fact that their receptor PPARγ is found
in adipose and not in muscle. This apparent paradox could finally be solved with the
recognition that adipocytes are highly active cells with potent autocrine, paracrine and
endocrine functions.
In the meantime, it has been established that adipose tissue has a key metabolic func-
tion that is (partly) mediated by its ability to secrete numerous proteins which regulate
glucose homoeostasis and other processes. The first hint came in 1987, when adipsin (also
known as complement factor D) was found to be released by adipose tissue [259]. In 1993,
TNFα was identified as a pro-inflammatory product of adipose tissue [260]. However,
the final breakthrough was in 1995, when it was found that adipocytes secrete leptin
[261, 262], a hormone involved in appetite control, thyroid function, insulin sensitivity,
reproductive function and the immune response. This finding led to the understanding of
adipose tissue as a key player in the regulation of whole-body homoeostasis. Since then,
many more factors that are released by adipocytes have been identified. These factors are
now collectively referred to as adipokines. Further to leptin, proteins that are typically
produced by adipose tissue include adiponectin, resistin and retinol-binding protein-4
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(RBP4) (see section 1.4.4). Additionally, adipocytes are also capable of producing several
factors that are normally characteristic of cells of the innate immune system (see section
1.5). Remarkably, it is more and more recognised that the cocktail of adipokines released
by ”obese” fat cells is different to the cocktail released by ”lean” fat cells. Furthermore,
the expression of adipokines varies also depending on the site where it is produced (e.g.
visceral adipocytes express different amounts of adipokines, when compared to subcuta-
neous adipose [54]).
1.4.4 Adipokines
Adipokines released by adipose are known to influence several processes including blood
pressure, angiogenesis, reproductive function, energy balance and, most notably, im-
mune function [263]. Whilst some of these adipokines are almost exclusively secreted
by adipocytes (e.g. leptin, adiponectin) the majority of secreted factors are cytokines or
chemokines that are typical of the immune system (see section 1.5.2). Many adipokines
are thought to play a role in obesity and T2DM and those of most interest are therefore
considered below.
Leptin. Leptin (greek leptos meaning thin) is the 16 kDa product of the obese gene
(ob) which was identified in 1994 in the ob/ob mouse by positional cloning [264]. Leptin-
deficient ob/ob mice have an uncontrolled food intake which causes them to become obese
and diabetic [265]. Conversely, daily administration of recombinant leptin to these mice
reverses the changes in body weight and restores glucose homoeostasis [266]. Further-
more, leptin also improves glucose homoeostasis in lipodystrophic mice and in humans
with lipodystrophy [267, 268, 269]. Thus, leptin plays a key role in regulating energy
intake, body weight and fat deposition and humans with mutations in the leptin or leptin
receptor genes are obese, although these gene defects are extremely rare [270]. Paradoxi-
cally, obesity is associated with high leptin levels which indicates the occurrence of leptin
resistance. This might explain why leptin treatment in humans with ’typical’ obesity has
so far not been successful [271].
The leptin-dependent effects on food intake and energy expenditure are mediated
through receptors of the central nervous system, partly at the level of MC4R signalling
[272]. Further to its effects on the central nervous system, leptin also improves insulin
sensitivity in muscles, liver and pancreas by stimulating fatty acid oxidation and reducing
intracellular triacylglycerol storage [273]. There has been the discussion of an ”adipoinsu-
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lar axis” as a dual hormonal feedback loop involving the hormones insulin and leptin [274].
According to this model, insulin stimulates the production and secretion of leptin whereas
leptin in turn suppresses insulin secretion by both central actions and direct actions on
β-cells (i.e. inhibition of proinsulin synthesis) [274]. Consistent with this idea, the dele-
tion of leptin receptors in pancreatic β-cells results in enhanced basal insulin secretion
and hypoglycaemia [275].
Adiponectin. Adiponectin is an insulin-sensitising adipokine with anti-diabetic and
anti-inflammatory properties. Like leptin, it is almost exclusively synthesised by adipocytes.
The 30 kDa protein consists of a collagen-like domain responsible for multimerisation [276].
Adiponectin is secreted into the circulation as three different forms: trimers, hexamers and
high molecular weight (HMW) oligomeric complexes of at least 18 monomers [277, 278].
All three forms are detectable in the blood, however there has been some controversy
about the active form of the hormone. As reviewed in [279], different adiponectin iso-
forms exert distinct biological properties: Whilst the HMW oligomer is the major active
form mediating the insulin-sensitising effects of adiponectin, the trimer and hexamer forms
are responsible for the central actions. Since adiponectin was identified by several differ-
ent groups, it has received several names such as apM1, GBP28, AdipoQ and ACRP30
[280]. Adiponectin circulates at remarkably high concentrations of 5-10 µg/ml which ac-
counts for 0.01% of all plasma protein [281]. Nonetheless, unlike many other adipokines,
circulating levels of adiponectin are paradoxically decreased in obesity and insulin resis-
tance [282, 283], whereas two groups have shown that part of the anti-diabetic action
of TZDs requires adiponectin [284, 285]. TZDs significantly increase plasma adiponectin
levels, mostly the HMW form, through effects on synthesis and secretion [286]. Although
adiponectin has no effect on insulin secretion in islets from healthy mice or humans, it
enhances glucose-stimulated insulin secretion in islets from diet-induced obese (DIO) mice
[287].
Resistin. Resistin is a member of the family of resistin-like molecules. The 12.5 kDa
protein was discovered in 2001 as a secreted product of mouse adipocytes [288]. It has been
shown that TZDs suppress circulating levels of resistin in mice, whereas resistin levels are
increased in diet-induced and genetic forms of obesity [288]. Furthermore, administration
of anti-resistin antibody improves blood glucose and insulin action in mice on a HFD
and treatment of normal mice with recombinant resistin impairs glucose tolerance and
insulin action [288]. In 2004, a study by Banerjee et al. [289] provided further evidence
for resistin as an important regulator of glucose metabolism in mice by demonstrating
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that resistin-deficient mice exhibit low blood glucose levels after fasting due to reduced
hepatic glucose production. However, despite these important findings in mice, there has
been less evidence for a similar effect in humans [290].
As with adiponectin, there are several multimeric forms of resistin circulating in
plasma: an abundant HMW hexamer and a less abundant but more active trimeric form
[291]. There is considerable controversy surrounding the role and cellular source of resistin
in humans. Although resistin was originally identified in adipose tissue, the majority of the
data suggest that human resistin is produced by macrophages and monocytes [292, 293],
whereas its production in mice seems to be restricted to adipocytes [288].
Retinol-binding protein 4 (RBP4). The finding of secondary insulin resistance in
muscle and liver of adipose-specific Glut4−/− mice [135] (see section 1.2.4) led to the
idea that insulin resistance in these mice might be caused in an endocrine manner via a
circulating factor [294]. Subsequent transcriptional profiling showed increased expression
of a 21 kDa protein termed RBP4 in adipocytes of adipose-specific Glut4−/− mice [294].
This accorded with the observation of elevated RBP4 levels in insulin-resistant mice and
humans with obesity and T2DM [294, 295]. One of the mechanisms by which RBP4
can induce insulin resistance may be via inhibitory phosphorylation of IRS-1, as RBP4
promotes IRS-1 Ser phosphorylation in human adipocytes [296]. Thus, RBP4 appears
to be an adipose tissue-secreted factor that is important for the regulation of glucose
homoeostasis and targeting RBP4 in obesity may be beneficial for the treatment of insulin
resistance [297].
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1.5 Inflammation as a link between obesity and in-
sulin resistance
As mentioned in section 1.1.5, different mechanisms including hypoxia, ER stress, visceral
adiposity and lipid mediators have been implicated in the induction of insulin resistance
and T2DM. What is common to these factors is that they are all thought to be associated
with inflammation [46]. In the course of the last two decades, several findings have
been made which indicate that obesity is directly associated with a chronic low-grade
inflammatory state. Notably, the inflammatory response present in obesity seems to be
triggered predominantly in adipose tissue, although other metabolically important sites
(i.e. the liver) may also become involved during the process [298].
In this section, I describe several findings from molecular, histological and clinical
studies, which provide evidence for the emergence of an inflammatory response in the
presence of obesity. Each of these studies has been paving the way to the concept that
obesity-induced inflammation plays a pivotal role in the development of insulin resistance
and T2DM (summarised in Tables 1.8 - 1.11).
First, however, it is useful to distinguish between acute and chronic inflammation. Tra-
ditionally, inflammation was characterised by the following four symptoms: dolor (pain),
calor (heat), rubor (redness) and turgor (swelling). These signs were described by the
Roman scholar Celsus about two thousand years ago and are typical of an acute inflam-
mation, which is the early and short-term response to an infection or an injury [299]. The
acute inflammatory response is normally rapidly terminated and the damaged tissue is
repaired. Chronic inflammation, however, occurs when the stimulus persists or during
autoimmune or autoinflammatory disease. An autoimmune disease such as RA is charac-
terised by dysfunctional activation of B and T cells as well as high-titer autoantibodies
to self-antigens (e.g. citrullinated proteins [300]). An autoinflammatory disease, on the
other hand, is distinguished from autoimmune disease by the absence of high-titer au-
toantibodies or antigen-specific T cells [301]. The concept was proposed in 1999 with the
identification of the genes underlying familial Mediterranean fever and the term autoin-
flammatory was coined to draw a clear distinction to autoimmune disease, where adaptive
immunity is involved in the onset of the disease. Because of the findings described in this
section, it has been proposed that T2DM is classified as an autoinflammatory disease
[301]. Nonetheless, more research on the underlying factors and the cell types involved is
required in order to determine which category T2DM really belongs to.
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CHAPTER 1
1.5.1 Obesity promotes the infiltration of immune cells into adi-
pose tissue
An important feature of inflammation is infiltration of inflamed tissues by immune cells
including granulocytes and macrophages. Mounting histological evidence shows that obe-
sity leads to remarkable changes in the cellular composition of adipose (Table 1.8). As
previously mentioned, adipose contains not only adipocytes, but also other cell types
including preadipocytes, endothelial cells, or fibroblasts. Despite of the known hetero-
geneity of adipose, it came as a great surprise in 2003 when two studies by Xu et al.
[8] and Weisberg et al. [9] simultaneously reported that adipose tissue of obese human
and mouse is characterised by elevated numbers of adipose-tissue-resident macrophages
(ATMs). This indicated that macrophages might infiltrate obese adipose as a result of
local adipose tissue inflammation.
In a later study, it was proposed that obesity triggers a ”phenotype switch” in ATMs
[302]. Whilst ATMs from lean mice expressed many genes characteristic of M2 or ”alter-
natively activated” macrophages (e.g. anti-inflammatory IL-10), ATMs from obese mice
expressed genes characteristic of M1 or ”classically activated” macrophages (e.g. pro-
inflammatory TNFα). According to Lumeng et al. [302], obese adipose tissue contains
high numbers of M1-polarised ATMs, whereas lean adipose tissue is reportedly popu-
lated by a small number of M2-polarised ATMs. Thus, obesity might cause a shift from
the non-inflammatory milieu maintained by M2-polarised, resident ATMs towards a pro-
inflammatory state. However, this finding has recently been challenged. Another study
has concluded that macrophages in the fat pads of obese mice have a mixed M1/M2
phenotype that is not pro-inflammatory [340]. Thus, the precise phenotype of ATMs still
remains elusive and it is not clear at present which macrophage phenotype (if any) may
potentially contribute to insulin resistance in obesity. Nonetheless, the finding of ATMs in
adipose tissue has complicated the understanding of whether a putative adipokine is ex-
pressed entirely by adipocytes or by ATMs. Of note, it has been shown that a macrophage
environment promotes the conversion of preadipocytes into macrophages, demonstrating
the cellular plasticity of these adipocyte precursors [341].
In addition to macrophages, recent studies have provided evidence that cells of the
adaptive immune system also infiltrate adipose tissue and contribute to obesity-associated
pathology in mice. It has been demonstrated that adipose tissue from obese mice contains
more activated CD8+ effector T cells and fewer CD4+ T cells than tissue obtained from
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lean mice [10, 11]. Moreover, the infiltration of CD8+ cells was observed several weeks
before the appearance of ATMs, and the depletion of CD8+ cells disrupted the vicious
circle of adipose tissue inflammation, ATM recruitment and insulin resistance [10]. Two
studies focusing on CD4+ T cells have found that the balance between regulatory and
effector CD4+ cells in adipose is crucial for the degree of insulin resistance [11, 303].
Furthermore, IFN-γ-producing T helper 1 (TH1) cells outnumber regulatory T (TREG)
cells and TH2 cells in obese adipose tissue [11, 303]. TREG cells are known to be important
for the maintenance of self-tolerance and the suppression of potential auto-reactive T
cells. Notably, induction of TREG cells in diabetic ob/ob mice has been shown to lead
to improved insulin sensitivity and decreased adipose inflammation, as assessed by a
reduction in CD11b+F4/80+ macrophages and TNFα in adipose tissue of these mice
[304]. It has also been suggested that the accumulation of TH1 cells in obese adipose
tissue may be driven by a yet unidentified ”obesity” antigen [11], but this is yet to be
confirmed. Altogether, CD8+ cells and TH1 cells are thought to contribute to insulin
resistance in obesity, whereas TREG cells and TH2 cells seem to counter it [303].
On the basis of these studies it should be mentioned that recently another interesting
link has been found between nutrition and TREG cells. Procaccini et al. [342] initially
set out to explore the question why TREG cells are anergic in vitro and fail to proliferate
in response to T cell receptor stimulation. Intriguingly, mice starved for 48 h or treated
with rapamycin (which inhibits the nutrient sensor mTOR) were found to have increased
proportions of TREG cells in peripheral lymph nodes. Furthermore, it was found that
TREG cells from starved mice have markedly reduced mTOR activity and increased rates
of in vitro proliferation in response to T cell receptor stimulation in vitro. The finding
that leptin contributes to the activation of the mTOR pathway in TREG cells finally led
Procaccini et al. to conclude that the anergic state of TREG cells in vitro may be due to
increased mTOR activity fuelled by the presence of nutrients and leptin.
1.5.2 Involvement of cytokines and pattern recognition recep-
tors
Ten years prior to the finding of obesity-induced macrophage infiltration into adipose,
Hotamisligil et al. [260] were the first to observe that the pro-inflammatory cytokine
TNFα is expressed in adipose tissue of different rodent models of obesity and diabetes.
Subsequent studies in human have come to the same finding: TNFα is also over-expressed
in adipose tissue and muscle of obese individuals, and exogenous TNFα administration has
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been shown induce insulin resistance [305, 343, 344]. In the meantime, it is well established
that TNFα induces insulin resistance in various tissue such as adipose, where it has been
shown to cause lipolysis, inhibit insulin signalling, and lead to alterations in expression
of adipocyte important genes (e.g. downregulation of GLUT4 [345]). As demonstrated in
a study by Yuan et al., TNFα inhibits the insulin signalling cascade through suppression
of insulin-stimulated Tyr phosphorylation of IRS-1/2 and of the insulin receptor [140].
Since the discovery of TNFα expression in obese adipose, many more pro-inflammatory
mediators have been found to be upregulated in obesity (Table 1.9). Most of them are
other cytokines including interleukin-(IL-)6 [5], IL-1 [309] and IL-18 [311], as well as
chemokines including IL-8 [308] and monocyte chemoattractant protein-1 (MCP-1) [308].
Mohamed-Ali et al. have calculated that approximately 30% of IL-6 in the circulation
is derived from subcutaneous adipose [5]. For this reason, IL-6 has been suggested as
one of the main culprits that mediate metabolic dysfunction in obesity. Nonetheless, the
proposed role of IL-6 in insulin resistance has been controversial [346]. It may be that the
different actions of IL-6 on insulin signalling may be due to its distinct effects on different
organs or the different sources of IL-6 [346]. Another well-studied molecule in the context
of obesity is MCP-1. Murine studies have shown that overexpression of MCP-1 in adipose
contributes to macrophage accumulation into adipose tissue and obesity-related insulin
resistance [315]. Accordingly, Mcp1−/− mice are protected against adipose tissue inflam-
mation and macrophage recruitment when consuming a HFD [315]. Nonetheless, another
study found no differences in adipose tissue inflammation or macrophage accumulation in
Mcp1−/− mice [316]. In addition to elevated levels of cytokines and chemokines, obesity
also leads to upregulation of acute-phase proteins such as CRP [6], plasminogen activator
inhibitor (PAI) [306] and serum amyloid A (SAA) [307]. An elevated level of CRP is
currently the best epidemiological biomarker for T2DM-associated cardiovascular disease
risk [309]. Remarkably, most of the pro-inflammatory mediators found in the serum of
patients with T2DM are IL-1 dependent, since blocking IL-1 signalling in human and
rodents has been shown to reduce their concentrations [337, 339].
Cytokines and acute-phase proteins are induced by inflammatory pathways such as
the NF-κB pathway (see Figure 1.7 on page 52). Pharmacological inhibition of IKKβ, a
component of the NF-κB pathway, has been shown to significantly improve insulin sensi-
tivity in obese rodents such as ob/ob mice and Zucker (fa/fa) rats which have a missence
mutation in the leptin receptor [140] (Table 1.11). Accordingly, mice heterozygous for
IKKβ (Ikbkb+/− mice) are protected from insulin resistance in both diet-induced and ge-
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netic obesity [140]. Since Ikbkb−/− mice die in utero because of enhanced liver apoptosis
[140], Arkan et al. [328] have generated liver-specific and myeloid-specific Ikbkb−/− mice.
Although liver-specific Ikbkb−/− retain insulin sensitivity in the liver on a HFD, they
develop insulin resistance in muscle and adipose. In contrast, myeloid-specific Ikbkb−/−
mice retain global insulin sensitivity and are protected from insulin resistance, underscor-
ing once more the important role of myeloid cells in obesity-induced insulin resistance.
In addition to IKKβ, the non-canonical IKK homolog IKK has recently been shown to
also play a role in the regulation of glucose homoeostasis in mice. IKK-deficient mice
reportedly gain less weight on a HFD and are therefore protected against diet-induced
insulin resistance and chronic inflammation (as assessed by a significant reduction in ATM
infiltration and decreased levels of inflammatory cytokines in serum and adipose) [329].
Additionally, these mice display increased energy expenditure and thermogenesis via en-
hanced expression of UCP-1 and this difference has only been observed in HFD-fed mice,
whereas lean IKK-deficient mice display the same energy expenditure and thermogene-
sis as lean control mice. IKK family members thus appear to play an important role in
obesity-induced metabolic disorders and may provide a promising target for the treatment
of insulin resistance and glucose intolerance.
An even more exciting target was unveiled in 2006, when a ground-breaking study
described a link between the innate immune receptors, saturated fatty acids (SFAs) and
insulin resistance in the mouse [12]. This study by Shi et al. provided evidence that the
innate immune receptor TLR4 (which is described in more detail in section 1.3.2) may
not only be activated by its common ligand LPS, but also by FFAs, whose levels are often
elevated in the metabolic syndrome. Even more intriguingly, it was demonstrated that
FFAs may directly activate TLR4 expressed by murine adipocytes, as FFAs stimulated
the secretion of TNFα and IL-6 protein in adipocytes derived from wild-type mice but not
in adipocytes derived from Tlr4−/− mice. In line with these observations, female Tlr4−/−
mice showed a remarkable reduction in obesity-associated adipose inflammation and this
was mirrored by a significant reduction in HFD-induced insulin resistance. This important
finding was subsequently corroborated by others [320, 321, 322, 323]. Although Suganami
et al. [320] and Tsukumo et al. [322] performed their investigations using a different mouse
model than Shi et al., both groups also reported that HFD-fed C3H/HeJ mice carrying a
loss-of-function mutation in the Tlr4 gene exhibit reduced adipose inflammation compared
to control C3H/HeN mice. The decrease in adipose inflammation was accompanied by
elevated adiponectin serum levels [320, 322], increased oxygen consumption [322] and
improved insulin sensitivity [320, 322] in these mice. Another investigation using DIO
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C57BL/10ScN mice (which have a deletion in the the Tlr4 gene) also found that these
mice have decreased inflammation and macrophage infiltration into adipose, leading to
improved insulin sensitivity [323]. The study of Kim et al. [321] further confirmed these
observations and additionally found a role for TLR4 in vascular inflammation, another
obesity-linked disorder. Generally, all these studies have come to the same major finding,
that is, TLR4 deficiency protects against insulin resistance. Nonetheless, it has to be
mentioned that there have been some inconsistent observations regarding the weight gain
of TLR4-deficient mouse strains. Whilst Shi et al. reported a significant increase in body
weight in female Tlr4−/− mice [12], others found the body weight of TLR4-deficient mice
to be unaffected [320, 321] or even decreased [322, 323]. It remains unclear whether this
difference stems from alterations in TLR4 mutations, mouse strains, or gender differences.
Since body weight is associated with the development of insulin resistance, it is impossible
to conclude whether the improvement in insulin sensitivity in two of the above mentioned
studies [322, 323] is a result of TLR4 deficiency or simply because of the reduction in body
weight. Nonetheless, this does not invalidate the other studies where TLR4 deficiency did
not protect from weight gain [12, 320, 321]. Based on these studies it seems noteworthy
to mention that the consumption of a HFD reportedly causes endotoxemia (i.e. increased
levels of plasma LPS) in human [347] and mouse [324]. Moreover, chronic experimental
metabolic endotoxemia through continuous subcutaneous infusion of LPS has been shown
to induce insulin resistance in mice, whereas mice mutant in CD14 (a co-receptor of TLR4)
are protected from both LPS- and HFD-induced insulin resistance [324].
Besides TLR4, a similar association has recently been found between TLR2 and in-
sulin resistance in HFD-fed mice [13, 319]. For instance, inhibition of TLR2 in DIO mice
using TLR2 antisense oligonucleotides improved insulin sensitivity and insulin signalling
in muscle and adipose of these mice [319]. This finding is in line with the observation
that TLR2-deficient mice are protected from HFD-induced insulin resistance and β cell
dysfunction [13]. In 2010, TLR5 joined the league of prospective metabolic regulators
when a landmark study demonstrated that Tlr5−/− mice exhibit hyperphagia and de-
velop hallmark features of metabolic syndrome. As reported by Vijay-Kumar et al. [14],
TLR5 deficiency caused significant weight gain, as well as hyperlipidemia, hypertension,
hyperglycaemia, insulin resistance and increased adiposity. Remarkably, these metabolic
changes correlated with changes in the composition of the gut microbiota, and transfer of
the gut microbiota from TLR5-deficient mice to wild-type germ-free mice conferred many
features of metabolic syndrome to the recipients. It has therefore been proposed that loss
of TLR5 produces alterations in the gut microbiota that induce low-grade inflammatory
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signalling, which may in turn lead to insulin resistance. Based on these studies, TLRs
might potentially play a fundamental role in the regulation of glucose handling and phar-
macological modulation of individual TLR pathways could become an important strategy
in the future for combating insulin resistance.
In addition to TLRs, a recent review by Schroder et al. [164] has listed several lines of
evidence suggesting that the NLRP3 inflammasome may function as a sensor for metabolic
stress. First, different activators of the inflammasome (e.g. ATP) have been shown to
induce the production of ROS which causes oxidative stress [348]. As demonstrated by
Zhou et al. [325], the increase in intracellular ROS induces dissociation of thioredoxin-
interacting protein (TXNIP) from the oxidoreductase thioredoxin. TXNIP is a protein
that has been previously linked to insulin resistance at the β cell level [349] and also at the
adipocyte level [327]. Notably, TXNIP can bind to NLRP3, leading to its activation as
assessed by caspase-1 activation and secretion of mature IL-1β [325]. The observation that
hyperglycaemia stimulates expression of TXNIP in human islets [349] and human adipose
tissue [327] suggests that NLRP3 might be a direct link between hyperglycaemia and the
IL-1β-mediated inflammation. This hypothesis is further supported by the notion that
Nlrp3−/− and Casp1−/− mice display improved glucose tolerance and insulin sensitivity
[318, 325].
A study by Vandanmagsar et al. [326] has added further weight to this hypothesis by
demonstrating that caloric restriction and weight loss in obese individuals with T2DM
is associated with a reduction in NLRP3 and IL-1β expression in subcutaneous adipose
tissue as well as improved insulin sensitivity. Moreover, it was found that the NLRP3
inflammasome senses lipotoxicity-associated increases in intracellular ceramide to induce
caspase-1 cleavage in macrophages and adipose tissue. Accordingly, obese Nlrp3−/− mice
exhibit improved insulin signalling and reduced effector T cell numbers in adipose tissue,
thereby corroborating the hypothesis of Schroder et al. that the NLRP3 inflammasome
senses obesity-associated danger signals and contributes to obesity-induced inflammation
and insulin resistance.
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1.5.3 Clinical evidence
As early as 1876, it was described that the non-steroidal anti-inflammatory drug sodium
salicylate had beneficial effects in the treatment of diabetes [330]. However, despite this
early observation of an association between inflammation and T2DM, the potential link
has been ignored for more than a century. It was not until the onset of the obesity and di-
abetes epidemic, that a fundamental interest arose to understand the role of inflammation
in T2DM.
In 2001, a landmark study described that high doses of salicylates reverse hypergly-
caemia, hyperinsulinemia, and dyslipidemia in obese rodents [140]. The proposed mecha-
nism by which salicylates counteract insulin resistance seems to involve inhibition of IKKβ
[350], which is part of the NF-κB pathway described in section 1.3.3. In terms of insulin
signalling, it was shown that salicylates improve insulin receptor Tyr phosphorylation and
phosphorylation of Akt in muscle and liver of obese subjects [140].
Following the discovery of TNFα as an adipose-tissue-secreted factor [260], it has
been demonstrated that its neutralisation improves insulin sensitivity in genetically obese
Zucker (fa/fa) rats [260]. Moreover, TNFα-deficient mice are protected from obesity-
induced insulin resistance [314]. However, despite the promising results obtained in ro-
dents, clinical trials in human to improve insulin sensitivity by blocking TNFα did not
provide the same satisfactory outcome until recently. Administration of a TNFα neu-
tralising antibody (CDP571) over a period of 4 weeks had no effect on insulin sensitivity
in obese T2DM subjects [333]. Likewise, TNFα blockade in patients with hallmarks of
the metabolic syndrome resulted in an increase in muscle adiposity [334]. Nonetheless,
another study has demonstrated a rapid beneficial effect of TNFα blockade (using the
monoclonal antibody infliximab) on insulin resistance and insulin sensitivity in periodi-
cally treated RA patients [335]. This finding is corroborated by a current study, which
shows that prolonged therapy with the TNFα inhibitor etanercept (a fusion protein) in
patients with the metabolic syndrome improves fasting glucose levels [336].
At present, three major compounds are being investigated to determine whether anti-
inflammatory drugs may represent a new treatment for T2DM. The first compound is
salsalate, a cheap non-acetylated prodrug of salicylate, which was originally used in the
treatment of RA. In a recent clinical trial involving 108 patients diagnosed with T2DM,
it was found that high-dose salsalate treatment resulted in a significant improvement in
glucose homoeostasis, as determined by a reduction in glycosylated haemoglobin (HbA1c)
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[331]. A further compound that is being examined for the treatment of T2DM is anakinra,
an antagonist of the IL-1R. A study by Larsen et al. [337] has shown that blocking IL-
1R signalling leads to a significant improvement in glucose homoeostasis: At 13 weeks,
the anakinra-treated group had significantly lower levels of glycated haemoglobin as well
as reductions in IL-6 and CRP plasma levels. Subsequent studies in diabetic rodents
such as DIO mice and diabetic Goto-Kakizaki rats (which have an early β cell defect)
demonstrated that this anti-diabetic effect of anakinra also applies to rodents [338, 339].
Finally, drug developing companies are currently performing efficacy testing trials of anti-
IL-1β monoclonal antibodies as another promising therapeutic strategy for the treatment
of T2DM [351]. Hence, inflammatory mediators provide an attractive new target for the
treatment for T2DM and the promising results obtained so far further support the idea
of inflammation as a major causative factor in the pathogenesis of T2DM.
Taken together, several lines of evidence link inflammation to obesity and metabolic
disorders such as T2DM. The infiltration of macrophages into adipose tissue in obesity
is now well established and the contribution of the adaptive immune system to tissue
inflammation and insulin resistance is gaining increasing attention. As outlined above,
recent and ongoing clinical studies demonstrate that anti-inflammatory strategies to com-
bat inflammation in obesity significantly improve insulin resistance and hyperglycaemia
in human. Nonetheless, the exact mechanisms by which innate immunity might directly
influence metabolic tissues remain poorly investigated, mostly because the connection
between these two fields was only recognised recently. In order to identify critical nodes
in the crosstalk between inflammation and adipose, the investigation of the potential in-
flammatory properties of adipocytes is now of great importance. This thesis will probe
some important questions regarding the functional consequence of exposing adipocytes to
TLR ligands, and gives further insight into how chronic inflammation might give rise to
insulin resistance.
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1.6 Aim
The aim of my thesis is to understand the link between inflammation and T2DM in hu-
mans. The recent realisation that a low-level chronic inflammation persists in adipose tis-
sue of obese subjects has motivated me to investigate how glucose metabolism might also
be altered. My journey has led me into the emerging field of immunometabolism, which
combines the two historically distinct disciplines of immunology and metabolism [352].
This thesis, performed entirely in physiologically relevant primary human adipocytes, ad-
dresses one of the central questions of this novel field: If inflammation and metabolism
work in parallel, what are the common regulatory factors?
At the beginning of this project, TLR4 was implicated as a crucial link between in-
flammation, obesity and insulin resistance in mouse, as TLR4-deficient mice are protected
from obesity-induced insulin resistance and T2DM [12, 320, 321, 322]. Moreover, it had
been discovered that murine adipocytes can express functional TLRs and release pro-
inflammatory cytokines in response to LPS [12, 178]. This finding was unexpected, as
TLRs are a key component of the innate immune system whereas adipocytes are char-
acteristic of the metabolic system. I thus investigated whether TLRs might be one of
the common factors that synchronise the immune system with metabolism. My thesis
is built around the idea that TLRs not only act as the gatekeepers of the innate im-
mune system, but also as important metabolic regulators, by coupling inflammation to
adipocyte function. For this, I established a cell culture model of in vitro differentiated
human adipocytes to test my hypothesis of TLRs as important metabolic regulators by
answering three major questions:
• Which TLRs are expressed in human adipocytes and which signalling pathways are
involved? (Chapter 3)
• Does inflammatory signalling in adipocytes have an impact on glucose metabolism?
(Chapter 4)
• Which are the candidate mechanisms responsible for immune-regulated glucose han-
dling? (Chapter 5)
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Materials and methods
2.1 Tissue culture
Unless otherwise stated, work in this thesis utilised exclusively in vitro cultures of both
human and murine primary cells. All cell cultures were maintained in uncoated tissue
culture flasks or plastic wells at 37◦C in 5% CO2 and 95% humidity.
2.1.1 Media and supplements
Dulbecco’s Modified Eagle’s medium (DMEM) containing glucose (4.5 g/L), L-glutamine
and sodium pyruvate, Roswell Park Memorial Institute (RPMI) medium containing 25
mM L-glutamine and the Antibiotic/Antimycotic solution containing penicillin, strepto-
mycin and amphotericin (PSA) were obtained as sterile solutions from PAA, Pasching,
Austria. M-CSF was from Peprotech, London, UK.
2.1.2 Serum, solutions and reagents
Heat-inactivated foetal calf serum (FCS) was purchased from GIBCO c/o Invitrogen, San
Diego, USA. Sterile tissue culture grade phosphate buffered saline (PBS) was made up
from 10x PBS (Lonza, Basel, Switzerland) and tissue grade distilled H2O (PAA, Pasching,
Austria). Dimethylsulfoxide (DMSO) for cryopreservation of preadipocytes was obtained
from Sigma, Poole, Dorset, UK. MTT used for determining cell viability was acquired
from Sigma, Poole, Dorset, UK. Trypsin-EDTA mixture was bought from PAA, Pasching,
Austria.
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2.1.3 Endotoxin testing
Background The presence of endotoxin in a solution can be detected by the limulus
amoebocyte lysate (LAL) test. The use of LAL for the detection of endotoxin evolved
from the observation that a gram-negative infection of Limulus polyphemus (the horseshoe
crab) results in intravascular coagulation [353]. Later on, it was demonstrated that this
clotting was the result of a reaction between endotoxin and a clottable protein in the
circulating amebocytes of Limulus [354]. The LAL test utilises the initial part of the
LAL endotoxin reaction, when LPS is detected by the activation of an enzyme that can
then cleave a synthetic substrate, resulting in the release of p-nitroaniline (pNA). A yellow
colour becomes visible which can be read on a photometer at an absorbance of 410 nm.
Protocol All cell culture reagents and media were tested for the presence of endotoxin
prior to their use by the LAL test QCL-1000 (Lonza, Walkersville, USA). This test was
routinely performed for the research group by Ms Patricia Green and Mr Sunil Modi. Only
reagents below the detection limit of the LAL assay (10 pg/ml) were used for experiments.
2.1.4 Isolation of human preadipocytes
Background It is technically difficult to work with mature adipocytes freshly isolated
from adipose tissue as the cells are not very long-lived, i.e. they cannot be kept in culture
for more than 48 h. Furthermore, the use of primary mature adipocytes in tissue culture
suffers two major drawbacks: Firstly, cells cannot be pelleted by centrifugation as they are
floating due to their high lipid content. Secondly, isolated adipocytes do not attach to the
bottom of a tissue culture flask or a plate. For this reason, the majority of experiments
in this thesis are performed using adipocytes that have been differentiated in vitro from
preadipocytes. The isolation procedure for purification of preadipocytes out of adipose
tissue is described in the protocol of this section.
Tissue Donors Unless otherwise stated, all adipose tissue was obtained from abdom-
inal subcutaneous (SC) adipose from healthy non-diabetic women with a BMI between
25 and 30 kg/m2 undergoing elective abdominal surgery. All subjects provided written
informed consent and the study was approved by the Hammersmith Hospital Research
Ethics Committee (ref number 07/Q0406/29). Patients exclusively underwent one of two
surgical procedures: The great majority underwent deep inferior epigastric perforators
(DIEP) flap breast reconstruction and there was also a small number of abdominoplasty
cases. Exclusion criteria for the study included: 1. infection, 2. active autoinflammatory
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/ autoimmune conditions (e.g. RA, inflammatory bowel disease), 3. malignancy (patients
undergoing flap reconstruction were all adjudged to be cured / in long term remission
from their breast cancer), 4. receiving anti-inflammatory drugs (e.g. steroids), 5. the
presence of diabetes.
In the course of my PhD at the Kennedy Institute, I acquired a total number of 82 in-
dividual adipose tissue samples (this included 72 samples from the Charing Cross Hospital
in London and 10 samples obtained from the Norfolk and Norwich University Hospital).
Cells of individual donors were never pooled for experimentation. All experiments were
performed using preadipocytes or in vitro differentiated adipocytes of single donors and
data was normalised and pooled afterwards.
Isolation protocol A schematic overview of the isolation procedure of human pre-
adipocytes is shown in Figure 2.1. The technique for primary human preadipocyte cultures
is well established [355]. Subcutaneous adipose tissue samples (weighing 0.5 - 1 kg)
were transported immediately from the operating theatre and processed under sterile
conditions. Pure adipose tissue samples were dissected free of blood vessels, skin and
connective tissue. After mechanical dispersal, fat lobules were subjected to enzymatic
digestion with 0.5 mg/ml collagenase from Clostridium histolyticum (Sigma, Steinheim,
Germany) and 0.1 mg/ml DNAse I from bovine pancreas (Roche, Mannheim, Germany)
for 30 - 45 min at 37◦C and constant shaking at 140 rpm. The digested tissue was then
filtered through a sterile nylon mesh before centrifuging for 5 min at 400 g. Supernatant
containing floating adipocytes was discarded and the remaining cell pellet containing the
stromal vascular fraction (SVF) was re-suspended in 1 ml of red cell lysis buffer for 1 min
(Sigma, Steinheim, Germany). Thereafter, the suspension was washed, centrifuged and
plated in basal media consisting of 4.5 g/L glucose-containing DMEM supplemented with
10% FCS and 1% antibiotic/antimycotic mixture. Cells were passaged for a maximum
of 3 passages with 1x trypsin-EDTA (0.05% / 0.02% in PBS) at a split ratio of 1:2. For
most experiments, however, cells were normally plated at P1 stage in the required plating
format.
The SVF described in the isolation procedure above is known to contain various
cell types besides preadipocytes, including fibroblasts, endothelial cells, erythrocytes and
macrophages. Since macrophages infiltrate adipose tissue in obesity, it was important to
ensure that cultures of primary human preadipocytes, which were isolated for this project,
were not contaminated with myeloid cells. The culture conditions used for preadipocytes
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were different than those used for macrophage culture, which might reduce the survival of
remaining cells such as endothelial cells or macrophages. However, as there is no method
up to now that allows the selective isolation of pure preadipocytes, I examined the cul-
tures after preadipocyte isolation by detailed microscopic control and was not able to
identify any macrophages. Additionally, in early experiments I performed FACS analy-
sis on preadipocytes for absence of CD45 (hematopoietic cell marker) and expression of
CD73 (reportedly expressed by mesenchymal stem cells) as described next. The protocol
for FACS analysis is described in section 2.2.3.
Primary human adipocyte precursors from subcutaneous adipose tissues are
CD45-negative and CD73-positive. CD45 is a protein Tyr phosphatase that is
present on all differentiated hematopoietic cells except erythrocytes and plasma cells.
This antigen can therefore be used as a marker for hematopoietic cells. CD14 and CD68,
two other markers commonly used as macrophage-specific markers, were recently found
to also be expressed by preadipocytes and adipocytes and are therefore not suitable
to distinguish adipocytes from macrophages [356]. CD73, which is also known as 5’-
nucleotidase, is used as a marker of lymphocyte differentiation and is also expressed by
preadipocytes/mesenchymal stem cells [357] from which adipocytes are derived. Up to
the present, there are no known adipocyte-specific surface markers for FACS analysis. For
this reason I decided to use antibodies targeting CD45 and CD73.
Cultures of primary human preadipocytes derived from subcutaneous adipose tissues
were examined after one passage for expression of CD45 and CD73 as shown in Figure
2.2. CD45-positive, CD73-negative monocyte-derived primary human macrophages were
included as a control. As expected, the preadipocyte population was found to be CD73-
positive but CD45-negative, providing evidence that the cells in this cell culture model are
derived from mesenchymal stem cells and are not contaminated by hematopoietic cells.
2.1.5 Cryopreservation of preadipocytes
Any primary human preadipocytes from cell isolation that were not immediately required
were stored in liquid nitrogen for later use. Cells were frozen before the first passage at P0
stage. Cells were trypsinised and centrifuged for 5 min at 400 g before being re-suspended
in ice-cold freezing medium (10% DMSO, 90% FCS) at a concentration of 1x106 cells/ml.
Cells were immediately transferred into cryotubes and placed into a freezing container
containing isopropanol which has a cooling rate of 1◦C/min. The freezing container was
79
CHAPTER 2
Figure 2.2: Primary human adipocyte precursors from subcutaneous adipose
tissues are CD45-negative and CD73-positive. (A) Flow cytometry analysis of
CD45 and CD73 expression by human preadipocytes after 1 passage. CD45 is used as
a marker for hematopoietic cells whereas CD73 can be used as a mesenchymal stem cell
marker. Isotype controls are shown in grey. (B) Monocyte-derived human macrophages
were included as a positive control for CD45 (n=1).
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moved into a -80◦C freezer overnight before being transferred to liquid nitrogen for long-
term storage. For recovery, cells were thawed and DMSO was immediately removed by
washing cells in complete medium prior to culture.
2.1.6 Differentiation of preadipocytes to adipocytes
Preadipocytes at P1-P3 were plated into the required format for experiments. Differenti-
ation was achieved by changing from basal media to adipogenic media 48 h after the cul-
tures had become confluent. Adipogenic media was changed every 4 days for 14 - 21 days
prior to experimentation. Adipogenic media contained basal media supplemented with
100 nM insulin, 1 µM dexamethasone (glucocorticoid that inhibits Pref-1 transcription),
0.2 mM indomethacin (PPARγ agonist), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX;
non-specific inhibitor of cAMP/cGMP phosphodiesterase), 33 µM biotin and 17 µM pan-
tothenate. Alternatively, in an early experiment additional conditions were tested by re-
moving supplements completely from the medium or removing IBMX and indomethacin
after day 4 (see section 2.1.8). Biotin plays a role in cell growth, production of fatty acids
and the metabolism of fats and amino acids. Pantothenic acid is critical for both the
metabolism and synthesis of carbohydrates, proteins, and fats. All reagents described in
this paragraph were purchased from Sigma, Dorset, UK.
2.1.7 Assessing quality of differentiation
Phenotype of differentiated cells was examined after 14 days by phase contrast microscopy
for the accumulation of lipid droplets. In early experiments, differentiation was also
demonstrated by Oil red O staining (Figure 2.3A). Differentiation was about 95% when
cells were plated at P1 stage and about 75% at P3. For this reason, cells were normally
used at P1 stage and, unless indicated, only mature adipocytes between day 14 and day
21 of differentiation were used for experiments.
Protocol for Oil red O staining Lipid accumulation in cells in which differentiation
to adipocytes had been induced was visualised for certain donors by staining with Oil
Red O. Thirty ml of stock solution (3 mg/ml Oil Red O in 99% isopropanol) was mixed
with 20 ml of deionised water as working solution. Cells were washed with PBS, fixed
with 4% formaldehyde for 5 min at room temperature, washed with water and treated
for 2 - 5 min with 60% isopropanol, followed by a 5 min staining with Oil Red O and
counter-staining with haematoxylin.
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Figure 2.3: Differentiation of preadipocytes into adipocytes. (A) The differenti-
ation of preadipocytes (preads) into adipocytes (ads) was visualised by staining of lipid
droplets with the lipophilic dye Oil Red O. Scale bars, 50µm. (B) Adipogenic differen-
tiation of preadipocytes leads to increased expression of the fatty acid binding protein
4 (FABP4 ) gene. The mRNA level detected in preadipocytes was normalised against
RPLP0 and attributed a value of 1. FABP4 transcript levels in in vitro differentiated
adipocytes and in freshly isolated adipocytes were expressed relative to preadipocytes.
Each panel shows the mean (± error) fold upregulation from triplicate real-time PCRs.
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In addition to the Oil Red O Stain, the model of in vitro differentiation was validated
by real-time PCR of the adipocyte-specific marker FABP4 (Figure 2.3B). Quantitative
PCR analysis was performed as described in section 2.2.4 on cultured preadipocytes,
in vitro differentiated adipocytes and on adipocytes directly harvested from fat tissue
specimens. As expected, preadipocytes expressed very low levels of FABP4. However,
differentiation led to a 450-fold upregulation by day 14. Mature adipocytes, collected dur-
ing preadipocyte isolation from the floating fat layer after centrifugation, were included
as control cells (2261-fold upregulation of FABP4 compared to preadipocytes). This indi-
cated that in vitro differentiated adipocytes express typical markers of mature adipocytes
and therefore provide a good model for studying this cell type in vitro.
2.1.8 Optimising the differentiation of human preadipocytes.
A cell culture medium normally contains fixed components (e.g. glucose) as well as
variable ones (e.g. serum-specific components such as bovine serum albumin (BSA) which
may vary between different batches). It is known that serum plays a crucial role not only in
the activation but also differentiation of a certain cell type. In order to optimise the culture
medium for the differentiation of preadipocytes into adipocytes, I tested the influence of
serum, IBMX, indomethacin and the vitamins biotin and pantothenate on differentiation.
Adipocytes were differentiated in a 24-well plate for 16 days as shown in Figure 2.4.
Two different types and batches of FCS were tested under the following conditions: (A)
DMEM supplemented with 10% FCS, 1% PSA, 1.7 µM insulin, 1 µM dexamethasone,
0.2 mM indomethacin, 0.5 mM IBMX for 16 days; (B) DMEM supplemented with 10%
FCS, 1% antibiotic/antimycotic mixture, 100 nM insulin, 1 µM dexamethasone, 0.2 mM
indomethacin, 0.5 mM IBMX, 33 µM biotin, 17 µM pantothenate for 16 days; (C) Day
1-4: medium B, day 5-16: medium B without IBMX and indomethacin (see Table 2.1).
In a quantitative analysis of differentiated adipocytes, cytoplasmic triglyceride accu-
mulation was measured by staining lipid droplets with Oil Red O as described in section
2.1.7. After staining, the dye was re-extracted from the cells with 100% isopropanol and
absorbance was measured spectrophotometrically at 492 nm. Absorbance values are dis-
played under each condition in Figure 2.4. Media ”A” and ”B” gave similar results with
a high degree of differentiation, whereas cells in medium ”C” differentiated poorly. Media
”B” was subsequently used throughout this thesis. Furthermore, GIBCO serum led to
higher OD values than Biosera, i.e. degree of differentiation, and was therefore used for
further experiments.
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Figure 2.4: Optimising the differentiation of human preadipocytes. Human
preadipocytes were differentiated in a 24-well for 16 days in the presence of two dif-
ferent types of FCS (Biosera or GIBCO) and using 3 different differentiation media as
listed in Table 2.1. Lipid droplets were stained with Oil Red O as described in section
2.1.7 at day 16 of differentiation. For quantification, the dye was subsequently extracted
from cell culture dishes with 100% isopropanol and absorbance was measured spectropho-
tometrically at 492 nm. Absorbance values are displayed under each picture as OD. Scale
bar, 100 µm
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Table 2.1: Examination of differentiation media
Condition Medium ”A” Medium ”B” Medium ”C”
Basal medium DMEM DMEM DMEM
FCS 10% GIBCO/ Biosera 10% GIBCO/Biosera 10% GIBCO/Biosera
Antibiotic 1% PSA 1% PSA 1% PSA
insulin 1.7 µM 1.7 µM 1.7 µM
dexamethasone 1µM 1µM 1µM
Indomethacin 0.2 mM 0.2 mM 0.2 mM
(only day 1-4)
IBMX 0.5 mM 0.5 mM 0.5 mM
(only day 1-4)
Biotin - 33 µM 33 µM
Pantothenate - 17 µM 17 µM
Abbreviations: Dulbecco’s Modified Eagle’s medium (DMEM), foetal calf serum (FCS)
3-isobutyl-1-methylxanthine (IBMX), penicillin, streptomycin and amphotericin (PSA)
2.1.9 Isolation of murine preadipocytes and in vitro differenti-
ation to adipocytes
For isolation of murine preadipocytes, 3 male wild-type C57BL/6J mice were sacrificed
and their epididymal fat pads were excised and minced. The tissue was digested for 30
min at 37◦C in serum-free DMEM containing 1.5 mg/ml collagenase and 1% BSA whilst
constantly shaking at 140 rpm. The suspension was subsequently mashed through a
sterile nylon mesh before centrifuging for 5 min at 400 g. Pelleted cells were washed twice
with culture medium (DMEM with 10% FCS and 1% antibiotic/antimycotic mixture)
and seeded into a 96-well plate. The following day non-adherent cells were discarded.
The adherent cells were allowed to reach confluence and differentiation was induced by
changing from basal media to adipogenic media (described in section 2.1.6) 48 h after the
cultures had become confluent. According to standard protocols for murine adipocytes,
cells were differentiated for 10 days prior to experimentation.
2.1.10 Isolation of human peripheral blood monocytes and dif-
ferentiation into macrophages
In some experiments monocyte-derived human macrophages were used as control cells.
Purification of monocytes was routinely done by other members of the cytokine biology
group at the KIR. Human peripheral blood monocytes were isolated from single donor
plateletphoresis residues (buffy coats) obtained from the North London Blood Trans-
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fusion service. Buffy coats were separated using Ficoll-Hypaque centrifugation which
separates peripheral blood monocytes from erythrocytes and granulocytes by a density
gradient. Peripheral blood monocytes were then further separated according to their size
by counter-flow centrifugal elutriation using a J20 elutriator (Bechman Coulter). Cells
were loaded into a specialised funnel-shaped elutriation column where they are exposed
to two opposing forces of centrifugal force and fluid flow velocity. Smaller cells exit the
chamber first, with the largest cells exiting last, as the fluid flow rat is gradually increased
by 1 ml/min during the elutriation. Monocytes were collected and purity was assessed by
flow cytometry based on cell size and granularity. Monocytes were cultured in petri dishes
in RPMI containing 10% FCS and differentiated by adding 100 ng/ml M-CSF (Pepro-
tech, London, UK) for 4 days. After 4 days, M-CSF monocyte-derived macrophages were
dissociated from dishes by incubation in non-enzymatic cell dissociation solution (Sigma)
for 45 min at 37◦C. Thereafter, cells were scraped, counted and re-plated in the required
plate format at a concentration of 106 cells/ml.
2.1.11 Cell stimulation
In order to examine TLRs in adipocytes, cells were stimulated with a range of different
TLR ligands which are described in more detail in section 1.3.2. Stimulation was per-
formed by plating primary human preadipocytes and adipocytes at 104 cells per well in
a 96-well plate and incubating the cells in media containing a specific ligand or in media
alone. After treatment, conditioned media were removed and stored at -20◦C. TLR lig-
ands are listed in Table 2.2 and recombinant cytokines used for cell stimulation are listed
in Table 2.3.
2.1.12 Cytokines
Human recombinant cytokines were used to stimulate cells or as concentration standards
in ELISA. They are summarised in Table 2.3.
2.1.13 Anakinra (Kineret)
In some experiments, the activity of the IL-1R was blocked with the recombinant human
IL-1R antagonist Anakinra (Kineret) which was purchased from Amgen, Thousand Oaks,
CA. The first batch was obtained from Upjohn Laboratories, Kalamazoo, Michigan, USA.
For each experiment, Anakinra was pre-incubated for 1 h prior to stimulation with TLR
ligands or cytokines.
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Table 2.2: TLR ligands
Receptors Ligand Description Source
TLR1/2 Pam3CSK4 synthetic tripalmitoylated lipopeptide InvivoGen
TLR2/6 MALP-2 synthetic diacylated lipopeptide Axxora
TLR3 Poly(I:C) synthetic dsRNA Axxora
TLR4 LPS lipopolysaccharide from E. coli Axxora
TLR5 Flagellin protein from S. typhimurium Axxora
TLR7/8 R848 small antiviral molecule Axxora
(imidazoquinoline compound)
TLR9 ODN M362 CpG oligonucleotide type C InvivoGen
(human TLR9 ligand)
TLR9 ODN 1669 CpG oligonucleotide type B InvivoGen
(murine TLR9 ligand)
Abbreviations: Pam3CysSerLys4 (Pam3CSK4), Macrophage-activating lipopeptide-2
(MALP-2), polyinosinic-polycytidylic acid (poly(I:C)), Lipopolysaccharide (LPS)
Table 2.3: Human recombinant cytokines
Cytokine Application Concentration Source
IL-6 ELISA 10000-13 pg/ml Peprotech, London, UK
mIL-6 ELISA 10000-13 pg/ml Peprotech, London, UK
IL-8 ELISA 10000-13 pg/ml RnD, Minneapolis, USA
MCP-1 ELISA 10000-13 pg/ml Peprotech, London, UK
IP-10 ELISA 10000-13 pg/ml RnD, Minneapolis, USA
ENA-78 ELISA 10000-13 pg/ml RnD, Minneapolis, USA
TNFα Cell culture 50 ng/ml RnD, Minneapolis, USA
IL-1α Cell culture 10 ng/ml RnD, Minneapolis, USA
IL-6 Cell culture 50 ng/ml RnD, Minneapolis, USA
IL-8 Cell culture 50 ng/ml RnD, Minneapolis, USA
Adiponectin Cell culture 10 µg/ml RnD, Minneapolis, USA
ENA-78 Cell culture 50 ng/ml RnD, Minneapolis, USA
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2.1.14 Transfection methods
Background Transfection is the process of deliberately introducing nucleic acids into
eukaryotic cells via non-viral methods. Common methods used for transfection are elec-
troporation, cationic liposomes or calcium phosphate. Electroporation leads to creation
of transient micro-sized holes in the plasma membrane that are caused by an externally
applied electrical field. Cationic liposomes are artificially prepared vesicles made of pos-
itively charged lipids that can fuse with the cell membrane, releasing the nucleic acid
into the cell (Figure 2.5). Calcium phosphate transfection, initially described in the early
1960s, is based upon the formation of precipitate containing calcium phosphate and DNA.
The DNA precipitate is thought to adhere to the cell surface and enter the cell by endo-
cytosis.
In this thesis, RNAi oligonucleotides (section 2.3) for knockdown of TLRs, TLR
adapter molecules and glucose transporters were transfected using cationic liposomes. For
investigation of GLUT4 translocation, cells were transfected with the HA-GLUT4-GFP
plasmid (section 2.2.8) using calcium phosphate transfection.
Protocol for transfection with cationic liposomes For transfection of RNAi oligonu-
cleotides the siIMPORTERTM siRNA transfection reagent from Upstate (Milton Keynes,
UK) was used, which is a cationic lipid formulation. For transfecting cells in a 96-well
plate, 7 µl of siRNA/siIMPORTERTM mixture was added into one well containing 93
µl of SF DMEM. The siRNA/siIMPORTERTM mixture was prepared by mixing 3 µl of
transfection reagent (diluted 1:6 in DMEM) with 4 µl siRNA diluent containing the re-
quired amount of siRNA. This mixture was first incubated for 10 min to allow formation
of siRNA/lipid complexes and then added to each well. The following day, the medium
was replaced with fresh culture medium.
Protocol for Calcium phosphate transfection For transfecting the HA-GLUT4-
GFP plasmid into adipocytes, a calcium phosphate transfection kit from SIGMA (Mis-
souri, USA) was used. The transfection procedure was performed according to the man-
ufacturer’s instructions as follows: Conditioned media was removed one day prior to
transfection and replaced by fresh media. The conditioned media was saved and added
back to cells after transfection for enhanced recovery. The transfection was performed in
a 12-well plate containing 500 µl/well of SF DMEM. 100 µl of precipitate (1 µg DNA) was
added per well and transfection was performed for 1.5 h. For 2 plates, 3 ml of total precip-
itate was prepared by slowly mixing 1.5 ml of a HEPES-buffered saline solution containing
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Figure 2.5: Liposome-mediated transfection. Cationic lipids form structures called
liposomes, which complex with nucleic acids (e.g. DNA). The complex then fuses with the
cell membrane and is internalised by endocytosis, resulting in the formation of a double-
layer inverted micellar vesicle. From there, the content might eventually escape into the
cytoplasm of the cell. This figure is adapted from [358].
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sodium phosphate (pH 7.05) with 1.5 ml of a solution containing calcium chloride and
high quality DNA (120 µg HA-GLUT4-GFP, 150 µl of 2.5M CaCl2). After transfection,
cells were washed with 1x sterile PBS and conditioned medium which had been saved was
added back on for at least 6 h.
2.2 Downstream Analysis
2.2.1 Enzyme-linked immunosorbent assay (ELISA)
The concentration of secreted cytokines in the media of stimulated cells was measured by
sandwich enzyme linked immuno-adsorbent assay (ELISA). This is a biochemical tech-
nique that uses specific paired antibodies to capture cytokines and detect them with the
use of a colorimetric assay. A schematic overview of the procedure is shown in Figure 2.6.
Background Two antibodies which recognise non-overlapping epitopes on the cytokine
were used as listed in Table 2.4. The primary antibody (capture antibody) is used to
coat the plate. It captures and immobilises the antigen. The immobilised antigen is
then detected by a second antibody (detection antibody) which is biotinylated. The
biotinylated tag of the detection antibody binds very tightly to the tetrameric protein
streptavidin. As a third step, streptavidin-HRP is added. Streptavidin is conjugated to
the enzyme HRP which catalyses the oxidation of TMB (3,3’,5,5’-tetramethylbenzidine)
into an intense blue product. This reaction can be stopped at any time by addition of an
acid solution (diluted H2SO4) which results in a deep yellow colour. This product absorbs
light at a wavelength of 450 nm which can be read on a spectrophotometric ELISA plate
reader to give an optical density (OD) reading. The OD of each unknown sample is
converted into a concentration by use of a standard curve.
Protocol 96-well ELISA plates were obtained from Corning Incorporated, Corning, NY,
USA. All washing steps were performed with 0.1% Tween in PBS. The capture antibody
was diluted in PBS and 50 µl was used to coat each well of the 96 well plate. The capture
antibody was left on over night at 4◦C or for 1 h at 37◦C. This was removed prior to
blocking the wells in 100 µl with 2% BSA in PBS for 2 h at room temperature to prevent
non-specific binding. Samples were appropriately diluted in 0.5% BSA in PBS and 50 µl
was added to the plate alongside a serial dilution of a recombinant cytokine (see Table 2.3)
for the standard curve. Samples were incubated on the plate for 2 h at room temperature
or overnight at 4◦C. The plate was washed and 50 µl secondary biotin-conjugated antibody
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Figure 2.6: Sandwich ELISA. In a sand-
wich ELISA, a plate is coated with a
capture antibody which recognises a spe-
cific epitope on the cytokine that needs
to be detected. Cell culture supernatant
is added and the desired cytokine is cap-
tured and immobilised through binding to
the capture antibody. The immobilised cy-
tokine is detected by a secondary biotiny-
lated detection antibody, which then binds
a streptavidin-HRP conjugate. HRP catal-
yses the oxidation of TMB, leading to a
blue colour.
Table 2.4: ELISA antibodies
Specificity Antibody Concentration Source
IL-6 Coat 1µg/ml BD Biosciences, Oxford, UK
Detect 0.5µg/ml BD Biosciences, Oxford, UK
mIL-6 Coat 1.5µg/ml RnD, Minneapolis, USA
Detect 0.2µg/ml RnD, Minneapolis, USA
IL-8 Coat 2µg/ml BD Biosciences, Oxford, UK
Detect 0.5µg/ml BD Biosciences, Oxford, UK
MCP-1 Coat 5µg/ml BD Biosciences, Oxford, UK
Detect 0.5µg/ml BD Biosciences, Oxford, UK
IP-10 Coat 2µg/ml BD Biosciences, Oxford, UK
Detect 0.1µg/ml BD Biosciences, Oxford, UK
ENA-78 Coat 2µg/ml RnD Systems, Minneapolis, USA
Detect 0.1µg/ml RnD Systems, Minneapolis, USA
streptavidin-HRP n.a. 1/400 RnD Systems, Minneapolis, USA
Abbreviations: horseradish peroxidase (HRP)
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diluted in 0.5% BSA in PBS was added to each well and incubated for 1 - 2 h. Thereafter,
50 µl streptavidin-HRP conjugate was added to the washed wells and incubated for 1 h.
Finally, 50 µl TMB peroxidase substrate and peroxidase substrate solution were added
(purchased from KPL, Gaithersburg, USA). The reaction was stopped by addition of 50 µl
1 M H2SO4. Absorbance was read at 450 nm on a spectrophotometric ELISA plate reader
(FLUOstar Omega, BMG Labtech) and analysed using the Omega version 1.02 software.
The standard curve was plotted using a 4 parameter fit algorithm and the concentration
of unknown samples which were within the range of the standard curve was automatically
determined by the Omega software.
In some figures, data from different donors were pooled for statistical analysis. In those
cases, the calculated mean of cytokine secretion was normalised separately for each donor
to the mean of the unstimulated cell fraction. The normalised data was then combined
and plotted as fold induction of cytokine secretion. For the knockdown experiments in
section 3.3 and 3.4, the normalised cytokine induction is displayed as percentage. For each
donor, the total amount of cytokines induced by a certain ligand was directly normalised
to the cytokine induction in untreated control cells.
2.2.2 Western blotting
Background Western blotting is a technique used for detection of specific proteins in a
sample. Proteins are separated using polyacrylamide gel electrophoresis (PAGE) and then
transferred to a membrane (typically nitrocellulose or polyvinylidene difluoride (PVDF)),
where they are detected using antibodies specific to the target protein. In this thesis, all
proteins were separated under denaturating and reducing conditions by sodium dodecyl
sulphate PAGE (SDS-PAGE). SDS is an anionic detergent which denatures proteins and
confers a negative charge to the polypeptide that is proportional to its length. Because
the charge-to-mass ratio is nearly the same among SDS-denatured polypeptides, the final
separation of proteins is almost completely due to differences in molecular weight. Dur-
ing this process a mixture of coloured proteins of known molecular weight are similarly
separated. This provides a basis for determining the size of proteins in comparison to
standards and therefore the expression of specific proteins in cellular lysates can be de-
termined. To obtain optimal resolution of proteins, a stacking gel is cast over the top
of the resolving gel. The stacking gel has a lower concentration of acrylamide, a lower
pH (e.g., 6.8) and a different ionic content. These conditions provide an environment for
Kohlrausch reactions determining molar conductivity. As a result, SDS-coated proteins
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are concentrated into a tight band during the first few minutes of electrophoresis before
entering the resolving portion of a gel. The proteins are transferred from the gel to the
PVDF membrane by electroblotting, where an electric current is used to pull proteins
from the gel into the membrane. The proteins move from within the gel onto the mem-
brane while maintaining the organization they had within the gel. As a result of this
blotting process, the proteins are exposed on a thin surface layer for detection. To de-
tect the proteins, the membrane is ”probed” for the protein of interest with a primary
antibody. Any unbound primary antibody is removed by washing and the membrane is
exposed to a secondary antibody, directed at a species-specific epitope on the primary
antibody. Antibodies come from animal sources or animal hybridoma cultures. An anti-
mouse secondary will therefore bind to almost any mouse-sourced primary antibody. The
secondary antibody is normally linked to horseradish peroxidase (HRP) which cleaves
a chemilumniescent agent, thereby producing luminescence which is proportional to the
amount of protein. A sensitive X-ray film is placed against the membrane and exposed to
the light from the reaction which creates an image of the antibodies bound to the blot.
Preparation of cell extracts In order to investigate intracellular signalling and ex-
pression of the glucose transporter proteins GLUT1 and GLUT4 SDS-PAGE and western
blotting were used. Generally, cells in a 24-well plate were washed in 1 ml ice-cold PBS
and resuspended in 100 µl of a selected lysis buffer containing protease and phosphatase
inhibitors (see Table 2.5). Lysis was performed on ice and the plates were immediately
placed into a - 80◦C freezer until further use. Nuclear extracts in the lysate were removed
by centrifugation in a bench top centrifuge at maximal speed for 10 min at 4◦C, after
which the pellet containing the nuclear extract was discarded.
Protocol for SDS-PAGE The proteins were denatured prior to electrophoresis by
addition of 5 x gel sample buffer (see Table 2.6) and boiling at 95◦C for 5 min. Proteins
were normally resolved on a 10% self-cast gel, but higher percentage gels and Criterion
precast gels (Biorad, Hercules, CA, USA) were also used where indicated. Gels were cast
between two glass plates in a protein Cell II cassette (Biorad). Electrophoresis was carried
out overnight at a voltage of 60-70V for big gels or for 2 h at 120V for midi precast gels.
Protocol for protein transfer Proteins separated by SDS-PAGE were transferred
from the gel onto a PVDF membrane to allow detection by specific antibodies. The
membrane was cut to the size of the gel, hydrated in methanol, and equilibrated in
transfer buffer (Table 2.6). The gel was placed onto three layers of filter paper pre-soaked
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in transfer buffer. The membrane was placed on the gel, ensuring that no air bubbles were
between them, and was overlaid with a further three layers of filter paper. The assembly
was then placed in a transfer cassette (BioRad, UK) that was placed in a transfer tank
(BioRad, UK) containing pre-cooled (4◦C) transfer buffer. The transfer cassette was
oriented so that the membrane was between the gel and the anode. The transfer tank
was attached to a cooling unit and 100V were applied to the cassette for 90 min.
Protocol for protein detection Antibodies used for detection of proteins are sum-
marised in Table 2.7. The membrane containing the transferred proteins was blocked in
5% dried milk powder in TBS/ 0.2% Tween-20 for 1 h and incubated with primary anti-
body overnight at 4◦C under continuous rotation. The membrane was washed 5 times for
10 min in TBS/ 0.2% Tween-20 between each step. To visualise the proteins, the mem-
brane was incubated with secondary HRP-conjugated antibody for 1 h prior to detection
using the chemiluminescent substrate solution ECL. The proteins were visualised by ex-
posing them to Fuji Medical X-Ray Film (Fujifilm) for varying times, and the exposed
films were developed by an automatic film processor (AGFA Cruis-60, AGFA-Gaevert,
Brentford, UK). In most experiments, the membranes were re-probed with a different pri-
mary antibody, after stripping the membrane using the Re-blot Recycling kit (Chemicon
International, CA, USA). Following stripping, the blots were washed with TBS/ 0.2%
Tween-20 before starting the immunodetection procedure.
Table 2.5: Protein extraction buffers
Buffer Composition
Triton lysis buffer 1% (v/v) Triton X100
10 mM Tris-HCl pH 7.6
150 mM NaCl
1 mM EDTA
*0.1 mM Na3VO4
*5 mM NaF
*1x SIGMA protease inhibitor cocktail
Hypotonic lysis buffer 20mM Tris/HCl pH 7.5
5mM EDTA
150mM NaCl
1% (v/v) Triton X100
* Added just before use.
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Table 2.6: Reagents for SDS-PAGE and western blotting
Reagent Composition
10% Resolving Gel 10% acrylamide
375 mM Tris pH 8.8
0.0625% APS
0.0625% TEMED
Stacking Gel 3.75% acrylamide
150 mM Tris pH 6.8
0.1% APS
0.1% TEMED
Running buffer 25 mM Tris-base
195 mM Glycine
0.1% (w/v) SDS
5x protein gel sample buffer 250 mM Tris-HCl pH 6.8
10% (w/v) SDS
50% (w/v) Glycerol
12.5% (v/v) β-mercaptoethanol
(Mix Tris, SDS and water. Heat to 50◦C.
Add glycerol, β-mercaptoethanol
and bromophenol blue)
Transfer buffer 25 mM Tris base
192 mM Glycine
20% (v/v) Methanol
Wash buffer 20 mM Tris pH 7.6
137mM NaCl
0.2% Tween 20
Blocking buffer (milk) Wash buffer
5% (w/v) skimmed milk powder
Abbreviations: Ammonium persulfate (APS), sodium dodecyl sulfate(SDS),
tetramethylethylenediamine (TEMED)
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Table 2.7: Western blotting antibodies
Specificity Species Dilution Source
Akt-P rabbit 1/1000 Cell Signaling, Danvers, USA
Akt rabbit 1/1000 Cell Signaling, Danvers, USA
GLUT1 mouse 1/1000 Abcam, Cambridge, UK
GLUT4 rabbit 1/2000 Abcam, Cambridge, UK
IκB-α rabbit 1/1000 Santa Cruz Biotechnology, USA
IL-1β rabbit 1/1000 Cell Signaling, Danvers, USA
p38 mouse 1/1000 Abcam, Cambridge, UK
STAT3 mouse 1/2000 Santa Cruz Biotechnology, USA
anti-mouse IgG HRP sheep 1/2000 GE Healthcare, Little Chalfont, UK
anti-rabbit IgG HRP donkey 1/2000 GE Healthcare, Little Chalfont, UK
Abbreviations: horseradish peroxidase (HRP)
Table 2.8: Flow cytometry antibodies
Specificity Species Dilution Source
CD45-FITC mouse 1/25 BD Pharmingen, San Diego, USA
CD73-PE mouse 1/25 BD Pharmingen, San Diego, USA
TLR-1 FITC mouse 1/25 Abcam, Cambridge, UK
TLR-2 FITC mouse 1/25 Imgenex, San Diego, USA
TLR-2 PE mouse 1/25 Imgenex, San Diego, USA
TLR-3 FITC mouse 1/25 Imgenex, San Diego, USA
TLR-4 FITC mouse 1/25 Imgenex, San Diego, USA
TLR-5 FITC mouse 1/25 Imgenex, San Diego, USA
TLR-6 FITC mouse 1/25 Imgenex, San Diego, USA
TLR-7 FITC rabbit 1/25 Imgenex, San Diego, USA
TLR-8 FITC mouse 1/25 Imgenex, San Diego, USA
TLR-9 FITC mouse 1/25 Imgenex, San Diego, USA
IgG1 PE mouse 1/25 BD Pharmingen, San Diego, USA
IgG2b PE mouse 1/25 BD Pharmingen, San Diego, USA
IgG FITC rabbit 1/25 Imgenex, San Diego, USA
IgG1 FITC mouse 1/25 Imgenex, San Diego, USA
IgG2a FITC mouse 1/25 SIGMA, Steinheim, GER
Abbreviations: Fluorescein isothiocyanate (FITC), phycoerythrin (PE)
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2.2.3 Fluorescence activated cell sorting (FACS)
Background Flow cytometry is a technique that is commonly used for identifying and
quantifying cell surface and intracellular proteins by means of their interaction with spe-
cific antibodies [359]. The cells are passed through the light of one or more lasers in the
FACS machine, both scattering light and emitting fluorescence. The light scatter provides
some information regarding the morphology of the particles, which can be analysed using
forward and sideward scatter. A fluorochrome coupled to the antibody emits light when
excited by a laser, and the light intensity is directly proportional correlated to the amount
of antigen present on/in the cell. In contrast to western blotting, FACS analysis allows
investigation of antigen expression on individual cells instead of whole cell culture.
Protocol Human preadipocytes were harvested using pre-warmed cell dissociation solu-
tion, for 20 min at 37◦C. 5 x 105 cells/condition were then washed in ice-cold FACS wash
buffer (5% human serum and 0.02% (v/v) NaNO3 in PBS). All washing steps consisted
of a spin cycle at 400 g for 5 min. To determine the location of the protein of interest,
the cells were surface- as well as intracellular stained. All FACS antibodies were titrated
to determine the optimum concentration for cell labelling. They are summarised in Table
2.8.
For surface staining, the cell surface was blocked for 15 min on ice in FACS wash
buffer. Following the blocking, the cells were washed once and then incubated with 10
µg/ml of the antibody and isotype controls (see Table 2.8) for 30 min on ice. Thereafter,
the cells were washed 3 times with FACS wash buffer and fixed using 0.5% formaldehyde
in PBS prior to analysis.
For intracellular staining, the cells were washed, blocked and fixed by incubation in
0.5% formaldehyde in PBS for 5 - 10 min on ice followed by triple washing with FACS
wash buffer. The cells were permabilised by incubation in FACS wash buffer containing
0.1% saponin. Thereafter, the cell were incubated for 1 h with 10 µg/ml of the cor-
responding antibody (including isotype control), followed by 3 washes with FACS wash
buffer containing 0.1% saponin. Then the cells were re-suspended in FACS wash buffer.
All cells were analysed on a Becton-Dickinson LSR flow cytometer by first gating on the
live cells and followed by quantification of the fluorescence intensity in the FITC or PE
channel (depending on the antibody used).
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2.2.4 Detection and quantification of mRNA transcript
2.2.4.1 Isolation of RNA
Preadipocyte and macrophage RNA was isolated using the QIAamp RNA Blood from
Qiagen, Maryland, USA according to the manufacturer’s instruction. Adipocyte RNA was
isolated using the RNeasy Lipid Tissue Mini Kit (Qiagen). Cell lysates were homogenised
by centrifugation through a shredder column. Ethanol was added leading to precipitation
of DNA and RNA. The sample was then applied to another spin column where RNA
could selectively bind to a silica-based membrane. Contaminants such as genomic DNA,
RNAses and enzyme inhibitors were washed away using salt containing solutions and total
RNA was finally eluted in 50 µl of RNase-free water.
2.2.4.2 Reverse transcription
For conventional PCR, potential DNA contamination was removed by DNAse digestion
using the TURBO DNA-freeTM kit (Ambion, Austin, USA) according to manufacturer’s
instructions. This kit contains a modified form of DNaseI protein which is then inactivated
and removed from the RNA after digestion. Total RNA was reverse-transcribed with
Superscript II RNase H-reverse transcriptase and oligo(dT) primer (Life Technologies,
Inc., Grand Island, NY) for 2 h at 42◦C. The reaction was terminated at 65◦C for 10 min
in order to inactivate the enzyme.
2.2.4.3 PCR
Background The polymerase chain reaction (PCR) is used to amplify a specific region
of DNA [360]. The method relies on thermal cycling, consisting of a series of 20 - 40 cycles
of repeated heating and cooling for DNA melting and enzymatic DNA replication. Each
cycle consists of usually 3 discrete temperature steps: Denaturation (DNA melting by
disruption of hydrogen bonds at 94◦C - 96◦C), Annealing (Binding of primers to the DNA
template at 65◦C) and Elongation (Synthesis of new DNA at 72◦C by the thermostable
Taq polymerase). The amplified product is then loaded onto an agarose gel to see whether
it has the desired molecular size.
Quantification of mRNA can be achieved by performing quantitative reverse transcript-
ase-PCR (qRT-PCR) whereby mRNA is first reverse-transcribed to its complementary
DNA (cDNA) sequence by the action of an enzyme from an RNA virus (called reverse
transcriptase). The cDNA from this reaction is then amplified by PCR on a real-time
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basis. Currently four different chemistries are available for real-time PCR: TaqMan (Ap-
plied Biosystems, Foster City, CA, USA), Molecular Beacons, Scorpions and SYBR Green
(Molecular Probes). They all allow detection of PCR products via the generation of a
fluorescent signal. In the course of my thesis I made use of the SYBR Green and TaqMan
method which are described in more detail in the next two paragraphs.
SYBR Green is a fluorescent dye that binds the minor groove of double-stranded DNA
and as the DNA is amplified the dye produces a signal that is directly proportional to
the DNA concentration. Since this method detects any double stranded DNA including
primer dimers, contaminating DNA, and PCR product from misannealed primers, the
melting curve was analysed for each reaction.
TaqMan probes rely on the 5’-3’ exonuclease activity of the Taq polymerase to cleave
a dual-labelled probe during hybridisation to the complementary target sequence. The
probes are oligonucleotides that consist of a fluorophore covalently attached to the 5’-end
and a quencher at the 3’-end. The quencher quenches the fluorescence emitted by the
fluorophore when excited by the cycler’s light source via fluorescence resonance energy
transfer (FRET). TaqMan probes are designed to hybridise to an internal region of a
PCR product. In the unhybridised state, the proximity of the fluor and the quench
molecules prevents the detection of fluorescent signal from the probe. During PCR, when
the polymerase replicates a template on which a TaqMan probe is bound, the 5’-nuclease
activity of the polymerase cleaves the probe. This releases the fluorophore from the probe
and breaks its close proximity to the quencher, allowing fluorescence of the fluorophore.
Hence, fluorescence increases in each cycle and is directly proportional to the amount of
probe cleavage and the amount of the PCR product.
Protocol for conventional PCR The range of TLRs expressed in human adipocytes
was analysed by conventional PCR. The primer sequences used for human TLR amplifi-
cation are listed in Table 2.9. They were all purchased from MWG, Ebersberg, Germany.
PCR amplification consisted of 40 cycles with an annealing temperatures of 60◦C for
TLR6, 7, 8, 9 & 10, 58◦C for TLR1, 4 & 5 and 62◦C for TLR2 & 3. The reaction was per-
formed in a Dyad PCR machine (MJ Instruments, Waltham, MA). After amplification,
the products were run on a 1.5% agarose gel containing ethidium bromide (a fluorescent
agent intercalating with DNA) and visualised under UV illumination.
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MATERIALS AND METHODS
Protocol for SYBR Green SYBR Green PCR was performed to analyse differentiation-
induced expression of the adipogenic gene FABP4. The primer sequences used for human
FABP4 amplification are listed in Table 2.9. Reverse transcribed cDNA was amplified
using the SYBR R©Premix Ex TaqTMmaster mix (Takara Bio USA). For a 12 µl reaction
volume, 0.1 µl of forward/reverse primer and 2.8 µl H2O was added to 6 µl master mix.
Amplification and analysis was performed as described in the next paragraph.
Protocol for TaqMan analysis Isolated mRNA (2 µl) was amplified in a 10 µl reaction
mix containing 5 µl 2x reaction buffer (Eurogentec), 0.5 µl 20x probe master mix (Applied
Biosystems), 0.05 µl enzyme (HotGoldStar; Eurogentec) and 2.45 µl RNAse-free H2O.
Assay-On-Demand premixed TaqMan probe master mixes for real-time qRT-PCR are
summarised in Table 2.10. They were purchased from Applied Biosystems, CA, USA.
Amplifications were conducted in triplicates on a Rotor-Gene 6000 (Corbett Research,
UK) for 40 cycles using the following parameters: reverse transcription at 48◦C for 30
min, denaturation at 95◦C for 10 min and then 40 cycles of denaturation at 95◦C for
3 s and annealing of primer and DNA synthesis at 60◦C for 35 s. Data was analysed
using the Rotor-gene 6000 real-time rotary analyser software (Corbett Research, UK). A
cycle threshold (Ct) was set to a level where the fluorescence was increasing exponentially.
Relative gene expression was calculated using the 2−∆∆CT method (section 2.2.4.4).
Table 2.10: TaqMan probes
Description Gene Probe No.
Adiponectin ADIPOQ Hs00605917m1
ARP RPLP0 Hs99999902m1
GLUT1 SLC2A1 Hs00892681m1
GLUT4 SLC2A4 Hs00168966m1
IL-1β IL1B Hs01555410m1
IL-6 IL6 Hs999999032m1
IP-10 CXCL10 Hs00171042m1
Mal/TIRAP TIRAP Hs01591922m1
MyD88 MYD88 Hs00182082m1
TRIF TICAM1 Hs01090712m1
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2.2.4.4 Analysis of relative gene expression by the 2−∆∆CT method
The analysis of relative gene expression was performed using the 2−∆∆CT method [361].
With this method, the data are presented as the fold change in gene expression normalised
to an endogenous reference gene and relative to a calibrator or untreated control. The
threshold cycle (CT ) indicates the cycle number in a PCR where the amount of amplified
target reaches a fixed threshold. It is determined from a log-linear plot of the PCR signal
versus the cycle number and therefore relates to the exponential phase of amplification.
The ∆CT of a sample is defined as CT (analysed gene) - CT (reference gene). To express
this difference in relation to an untreated control, the ∆∆CT is calculated which is:
∆CT , sample - ∆CT , control. To account for the exponential nature of the ∆∆CT the
term is finally converted into the linear form by the 2−∆∆CT calculation. In this thesis, the
acidic ribosomal protein (ARP, also known as large ribosomal protein P0, gene symbol:
RPLP0 ) was used as the endogenous reference gene and untreated cells or preadipocytes
were used as the calibrator.
2.2.5 Cell separation for analysis of gene expression in adipocytes
vs the stromal vascular fraction (including preadipocytes)
The protocol for separation of adipocytes from undifferentiated preadipocytes and the
SVF was kindly provided by the group of Prof. Michael K. McIntosh, Department of
Nutrition, Greensboro, USA.
Background Mixed cultures of undifferentiated preadipocytes and adipocytes can be
separated by centrifugation in a solution with the density of 1.03 mg/ml. Undifferentiated
cells will pellet as their density is approximately 1.09 mg/ml. Differentiated adipocytes
float as their density is slightly less than 1.03 mg/ml. Prior to separation, cells are
treated as required and then brought into suspension. The cell suspension is layered on
a 1.03 mg/ml separation solution containing iodixanol (OptiPrepTM) which forms a self-
generated, uniform gradient during centrifugation, leading to cell separation according to
their density. Centrifugation at a low temperature slows down metabolism and minimises
changes in gene expression during separation. Pelleted SVF (including preadipocytes) are
lysed separately from floating adipocytes and RNA is extracted as described in section
2.2.4.1.
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Figure 2.7: Cell separation by density
centrifugation. Mixed cultures of undif-
ferentiated preadipocytes and adipocytes can
be separated by centrifugation in a solution
with the density of 1.03 mg/ml. Undiffer-
entiated cells will pellet as their density is
approximately 1.09 mg/ml. Differentiated
adipocytes float as their density is slightly
less than 1.03 mg/ml.
Protocol Cultures of in vitro differentiated adipocytes were incubated for 3 or 48 h
in medium containing 10 ng/ml LPS. Thereafter, cells were rapidly washed with PBS to
remove the culture medium. EDTA was added to the buffer to chelate remaining ions
that interfere with detachment of cells from the plate. This was followed by addition of
cell dissociation buffer (SIGMA) to detach cells from the plate. The cell suspension was
loaded onto the top of the separation solution (9 ml HBSS, 1 ml OptiPrepTM , 5% BSA)
and then centrifuged at 800 g for 30 min at 4◦C. After centrifugation, floating adipocytes
were collected and spun for another 3 min at 1000 g in a bench top centrifuge, whereas
the pellet containing the SVF and preadipocytes was directly lysed for RNA extraction.
2.2.6 Cytokine/Adipokine array
A proteomic approach was used to to identify novel cytokines/adipokines released by
human adipocytes. Human Adipokine Antibody Array 1 (AAH-ADI-1) and Human Cy-
tokine Antibody Array C Series 1000 (AAH-CYT-1000) were obtained from RayBiotech,
Norcross, GA, USA. Both are membrane antibody arrays that recognise cytokines and
adipokines in cell supernatant. In vitro differentiated adipocytes of one donor, which
behaved as expected in other assays, were cultured with TLR ligands over a period of
48 h in 1% DMEM. After 48 h, conditioned media of stimulated cells was removed to
analyse protein secretion. Conditioned media of untreated cells of the same donor was
included as a control. All buffers and antibodies used for protein detection were provided
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by RayBiotech and were prepared according to the manufacturer’s instruction. Array
membranes were first blocked in 2 ml of blocking buffer and incubated for 30 min at RT.
1 ml of undiluted conditioned media was then added and incubated at 4◦C overnight. The
following morning, membranes were washed 5 times for 5 min with 2 ml of 1x washing
buffer. Thereafter, membranes were incubated with 1 ml of biotin-conjugated antibody
solution for 2 h at RT. After additional washes, 2 ml of 1000-fold diluted HRP-conjugated
streptavidin was added to each membrane and left on for another 2 h. For protein detec-
tion, membranes were incubated for 2 min with detection buffer. Membranes were exposed
to Kodak X-Omat film at RT for 30 s - 5 min and the exposed films were developed by
an automatic film processor as before. Relative intensity of each dot was quantified by
densitometry analysis using the phoretix version 5.2 software (Nonlinear Dynamic Ltd,
Newcastle, UK). Positive control dots on each membrane were used to normalise the re-
sults from different membranes against each other. By comparing the signal intensities,
relative expression levels of produced cytokines/adipokines could be calculated. Data
was finally analysed by the RayBio Analysis Tool from RayBiotech, which facilitated the
compiling and organisation of the data.
2.2.7 3H-2-deoxy-D-glucose (3H-2DOG) uptake assay
Background In order to investigate glucose uptake in adipocytes I first had to establish
a 3H-2DOG Uptake Assay [362]. 2DOG is a glucose analogue which has the 2-hydroxyl
group replaced by a hydrogen. As with normal glucose, 2DOG is taken up by the glucose
transporters of the cell. However, in contrast to normal glucose, 2DOG is not metabolised
by the cell and it can therefore be detected in the cytosol after it has been taken up [363].
The 2DOG molecule used in this thesis is labelled with tritium which is a radioactive
isotype of hydrogen. As tritium is a low-energy beta emitter its radiation can be detected
by liquid scintillation counting, whereby beta particles emitted from tritium in the sample
transfer energy to fluors present in the scintillation cocktail [364]. The excited fluor
molecules dissipate the energy by emitting light which is then detected in the counter as
decays per minute (dpm), and so the number of dpm is directly proportional to 2DOG
uptake by the cell.
Protocol After insulin stimulation, glucose uptake activity was analysed by measuring
the uptake of the glucose analog 3H-2DOG by the cells. For this, preadipocytes were
seeded in 12-well plates and allowed to differentiate for 14 - 21 days. Two days prior
to the experiment, media was exchanged for low glucose containing DMEM (1g/L) with
104
MATERIALS AND METHODS
F
ig
u
re
2.
8:
3
H
-2
-d
e
o
x
y
-D
-g
lu
co
se
(2
D
O
G
)
u
p
ta
k
e
a
ss
a
y
.
A
d
ip
o
cy
te
s
in
a
12
-w
el
l
p
la
te
w
er
e
in
cu
b
at
ed
fo
r
48
h
in
th
e
p
re
se
n
ce
of
T
L
R
li
ga
n
d
s
or
m
ed
ia
al
on
e.
In
su
li
n
at
a
fi
n
al
co
n
ce
n
tr
at
io
n
of
20
0n
M
w
as
ad
d
ed
to
st
im
u
la
te
th
e
ce
ll
s
fo
r
30
m
in
,
fo
ll
ow
ed
b
y
ad
d
it
io
n
of
3
H
-2
D
O
G
fo
r
an
ad
d
it
io
n
al
10
m
in
.
T
h
er
ea
ft
er
,
ce
ll
s
w
er
e
w
as
h
ed
,
ly
se
d
an
d
ra
d
io
ac
ti
v
it
y
of
ea
ch
sa
m
p
le
w
as
m
ea
su
re
d
b
y
li
q
u
id
sc
in
ti
ll
at
io
n
co
u
n
ti
n
g.
105
CHAPTER 2
10 % FCS and either the presence or absence of TLR ligands. After 48 h cells were
washed three times with Krebs-Ringer-HEPES (KRH) buffer (128 mM NaCl, 4.7 mM
KCl, 1.25 mM CaCl2, 1.25 mM MgSO4, 25 mM HEPES, pH 7.4) and incubated for 2 -
3 h in 1 ml KRH containing 0.5% BSA and 2 mM sodium pyruvate. Thereafter, insulin
(final concentration: 200nM) was added and cells were stimulated at 37◦C for 30 min.
Glucose uptake was initiated by adding 20 µl KRH buffer containing hot (3H-2DOG;
Perkin Elmer) and cold 2DOG (Sigma) at a ratio of 1:100 (final concentration: 100 µM,
1 µCi per well). The uptake was terminated after 10 min by washing the cells 3x with
ice-cold PBS. Cells were lysed in 1% SDS and radioactivity of each sample was measured
by liquid scintillation counting. For this, the lysate was transferred to a scintillation vial
and 4 ml of scintillation cocktail (GOLD STAR, Meridian Biotechnologies, Epsom, UK)
was added per vial. Scintillation was read on a Hidex 300 SLTMliquid scintillation counter
(Hidex Oy, Turku, Finland). Each assay was performed in triplicate and raw data were
expressed as disintegrations per minute (dpm). For analysis, the counts in dpm for each
sample were normalised to the untreated, unstimulated control.
2.2.8 Confocal microscopy for GLUT4 translocation
Background Traditional wide-field fluorescence microscopy has its limitations: As the
entire specimen is flooded evenly in light, all parts of the specimen in the optical path are
excited at the same time and the resulting image includes a large amount of unfocused
background. This problem is overcome by confocal microscopy, which uses point-by point
illumination of the specimen and a pinhole in an optically conjugate plane in front of
the detector. The pinhole blocks out-of-focus light from the specimen that is not from
the microscope’s focal plane, thereby increasing optical resolution and contrast of the
micrograph. As each acquired image only represents a thin cross-section of the specimen,
fine details are observed. The thin slices can be assembled together to create a three-
dimensional reconstruction of the specimen.
HA-GLUT4-GFP plasmid The HA-GLUT4-GFP plasmid was a kind gift from Prof.
Jeremy Tavare´, University of Bristol, UK. Details of its construction are described in Daw-
son et al. [365] (see Figure 2.9). The hemagglutinin (HA)-tagged human GLUT4 gene
from a pHA-GLUT4 vector in-frame with the enhanced green fluorescent protein (GFP)
at the GLUT4 C-terminus in the GFP expression vector pQBI25 (Quantum Biotechnolo-
gies, Montreal, CA). The plasmid was transfected into adipocytes by calcium phosphate
transfection as described in section 2.1.14.
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Figure 2.9: Schematic illustration of HA-GLUT4-GFP plasmid construction.
The HA-GLUT4-GFP plasmid was generated by Dawson et al. [365] from the pHA-
GLUT4 vector [366] and the GFP expression vector pQBI25 (Quantum Biotechnologies,
Montreal, CA). The restriction sites Hind III and Kpn I were initially inserted into the
pQBI25 plasmid upstream of the GFP gene. pHA-GLUT4 was cloned into these site
in-frame with GFP, where the STOP codon was replaced by a Gly and Thr residues.
GFP allows for visualisation of total distribution of GLUT4 whereas the HA-tag allows
for visualisation of GLUT4 localised at the cell surface. This was achieved by staining
the unpermabilised cell with anti-HA antibodies. The HA-GLUT4 sequence without the
STOP codon was then inserted in between these restriction sites to yield pHA-GLUT4-
GFP.
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Protocol for HA-GLUT4-GFP translocation assay In order to investigate insulin-
stimulated translocation of GLUT4, differentiated adipocytes on 18mm cover slips (VWR
International) in a 12-well plate were transfected with the HA-GLUT4-GFP plasmid
and then treated with TLR ligands as required (section 2.1.11). Thereafter, cells were
stimulated with 200 nM insulin for 30 min (or left unstimulated) and immediately fixed in
4% (w/v) paraformaldehyde for 15 min at RT. After fixing, cells were washed 3 times in
PBS before being blocked in PBS containing 3% BSA, 1% goat serum and 1% mouse serum
for 45 min at RT. Thereafter, block was removed and cells were incubated with mouse
monoclonal anti-HA (Covance, Emeryville, USA) at a dilution of 1:500 in 3% BSA/PBS
at RT. After 45 min, primary antibody was removed and cells were washed 5 times with
PBS. Surface bound anti-HA was detected using goat anti-mouse IgG labelled with Alexa
Fluor 633 (Molecular Probes, Oregon, USA) at a dilution of 1:1000 in 3% BSA/PBS for 45
min at RT. Secondary antibody was finally removed by washing cells 5 times in PBS. Cells
were mounted onto glass slides using hydromount (National Diagnostics, Sommerville, NJ,
USA).
Table 2.11: Antibodies for confocal microsopy
Specificity Species Dilution Source
HA.11 mouse 1/500 Covance
anti-mouse Alexa Fluor 633nm goat 1/1000 Molecular Probes
Acquisition and analysis Cells expressing the HA-GLUT4-GFP construct were iden-
tified based on their GFP fluorescence. Images of HA-GLUT4-GFP expressing cells were
collected for both the 530 nm (GFP) and the 633 nm (HA) channel. The settings were
kept constant during the collection to ensure that the measured intensities were compara-
ble between the cells. For each condition within the experiment, 25 slices were collected
per cell and 3 cells were acquired per condition. Data was acquired at the Henry Well-
come Laboratory for Cell Imaging at the University of East Anglia, Norwich, UK, on
a Zeiss LSM510 Meta confocal microscope, with the kind help of Dr. Paul Thomas.
Quantitative analysis was performed using the Volocity software. A region of interest was
assigned to each HA-GLUT4-GFP expressing cell based on its GFP fluorescence. This
was then transferred to the HA channel so that the area of the region of interest was
identical for both channels. The Fluorescence intensity (F) within the area of interest
was determined for both channels for each layer of the cell. The mean fluorescence in-
tensity of the surface (FSURFACE(HA)) was then divided by the mean total fluorescence
intensity of the cell (FTOTAL(GFP )). This HA/GFP ratio represents the surface-to-total
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distribution of HA-GLUT4-GFP plasmid and can be used to quantify the appearance of
GLUT4 to the cell surface in response to insulin stimulation, so that GLUT4 translocation
= FSURFACE(HA)/FTOTAL(GFP ).
2.2.9 Lipolysis assay
Background Lipolysis is the hydrolysis of triglycerides into free fatty acids and glyc-
erol. Glycerol can be detected by a coupled enzyme reaction whereby glycerol is first
phosphorylated by glycerol kinase (GK) forming glycerol-1-phosphate (G-1-P). G-1-P is
then oxidised by glycerol phosphate oxidase (GPO) to dihydroxyacetone phosphate (DAP)
and hydrogen peroxide (H2O2). Peroxidase (POD) catalyses the coupling of H2O2 with
4-aminoantipyrine (4-AAP) and sodium N-ethyl-N-3-sulfopropyl m-anisidine (ESPA) to
produce a quinoneimine dye that shows an absorbance maximum at 540 nm. The increase
in absorbance at 540 nm is directly proportional to the free glycerol concentration of the
sample.
Protocol Glycerol release into the cell culture medium was determined by using the
Free Glycerol Reagent kit from SIGMA (Saint Louis, Missouri, USA). The kit is based
on a coupled enzyme reaction as described in the previous paragraph. Cells in a 96 well
plate were incubated in the presence of TLR ligands for 3 days. Free glycerol reagent
and the standard curve were prepared according to the manufacturer’s instruction. 25
µl of standard/sample was mixed with 175 µl of free glycerol reagent in a ELISA plate.
Absorbance was read after 15 min at 540 nm on a spectrophotometric ELISA plate reader
to give an optical density (OD) reading. The OD of each unknown sample was converted
into a concentration by using the standard curve ranging from 2031 ng/ml up to 130
µg/ml.
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Figure 2.10: Glycerol Assay Enzymatic Reactions. The glycerol detection assay
is based on a cascade of enzyme reactions, whereby glycerol is first phosphorylated
by glycerol kinase (GK) to form glycerol-1-phosphate (G-1-P). G-1-P is oxidised by
glycerol phosphate oxidase (GPO) to dihydroxyacetone phosphate (DAP) and hydro-
gen peroxide (H2O2). Peroxidase (POD) finally catalyses the coupling of H2O2 with
4-aminoantipyrine (4-AAP) and sodium N-ethyl-N-3-sulfopropyl m-anisidine (ESPA) to
produce a quinoneimine dye.
Table 2.12: RNAi oligonucleotides
Target Gene Symbol siRNA ID Source
Negative Control AM4635 Ambion, CA, USA
(Scrambled)
MyD88 MYD88 s9136 Ambion, CA, USA
MyD88 MYD88 s224080 Ambion, CA, USA
GLUT1 SLC2A1 s12925 Ambion, CA, USA
GLUT1 SLC2A1 s12927 Ambion, CA, USA
GLUT4 SLC2A4 s12935 Ambion, CA, USA
GLUT4 SLC2A4 s12936 Ambion, CA, USA
STAT3 STAT3 s743 Ambion, CA, USA
STAT3 STAT3 s6880 Ambion, CA, USA
TRIF TICAM1 s45113 Ambion, CA, USA
TRIF TICAM1 s45115 Ambion, CA, USA
Mal TIRAP s195607 Ambion, CA, USA
Mal TIRAP s41563 Ambion, CA, USA
TLR2 TLR2 s168 Ambion, CA, USA
TLR2 TLR2 s169 Ambion, CA, USA
TLR3 TLR3 s236 Ambion, CA, USA
TLR3 TLR3 s235 Ambion, CA, USA
TLR4 TLR4 s14195 Ambion, CA, USA
TLR4 TLR4 s14194 Ambion, CA, USA
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2.3 RNA Interference (RNAi)
Background Long double-stranded RNAs (typically > 200 nt) can be used to silence
the expression of target genes in a variety of organisms and cell types. This phenomenon
was first discovered in plants in the early 1990s and later in the nematode Caenorhabditis
elegans by Craig C. Mello and Andrew Fire [367]. Upon introduction, the long dsRNAs
enter a cellular pathway known as the RNA interference (RNAi) pathway. First, the
dsRNAs are processed into 21 - 23 nucleotide (nt) small interfering RNAs (siRNAs) by an
enzyme called Dicer [368]. Next, the siRNAs are recognised by the RNA-induced silencing
complex (RISC) [369]. The siRNA strands then guide the RISCs to complementary
mRNA molecules, where they cleave and degrade the target mRNA [370].
In practice, short synthetic siRNA can be be directly introduced into the cell, therefore
circumventing Dicer. According to Whitehead et al. [371], this short-cut should reduce the
potential for an innate immune IFN response which can occur following the introduction
of long pieces (> 30 nt) of dsRNA into the cell.
Protocol For RNAi in adipocytes, cells that had been differentiated for 14 days were
transfected with targeting siRNA using the siIMPORTERTM siRNA transfection reagent
from Upstate (Milton Keynes, UK) as described in section 2.1.14. RNAi oligonucleotides
were used at a concentration ranging from 10 nM - 100 nM and are summarised in
Table 2.12. All experiments with transfected cells were performed on day 2 - 3 following
transfection. Cells transfected using the DharmaFECT or electroporation method showed
loss of viability 24 h after transfection and therefore these methods could not be used for
this study.
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TLR function and signal
transduction in primary human
adipocytes
Based on the potential link between TLR4 and obesity-induced insulin resistance and
the ability of murine adipocytes to respond to TLR ligands [12, 178], I hypothesised
that human adipocytes might also express functional TLRs and that TLR activation in
adipocytes may play a key role in mediating insulin resistance and T2DM in obesity. To
investigate this hypothesis, I established a model of primary human in vitro differenti-
ated adipocytes derived from subcutaneous adipose tissue of healthy human donors (see
sections 2.1.4 and 2.1.6). I then used this model to define the TLR expression pattern
in adipocytes and the unique responsiveness of these cells to common TLR ligands. Fol-
lowing on from this I went on to study NF-κB signalling following stimulation with these
ligands and investigated the participation of different TLR adapter molecules in TLR sig-
nalling in adipocytes. To my knowledge, this study is the first description of TLR adapter
usage in adipocytes. Inhibiting TLR-induced inflammatory signalling in adipocytes by
specifically targeting its adapter molecules may form the basis of future treatments for
the metabolic syndrome and other obesity-related conditions.
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3.1 Investigation of TLR expression by RT-PCR and
FACS analysis
In order to investigate whether human adipocytes might express TLRs, similarly to murine
adipocytes, I initially used a FACS approach with antibodies directed against TLR2,
TLR3, and TLR4. Attempts with in vitro differentiated adipocytes were not successful,
however, since these highly lipidated cells are extremely agglutinant and fragile which
causes them to lyse in the FACS machine. In addition, their decreased density makes
them difficult to wash, because they do not pellet under centrifugation and, instead,
float on the surface where they easily stick to the rim of the tube. Therefore TLR protein
expression was instead examined in preadipocytes as well as primary human macrophages
as a positive control. As shown in Figure 3.1, I was able to show that preadipocytes, like
macrophages, express a high amount of both intracellular and cell surface TLR4, with
the antibodies causing a substantial shift in the mean fluorescent intensity of gated live
cells. In contrast, no shift in fluorescence was seen for antibodies directed against TLR2
and TLR3 proteins, despite similar conditions successfully detecting their presence in
macrophages. This suggests that either these TLRs are not expressed, or potentially that
they might be expressed to a very low level, below the detection limit of the antibody
used.
Because of the limitations of the FACS approach, and a lack of good western blot
antibodies, I instead approached this question by examining whether the cells express the
mRNA for the different TLRs. Here, total RNA was isolated from preadipocytes and
in vitro differentiated adipocytes derived from both subcutaneous and visceral adipose
tissue and used as a template for RT-PCR. In addition, primary human macrophage
RNA was used as a positive control, since they are known to express all TLRs 1 - 10 [170].
Using the PCR primers described in Table 2.9, specific amplification of each TLR could
be demonstrated in macrophages, in each case giving a single band of the expected size
(Figure 3.2). Furthermore, no amplification in the no template controls indicated a lack of
contamination of reagents. In contrast to FACS analysis, I found that both preadipocytes
and adipocytes express the mRNA for TLR2, TLR3 and TLR4. Furthermore, all of the
known human TLRs (TLR1 - TLR10 ) could be successfully amplified by this method
(Figure 3.2), although some of the bands showed lower intensities. This PCR was only
semi-quantitative, and therefore, although this might reflect lower expression of these
TLRs, this was not investigated in more detail by this method.
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Figure 3.1: TLR4 protein is highly expressed in human preadipocytes. Flow cy-
tometry of preadipocytes for TLR expression. Top panel: surface stain of preadipocytes
for TLR2 and TLR4; middle panel: intracellular staining of preadipocytes for TLR2, 3
and 4; bottom panel: monocyte-derived human macrophages were stained for extracel-
lular TLR2, intracellular TLR3 and extracellular TLR4 as a positive control. Figure is
representative of 3 independent donors.
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Figure 3.2: Human adipocytes express mRNA for all known human TLRs. RNA
was extracted from preadipocytes, adipocytes and monocyte-derived human macrophages
to generate cDNA, which was subsequently analysed by RT-PCR for the expression of
TLRs. cDNA from primary human monocyte-derived macrophages was used as a positive
control. The bands were detected at their predicted size (see Table 2.9 on page 100) when
compared to molecular weight size markers. This figure is representative of 3 independent
donors.
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3.2 Responsiveness to TLR ligands
3.2.1 Investigation of cytokine response to TLR 1 - 9 ligands
In order to examine the response of adipocytes to TLR ligands, preadipocytes and in vitro
differentiated adipocytes were stimulated with a panel of TLR ligands. As for differentia-
tion, the FCS may affect cell stimulation. Three different types of sera (GIBCO, Biosera,
PAA) were therefore tested for suitability. Both GIBCO and Biosera led to a strong induc-
tion of cytokines whereas the response in the presence of PAA was slightly weaker. Since
GIBCO was already found to be optimal for cell differentiation (Figure 2.4, page 84), the
same batch was used throughout. Cells were plated into a 96-well plate at a density of 104
cells/well to perform a dose titration using the following ligands: Pam3CSK4 (TLR1/2),
MALP-2 (TLR2/6), poly(I:C) (TLR3), LPS (TLR4), Flagellin (TLR5), R848 (TLR7/8)
and CpG (TLR9). The concentrations of TLR ligands used were based on other protocols
in the laboratory used for stimulation of macrophages. Supernatant of stimulated cells
was harvested after 6 h to determine levels of IL-6, IL-8 and MCP-1 (Figure 3.3). This
revealed a unique TLR responsiveness pattern in preadipocytes and adipocytes. Stimu-
lation of (pre-)adipocytes with TLR 2, 3 and 4 ligands (Pam3CSK4, MALP-2, poly(I:C),
LPS) resulted in a strong dose-dependent induction of cytokine secretion. However, cells
were not responsive to stimulation with Flagellin, R848 or CpG, indicating that TLR5,
TLR7/8 and TLR9 are either not expressed or not functional in this model system.
Stimulation of TLR 3, 4, 7/8 and 9 can induce anti-viral immune responses by trig-
gering the production of type I IFN [372]. As IP-10 is an IFN target gene [373], this
response can be detected indirectly by assaying IP-10 secretion after 24 h. Preadipocytes
and adipocytes were stimulated with increasing concentrations of poly(I:C), LPS, R848
and CpG. Supernatant of stimulated cells was harvested to determine IP-10 secretion. As
shown in Figure 3.4A, poly(I:C) stimulation resulted in strong dose-dependent induction
of IP-10. This was in agreement with induction of IP10 mRNA, which was strongly in-
duced by poly(I:C), showing an exponential increase between 1 and 16 h (Figure 3.4B).
However, cells were not responsive to stimulation with R848 or CpG. LPS, previously
found to be a potent inducer of pro-inflammatory cytokines (Figure 3.3), did not lead to
substantial production of IP-10 (Figure 3.4A), although it has to be mentioned that in
some donors a very small, but distinctive, response to LPS was observed. Accordingly,
only a very modest induction of IP10 mRNA could be observed in response to LPS in
comparison with poly(I:C) (Figure 3.4B).
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Figure 3.3: Stimulation with ligands for TLR 2, 3 and 4 triggers production
of pro-inflammatory cytokines. Primary subcutaneous human preadipocytes and
in vitro differentiated adipocytes were plated into a 96-well plate at a density of 104
cells/well and stimulated with various doses of TLR ligands. Culture supernatant were
harvested after 6 h to assay cytokine production by ELISA. The cells did not respond to
stimulation with Flagellin, R848 or CpG. Each bar represents the mean ± SD of results
from triplicates. The experiment was repeated with cells from 3 independent donors with
consistent results.
118
TLR FUNCTION AND SIGNAL TRANSDUCTION
Figure 3.4: The TLR3 ligand poly(I:C) induces IP-10. (A) Cells were plated into a
96-well plate at a density of 104 cells/well and left untreated or stimulated with various
concentration of poly(I:C) for 24 h. Culture supernatant were harvested to assay IP-10
production by ELISA. Each bar represents the mean ± SD of results from triplicates of
one representative donor. The experiment was repeated with cells from 3 independent
donors with consistent results. (B) In vitro differentiated adipocytes in a 12-well plate
were stimulated with 20 µg/ml poly(I:C) or 10 ng/ml LPS. Normalised relative amount of
IP10 mRNA expression was determined by qRT-PCR in 6 independent donors. For each
donor, the mRNA level detected in unstimulated cells was normalised against RPLP0 and
attributed a value of 1. IP10 transcript levels of stimulated cells was expressed relative
to unstimulated cells. Shown is the mean fold upregulation ± SEM of the mean ratio of
IP10 to RPLP0 (6 pooled donors).
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3.2.2 Activation of downstream signalling by poly(I:C) and LPS
The finding that poly(I:C) not only induced IP-10 (Figure 3.4) but also the release of pro-
inflammatory IL-6, IL-8 and MCP-1 (Figure 3.3) was a rather unexpected finding. This
stands in contrast to primary human macrophages and dendritic cells, where TLR3 only
induces IP-10 but not pro-inflammatory cytokines such as IL-6 [207]. Thus, I speculated
that poly(I:C) might activate the NF-κB pathway which plays a central role in controlling
pro-inflammatory cytokines including IL-6. It has been previously reported that TLR3
stimulation in ”non-professional” immune cells such as fibroblast or endothelial cells can
lead to NF-κB activation [207].
I therefore set out to examine whether poly(I:C) could activate NF-κB signalling by
investigating the degradation of IκBα by western blot analysis in in vitro differentiated
adipocytes from 5 independent donors. LPS, a potent activator of the NF-κB pathway,
was used as a control stimulus and primary human monocyte-derived macrophages were
included as control cells. As shown in Figure 3.5A, LPS stimulation of macrophages
induced rapid degradation of IκBα within 15 min as expected. This was followed by
detection of phosphorylated bands of newly synthesised IκBα isoforms starting 30 min
after stimulation. As expected, LPS also led to IκBα degradation in adipocytes starting
at 30 min post stimulation (Figure 3.5B). However, the kinetics of LPS-induced IκBα
degradation in adipocytes was slower compared to macrophages, and newly synthesised
protein was not detected until 180 min post stimulation (observed during a prolonged time-
course in a different donor which is not shown here). Somewhat unexpectedly, poly(I:C)
treatment completely failed to induce IκBα degradation in adipocytes at any time-point
analysed even up to 4 h (not shown). This may indicate that poly(I:C)-induced production
of pro-inflammatory cytokines is mediated via an alternative pathway. Another possible
explanation could be that NF-κB is activated later than 4 h, maybe as a secondary event
following poly(I:C) stimulation.
I next examined the induction of IL6 transcript by qRT-PCR (Figure 3.5C). These
findings agreed with western blot analysis, and showed that LPS-induced IL6 transcrip-
tion in adipocytes was induced immediately following IκBα degradation, with a maximal
induction of IL6 mRNA at 1 h post stimulation. Conversely, poly(I:C)-induced IL6
mRNA was not detected until 16 h following stimulation. Taken together, these data
suggest that poly(I:C) may induce pro-inflammatory cytokines via an indirect mecha-
nism in adipocytes, resulting either in very late NF-κB activation or being completely
NF-κB-independent.
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Figure 3.5: LPS, but not poly(I:C), leads to early activation of the NF-κB path-
way. Monocyte-derived human macrophages (A) and in vitro differentiated adipocytes
(B) were stimulated in a 24-well plate with poly(I:C) or LPS at time-points indicated.
Cells were lysed in 1% triton containing phosphatase inhibitors to extract cytoplasmic
proteins. Proteins were separated by SDS-PAGE, transferred to PVDF membranes, and
probed with anti-IκBα and anti-p38 (loading control). The bands were detected at their
expected molecular weight of 40 kDa and 38 kDa, respectively. Blots shown are repre-
sentative for 1 (A) and 5 (B) independent donors. (C) In vitro differentiated adipocytes
in a 12-well plate were stimulated with 20 µg/ml poly(I:C) or 10 ng/ml LPS. Normalised
relative amount of IL6 mRNA expression was determined by qRT-PCR in 3 independent
donors. For each donor, the mRNA level detected in unstimulated cells was normalised
against RPLP0 and attributed a value of 1. IL6 transcript levels of stimulated cells was
expressed relative to unstimulated cells. Shown is the mean fold upregulation ± SEM of
the mean ratio of IL6 to RPLP0 (3 pooled donors).
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3.2.3 Time-course of IL-6 secretion by subcutaneous adipocytes
after TLR stimulation
Figure 3.6 shows a 24 h time-course where primary human preadipocytes and in vitro
differentiated adipocytes derived from subcutaneous adipose tissue were stimulated with
TLR-specific ligands (Pam3CSK4, MALP-2, poly(I:C), LPS, Flagellin, R848 and CpG).
Supernatant was collected at time-points indicated. In agreement with the previous ob-
servation shown in Figure 3.3, I found that both preadipocytes and adipocytes respond
to stimulation with Pam3CSK4, MALP-2, poly(I:C) and LPS (Figure 3.6) but not to
stimulation with Flagellin, R848 or CpG (not shown). This further demonstrates that
only TLR2, TLR3 and TLR4 may be functional in these cells. Figure 3.6 also shows that
primary human preadipocytes and adipocytes constitutively release IL-6, and that this is
augmented by TLR stimulation.
3.2.4 Range of cytokine secretion by human adipocytes
The literature suggests that adipose tissue is a source of various pro-inflammatory cy-
tokines and chemokines such as TNFα [260, 305], IL-6 [5], IL-8 [374], IL-18 [375] and
MCP-1 [376]. However, these reports have been derived from both primary cells or
cell lines and from various systems including rat, mouse and human. It was therefore
important to investigate the range of inducible cytokines in the human in vitro differ-
entiated adipocyte model system. As described in the previous paragraph, I found that
preadipocytes and adipocytes in culture constantly release the cytokines IL-6, IL-8 and
MCP-1. In addition, I tested human preadipocytes and adipocytes for release of TNFα,
IL-18 or soluble tumour necrosis factor receptor II (TNFR-II), all of which have been de-
scribed to derive from adipose tissue in previous studies [260, 305], [375], [377]. However,
in the cells employed in this system, these cytokines were below the limit of detection (50
pg/ml) and therefore the data is not shown.
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Figure 3.6: Stimulation with ligands for TLR 2, 3 and 4 induces IL-6
(time-course). Primary subcutaneous human preadipocytes and in vitro differentiated
adipocytes were plated into a 96-well plate at a density of 104 cells/well and stimulated
either with 1 µg/ml Pam3CSK4, 30 ng/ml MALP-2, 20 µg/ml poly(I:C) or 10 ng/ml LPS
(dark bars) or left unstimulated (light bars). IL-6 secretion was determined by collect-
ing cell culture supernatant at the indicated time-points and performing ELISA analysis.
Each bar represents the mean ± SD of results from triplicates. The experiment was re-
peated with cells from 3 independent donors with consistent results. Note the difference
in scaling on the Y axis after the scale break.
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3.2.5 Examining the potential differences in the response to
TLR ligands between human and murine adipocytes
Most published data on TLR expression in adipocytes are derived from mouse models and
murine cell lines. However, these findings cannot be directly applied to the human system.
To specify/highlight the differences in TLR functionality between murine and human
adipocytes, I assessed TLR responsiveness in in vitro differentiated murine adipocytes.
Murine preadipocytes isolated from the epididymal fat pads of 4 wild-type C57BL/6J
mice were seeded into a 96-well plate and differentiated in vitro to obtain adipocytes.
On day 10 following differentiation, the cells were stimulated for 24 h with TLR1 - TLR9
ligands. Figure 3.7 shows that murine adipocytes respond to stimulation with Pam3CSK4,
MALP-2, poly(I:C), LPS, Flagellin and R848, although only poly(I:C) and LPS reach
statistical significance. In contrast, the response to CpG was almost undetectable. These
data suggest that besides TLR3 and TLR4, TLR 1-7 may function in murine adipocytes
(TLR8, which is another receptor for R848 in human, has been shown to be non-functional
in mice, as reported by Jurk et al. [378]).
Conversely, human preadipocytes and adipocytes induce pro-inflammatory cytokines
only after stimulation with Pam3CSK4, MALP-2, poly(I:C) and LPS, whereby only the
response to poly(I:C) and LPS was statistically significant (Fig 3.7).
124
TLR FUNCTION AND SIGNAL TRANSDUCTION
F
ig
u
re
3.
7:
M
u
ri
n
e
a
d
ip
o
cy
te
s
re
sp
o
n
d
to
a
b
ro
a
d
e
r
ra
n
g
e
o
f
T
L
R
li
g
a
n
d
s
th
a
n
h
u
m
a
n
p
re
a
d
ip
o
cy
te
s
a
n
d
a
d
ip
o
cy
te
s.
C
el
ls
w
er
e
p
la
te
d
in
96
-w
el
l
p
la
te
s
at
a
d
en
si
ty
of
10
4
ce
ll
s/
w
el
l
an
d
st
im
u
la
te
d
fo
r
24
h
in
th
e
p
re
se
n
ce
of
m
ed
iu
m
al
on
e
or
m
ed
iu
m
co
n
ta
in
in
g
1
µ
g/
m
l
P
am
3C
S
K
4,
30
n
g/
m
l
M
A
L
P
-2
,
20
µ
g/
m
l
p
ol
y
(I
:C
),
10
n
g/
m
l
L
P
S
,
20
n
g/
m
l
F
la
ge
ll
in
,
1
µ
g/
m
l
R
84
8
or
2.
5
µ
M
C
p
G
.
C
u
lt
u
re
su
p
er
n
at
an
t
w
er
e
h
ar
ve
st
ed
to
as
sa
y
cy
to
k
in
e
p
ro
d
u
ct
io
n
b
y
E
L
IS
A
.
T
h
e
d
at
a
sh
ow
n
ar
e
p
o
ol
ed
fr
om
4
in
d
ep
en
d
en
t
d
on
or
s
an
d
re
p
re
se
n
t
th
e
fo
ld
in
d
u
ct
io
n
of
IL
-6
se
cr
et
io
n
co
m
p
ar
ed
to
u
n
st
im
u
la
te
d
co
n
tr
ol
ce
ll
s
(m
ea
n
±
S
E
M
).
F
or
ea
ch
d
on
or
,
th
e
ca
lc
u
la
te
d
m
ea
n
of
IL
-6
se
cr
et
io
n
w
as
n
or
m
al
is
ed
to
th
e
m
ea
n
of
th
e
u
n
st
im
u
la
te
d
ce
ll
fr
ac
ti
on
.
S
ta
ti
st
ic
al
si
gn
ifi
ca
n
ce
w
as
d
et
er
m
in
ed
u
si
n
g
a
on
e-
w
ay
an
al
y
si
s
of
va
ri
an
ce
(A
N
O
V
A
)
w
it
h
D
u
n
n
et
ts
m
u
lt
ip
le
co
m
p
ar
is
on
.
125
CHAPTER 3
3.3 Knockdown of TLR2, TLR3 and TLR4 by RNA
interference
At present TLRs are the best characterised PRRs, however, other receptors including
NLRs and RLRs also play a role in pathogen recognition. Until the discovery of TLR3,
the recognition of dsRNA was believed to be mediated by intracellular receptors such
as the dsRNA-dependent protein kinase R [379]. Recent reports implicated a role for
the NLRP3 inflammasome in mediating poly(I:C)-induced cell activation independent of
TLR3 [380, 381]. Similarly for TLR4, additional receptors have been implicated in LPS
recognition. These include the macrophage scavenger receptor (SR-AI/II) and the β2
(CD11/CD18) leukocyte integrins [382]. As TLR2 and 3 protein in preadipocytes could
not be detected by FACS analysis (Figure 3.1), I decided to perform siRNA-mediated TLR
knockdowns to confirm that the tested TLR ligands acted via their specified receptors.
In order to knock down TLR2, 3 and 4, the siRNA transfection procedure had to be
optimised for human adipocytes. I tested two different lipid-based transfection reagents
which are commonly used in our laboratory for transfection of macrophages or fibrob-
lasts: DharmaFECT and siIMPORTERTM Transfection Reagent using oligos directed
against STAT3 that are known to efficiently knock down STAT3 protein. Each trans-
fection reagent was tested according to the manufacturers’ instruction. Adipocytes were
transfected with siRNA against STAT3 (s743 and 6880) or scrambled siRNA (negative
control) and lysed 48 h after transfection. Cells transfected with DharmaFECT showed
loss of viability 24 h after transfection and therefore could not be analysed. Western
blot analysis demonstrated successful knockdown of STAT3 at a range of 10 - 100 nM
siRNA oligos 48 h after transfection (Figure 3.8A). Transfection of adipocytes with the
siIMPORTERTM Transfection Reagent could also be visualised by UV-microscopy 24 h
after transfection with 100 nM fluorescent siRNA oligos (Figure 3.8B).
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Figure 3.8: siRNA transfection of in vitro differentiated human adipocytes.
Cells were transfected with siRNA against STAT3 (s743 and 6880) or scrambled siRNA
(negative control). Cells were lysed in 1% triton at 48 h after transfection with
siIMPORTERTM to estimate knockdown by western blot analysis (A). The bands for
STAT3 and p38 were detected at their predicted size of 75 kDa and 38 kDa, and
a concentration-dependent knockdown of STAT3 was observed. (B) Transfection of
adipocytes was monitored by using 100 nM 5 carboxy-fluorescein (FAM)-labelled siRNA
control (Ambion). Cells were transfected for 4 h only using the siIMPORTERTM Trans-
fection Reagent from Upstate. siRNA without importer was added as a negative control.
Cells were washed twice with PBS before being analysed by UV microscopy (left) or bright
field/UV microscopy (right). Scale bar, 50µm.
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3.3.1 TLR2 knockdown
Having established the transfection technique for delivery of siRNA into adipocytes, cells
were transfected with siRNA oligos targeting TLR2. In order to examine the dose depen-
dence of siRNA, transfection was performed at concentrations of 10 - 100 nM. Three days
after knockdown, cells were stimulated for 24 h with Pam3CSK4 to examine secretion
of IL-6, IL-8 and MCP-1. Figure 3.9 shows a dose-dependent inhibition of Pam3CSK4-
induced cytokine secretion with the greatest effect occurring at 100 nM. As shown in
Figures 3.12 and 3.13, TLR2 knockdown had no effect on poly(I:C)- or LPS-induced cy-
tokines. Nonetheless, poly(I:C)-induced cytokine production was significantly affected by
the transfection procedure. The possible underlying cause of this observation is investi-
gated in section 3.5. Altogether, TLR2 knockdown appeared to confirm the involvement
of TLR2 in Pam3CSK4-induced inflammation and suggests that the expression level of
this receptor might be too low to be detected by FACS analysis (Figure 3.1). Confirma-
tion of knockdown of TLR2 protein was not performed because it was not possible to
obtain reliable western blot antibodies against TLRs from commercial sources.
3.3.2 TLR3 knockdown
I concurrently addressed the question of whether TLR3 was involved in poly(I:C)-induced
cytokine production. Like TLR2, TLR3 had not been detectable by FACS analysis (Figure
3.1). As shown in Figures 3.10 and 3.12, TLR3 knockdown did not inhibit poly(I:C)-
induced IL-6, IL-8, MCP-1 or IP-10. Together with FACS analysis, these results suggest
that TLR3 may not be involved in poly(I:C)-induced signalling in adipocytes, indicating
that poly(I:C) might signal through alternative receptors in these cells. This is discussed
in more detail at the end of this chapter in section 3.6. Once again, the transfection
reagent had a profound effect on the response to poly(I:C).
3.3.3 TLR4 knockdown
In addition, I investigated the involvement of TLR4 in LPS-induced cytokine secretion by
using the same experimental protocol as described for the other TLRs. Figure 3.11 shows
dose-dependent inhibition of cytokines after transfection with oligos targeting TLR4. Fig-
ure 3.13 further demonstrates that LPS signals specifically via TLR4, whereas poly(I:C)-
induced cytokines were not affected by TLR4 knockdown (3.12). These results, in com-
bination with the data from the FACS analysis (Figure 3.1), suggest that LPS-induced
cytokine secretion is mediated via TLR4.
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Figure 3.9: TLR2 knockdown leads to a dose-dependent inhibition of
Pam3CSK4-induced cytokines. In vitro differentiated adipocytes in a 96-well plate
were transfected with different doses of siRNA oligos targeting TLR2 (s168, s169) or
scrambled control (Scr) or the transfection reagent alone (liposome) as a negative control.
Three days after knockdown, cells were stimulated with 1 µg/ml Pam3CSK4 (grey bars)
or left unstimulated (open bars). Supernatant was harvested after 24 h and analysed by
ELISA for production of IL-6 (A) , IL-8 (B) and MCP-1 (C). Each bar represents the
mean ± SD of results from triplicates. The experiment was repeated with cells from 2
independent donors with consistent results.
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Figure 3.10: TLR3 knockdown does not inhibit poly(I:C)-induced cytokines. In
vitro differentiated adipocytes in a 96-well plate were transfected with different doses of
siRNA oligos targeting TLR3 (s236, s235) or scrambled control (Scr) or the transfection
reagent alone (liposome) as a negative control. Three days after knockdown, cells were
stimulated with 20 µg/ml poly(I:C) (grey bars) or left unstimulated (open bars). Su-
pernatant was harvested after 24 h and analysed by ELISA for production of IL-6 (A) ,
IL-8 (B) and MCP-1 (C), and IP-10 (D). Each bar represents the mean ± SD of results
from triplicates. The experiment was repeated with cells from 3 independent donors with
consistent results.
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Figure 3.11: TLR4 knockdown leads to a dose-dependent inhibition of LPS-
induced cytokines. In vitro differentiated adipocytes in a 96-well plate were transfected
with different doses of siRNA oligos targeting TLR4 (s14195, s14194) or scrambled control
(Scr) or the transfection reagent alone (liposome) as a negative control. Three days after
knockdown, cells were stimulated with 10 ng/ml LPS (black bars) or left unstimulated
(open bars). Supernatant was harvested after 24 h and analysed by ELISA for production
of IL-6 (A) , IL-8 (B) and MCP-1 (C). Each bar represents the mean ± SD of results
from triplicates. The experiment was repeated with cells from 3 independent donors with
consistent results.
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Figure 3.12: Poly(I:C)-induced IL-6, IL-8 and MCP-1 production is not medi-
ated via TLR3. In vitro differentiated adipocytes in a 96-well plate were transfected
with 100 nM siRNA oligos targeting TLR2 (s168, s169), TLR3 (s236, s235) and TLR4
(s14195, s14194), or 100 nM scrambled control (Scr) or the transfection reagent alone
(liposome) as a negative control. Three days after knockdown, cells were stimulated with
20 µg/ml poly(I:C). Supernatants were analysed by ELISA for secretion of IL-6 (A), IL-8
(B) or MCP-1 (C). For each donor, data were separately normalised to untreated con-
trol cells before pooling. Graphs represent pooled data of 3 individual donors (mean ±
SEM). No significant difference of knockdowns compared to scrambled was observed as
determined by one-way ANOVA with Dunnetts multiple comparison test.
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Figure 3.13: LPS-induced IL-6, IL-8 and MCP-1 production is mediated via
TLR4. In vitro differentiated adipocytes in a 96-well plate were transfected with 100
nM siRNA oligos targeting TLR2 (s168, s169), TLR3 (s236, s235) and TLR4 (s14195,
s14194), or 100 nM scrambled control (Scr) or the transfection reagent alone (liposome)
as a negative control. Three days after knockdown, cells were stimulated with 10 ng/ml
LPS. Supernatants were analysed by ELISA for secretion of IL-6 (A), IL-8 (B) or MCP-1
(C). For each donor, data were separately normalised to untreated control cells before
pooling. Graphs represent pooled data of 3 individual donors (mean ± SEM). **/*** p
<0.01/0.001 vs. scrambled as determined by one-way ANOVA with Dunnetts multiple
comparison test.
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3.4 TLR adapter utilisation in adipocytes
TLR adapter molecules are essential in propagating TLR signal transduction by bridg-
ing the intracellular receptor domain to downstream effector molecules. Thus, adapter
molecules could represent attractive drug targets for the treatment of TLR-induced in-
flammatory disorders [383, 384]. As illustrated in Figure 3.14, TLR 2, 3 and 4 mediated
signal transduction requires the adapters Mal (TIRAP) (TLR2 and 4), TRIF (TICAM1)
(TLR3 and 4) and TRAM (TLR4). MyD88-independent signalling has so far only been
reported for TLR3 and TLR4. It is important to note that usage of TLR adapters is very
species- and cell-type specific, i.e. primary human cells differ from transgenic cell lines
and murine cells.
Despite the importance of TLR adapter molecules in signal propagation and the at-
tractiveness as potential drug targets, their function in adipose remains an unexplored
area. To investigate the utilisation of the adapter molecules Mal, MyD88 and TRIF in
human adipocytes, I decided to follow my optimised technique of siRNA-mediated protein
knockdown. My findings are described in the next few paragraphs, sorted by each adapter
molecule. To summarise the large amount of graphs and data on the next few pages, I
include 2 tables (Table 3.1 and 3.2) at the end of this section which illustrate my findings
from the TLR ligand’s perspective.
Knockdown of TLR adapter molecules was performed as described in section 2.3.
Since I was unable to find suitable western antibodies targeting MyD88, Mal or TRIF
for primary cells, I confirmed the efficiency of the knockdown by qRT-PCR as shown in
Figures 3.15A, 3.16A and 3.17A. For each adapter, two different oligos were employed,
ranging from 10 -100 nM. For all 3 adapters, knockdown led to a dose-dependent reduction
of mRNA compared to control conditions (untransfected cells, transfection reagent only,
scrambled oligos).
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3.4.1 Dose-dependence of adapter knockdown on IL-6 secretion
Having confirmed the efficiency of the knockdown by qRT-PCR, cells of one donor were
transfected with siRNA oligos targeting MyD88, Mal and TRIF at increasing concen-
trations of 10, 50 and 100 nM. On day 2 after knockdown, cells of each condition were
stimulated with Pam3CSK4, poly(I:C) or LPS. Supernatant was harvested after 24 h to
analyse IL-6 secretion by ELISA. This led to the following observations:
MyD88 knockdown seemed to inhibit IL-6 secretion in a dose-dependent manner after
stimulation with Pam3CSK4, poly(I:C) and LPS, with the greatest effect occurring at
100 nM (Figure 3.15). In contrast, Mal knockdown appeared to have a dose-dependent
effect only on Pam3CSK4 and LPS-induced IL-6 production, whereas poly(I:C)-triggered
IL-6 secretion seemed to be unaffected (Figure 3.16). Finally, it was hard to draw any
firm conclusions from this single TRIF knockdown (Figure 3.17). Although there might
be a tendency for dose-dependent inhibition of IL-6 secretion after stimulation with all 3
ligands, a non-specific inhibition of basal IL-6 production could be observed.
3.4.2 Effect of MyD88 knockdown on other cytokines
In order to obtain a finer picture of the role of MyD88 in TLR-induced signalling and to
perform meaningful statistical analysis, I repeated the knockdown at a single concentra-
tion of oligos in additional donors. Cells on day 2 following transfection were stimulated
with Pam3CSK4, poly(I:C) or LPS. As before, MyD88 knockdown with both siRNA oli-
gos resulted in a highly significant reduction of cytokine secretion after TLR2 and TLR4
stimulation (see Figure 3.18 and Table 3.1 on page 146). Importantly, poly(I:C)-induced
pro-inflammatory cytokines were also significantly decreased after MyD88 knockdown
whereas no significant reduction in IP-10 production was observed (see Figure 3.18 and
Table 3.2 on page 147). This suggests that poly(I:C)-induced IL-6, IL-8 and MCP-1 (but
not IP-10) secretion is mediated via MyD88 in human adipocytes.
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Figure 3.15: siRNA oligos targeting MyD88 work at concentrations of 50 -
100 nM. (A) qRT-PCR analysis was performed to test the effectiveness of RNA target
knockdown in in vitro differentiated adipocytes transfected with siRNA oligos. The fold
change in MYD88 expression relative to RPLP0 was monitored on day 2 post transfection.
Scrambled (Scr) control was tested in addition to two different siRNA oligos (s9136,
s224080) for MyD88. Analysis was performed using the 2−∆∆CT method as described in
Methods. Each dot represents the mean ± error of 1 representative donor (out of 2). (B-
D) TLR-induced IL-6 secretion by adipocytes after siRNA-mediated MyD88 knockdown
in one donor. Cells in a 96-well plate were stimulated on day 2 after knockdown with 1
µg/ml Pam3CSK4 (light grey), 20 µg/ml poly(I:C) (grey) or 10 ng/ml LPS (black) or left
unstimulated (white bars). Supernatant was harvested after 24 h and analysed by ELISA
for IL-6 secretion. Each bar represents the mean ± SD of results from triplicates.
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Figure 3.16: siRNA oligos targeting Mal (TIRAP) work at concentrations of
50 - 100 nM. (A) qRT-PCR analysis was performed to test the effectiveness of RNA
target knockdown in in vitro differentiated adipocytes transfected with siRNA oligos.
The fold change in TIRAP expression relative to RPLP0 was monitored on day 2 post
transfection. Scrambled (Scr) control was tested in addition to two different siRNA oligos
(s195607, s41563) for Mal. Analysis was performed using the 2−∆∆CT method as described
in Methods. Each dot represents the mean ± error of 1 representative donor (out of 2).
(B-D) TLR-induced IL-6 secretion by adipocytes after siRNA-mediated Mal knockdown
in one donor. Cells in a 96-well plate were stimulated on day 2 after knockdown with 1
µg/ml Pam3CSK4 (light grey), 20 µg/ml poly(I:C) (grey) or 10 ng/ml LPS (black) or left
unstimulated (white bars). Supernatant was harvested after 24 h and analysed by ELISA
for IL-6 secretion. Each bar represents the mean ± SD of results from triplicates.
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Figure 3.17: siRNA oligos targeting TRIF (TICAM-1) work at concentrations
of 50 - 100 nM. (A) qRT-PCR analysis was performed to test the effectiveness of RNA
target knockdown in in vitro differentiated adipocytes transfected with siRNA oligos.
The fold change in TRIF expression relative to RPLP0 was monitored on day 2 post
transfection. Scrambled (Scr) control was tested in addition to two different siRNA oligos
(s45113, s45115) for TRIF. Analysis was performed using the 2−∆∆CT method as described
in Methods. Each dot represents the mean± error of 1 representative donor (out of 2). (B-
D) TLR-induced IL-6 secretion by adipocytes after siRNA-mediated MyD88 knockdown
in one donor. Cells in a 96-well plate were stimulated on day 2 after knockdown with 1
µg/ml Pam3CSK4 (light grey), 20 µg/ml poly(I:C) (grey) or 10 ng/ml LPS (black) or left
unstimulated (white bars). Supernatant was harvested after 24 h and analysed by ELISA
for IL-6 secretion. Each bar represents the mean ± SD of results from triplicates.
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Figure 3.18: MyD88 knockdown inhibits TLR-induced IL-6, IL-8 and MCP-1
production (but not IP-10). Legend on next page.
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Figure 3.18: MyD88 knockdown inhibits TLR-induced IL-6, IL-8 and MCP-1
production (but not IP-10). In vitro differentiated adipocytes in a 96-well plate were
transfected with 100 nM MyD88 oligos (s9136, s224080) or 100 nM scrambled control
(Scr) or the transfection reagent alone (liposome) as a negative control. On day 2 after
knockdown, cells were stimulated overnight with 1 µg/ml Pam3CSK4, 20 µg/ml PolyIC,
10 ng/ml LPS or left unstimulated. Supernatants were analysed by ELISA for secretion
of IL-6 (A), IL-8 (B), MCP-1 (C) or IP-10 (D). For each donor, data were separately
normalised to untreated control cells before pooling. Graphs represent pooled data of
4-6 individual donors (mean ± SEM). */**/*** p <0.05/0.01/0.001 vs. scrambled as
determined by one-way ANOVA with Dunnetts multiple comparison test.
Some of my own preliminary experiments had demonstrated that adipocytes are highly
responsive to the cytokines TNFα and IL-1 (which is described in more detail in chapter
5). Since MyD88 is involved in IL-1R signalling, but not in TNFα-induced signal trans-
duction [169], I performed additional control experiments where cells were stimulated
with recombinant human IL-1 and TNFα following MyD88 knockdown (Figure 3.19).
As expected, IL-1-induced cytokine production was significantly reduced after MyD88
knockdown. In contrast, MyD88 knockdown had no consistent effect on TNFα-induced
cytokines. Although in some cases a statistical significant effect was observed, this effect
was not replicated by both targeting oligos.
141
CHAPTER 3
Figure 3.19: MyD88 knockdown inhibits IL-1-induced IL-6, IL-8 and MCP-
1 production. In vitro differentiated adipocytes in a 96-well plate were transfected
with 100 nM MyD88 oligos (s9136, s224080) or 100 nM scrambled control (Scr) or the
transfection reagent alone (liposome) as a negative control. On day 2 after knockdown,
cells were stimulated over night with 10 ng/ml IL-1, 50 ng/ml TNFα or left unstimulated.
Supernatants were analysed by ELISA for secretion of IL-6 (A), IL-8 (B) or MCP-1
(C). For each donor, data were separately normalised to untreated control cells before
pooling. Graphs represent pooled data of 4 individual donors (mean ± SEM). */**/***
p <0.05/0.01/0.001 vs. scrambled as determined by one-way ANOVA with Dunnetts
multiple comparison test.
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Figure 3.20: Mal (TIRAP) knockdown inhibits Pam3CSK4- and LPS-induced
cytokines. In vitro differentiated adipocytes in a 96-well plate were transfected with 100
nM Mal oligos (s195607, s41563) or 100 nM scrambled control (Scr) or the transfection
reagent alone (liposome) as a negative control. On day 2 after knockdown, cells were
stimulated over night with 1 µg/ml Pam3CSK4, 20 µg/ml PolyIC, 10 ng/ml LPS or left
unstimulated. Supernatants were analysed by ELISA for secretion of IL-6 (A), IL-8 (B)
or MCP-1 (C). For each donor, data were separately normalised to untreated control cells
before pooling. Graphs represent pooled data of 4-6 individual donors (mean ± SEM).
*/**/*** p <0.05/0.01/0.001 vs. scrambled as determined by one-way ANOVA with
Dunnetts multiple comparison test.
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Figure 3.21: TRIF (TICAM1) knockdown inhibits LPS-induced cytokines
whereas poly(I:C)-induced cytokines remain unaffected. Legend on next page.
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Figure 3.21: TRIF (TICAM1) knockdown inhibits LPS-induced cytokines
whereas poly(I:C)-induced cytokines remain unaffected. In vitro differentiated
adipocytes in a 96-well plate were transfected with 100 nM TRIF oligos (s45113, s45115)
or 100 nM scrambled control (Scr) or the transfection reagent alone (liposome) as a
negative control. On day 2 after knockdown, cells were stimulated over night with 1
µg/ml Pam3CSK4, 20 µg/ml PolyIC, 10 ng/ml LPS or left unstimulated. Supernatants
were analysed by ELISA for secretion of IL-6 (A), IL-8 (B), MCP-1 (C) or IP-10 (D).
For each donor, data were separately normalised to untreated control cells before pool-
ing. Graphs represent pooled data of 4-6 individual donors (mean ± SEM). */**/***
p <0.05/0.01/0.001 vs. scrambled as determined by one-way ANOVA with Dunnetts
multiple comparison test.
3.4.3 Effect of Mal knockdown on other cytokines
Figure 3.20 shows the effect of Mal knockdown on cytokine secretion in pooled data of 4-6
individual donors. Cells were transfected with 100 nM oligos against Mal and stimulated
with Pam3CSK4, poly(I:C) or LPS. Supernatant was harvested after 24 h to analyse
secretion of cytokines. As expected, Mal knockdown resulted in a significant decrease
in IL-6, IL-8 and MCP-1 secretion following TLR2 and TLR4 stimulation (Table 3.1,
page 146), confirming that Mal is required by both these receptors for propagating the
signal. On the other hand, poly(I:C)-induced cytokine secretion remained unaffected
(Table 3.2, page 147) and therefore Mal does not seem to be involved in TLR3-mediated
signal transduction.
3.4.4 Effect of TRIF knockdown on other cytokines
Finally, I investigated the effect of TRIF knockdown on Pam3CSK4, poly(I:C) and LPS-
induced cytokines in 4-6 individual donors (Figure 3.21). When analysing the pooled
data, it became evident that TRIF only participates in LPS- but not in poly(I:C)-induced
cytokine secretion, as TRIF knockdown significantly inhibited LPS-induced IL-6 and IL-
8 (but not MCP-1) secretion. In contrast, the effect of TRIF knockdown on poly(I:C)-
induced cytokines did not reach any statistical significance. Especially remarkable was the
fact that TRIF knockdown had no effect on poly(I:C)-induced IP-10 secretion. In addition
to my previous observations made by FACS analysis (Figure 3.1) and TLR3 knockdown
(Figure 3.12), these results add more evidence to my hypothesis that poly(I:C) signals
via a TLR3-independent pathway in adipocytes. This will be further discussed in section
3.6.
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3.5 Investigation of RNA-induced tolerance
Prior exposure of innate immune cells to low concentrations of LPS causes them to become
transiently unresponsive to subsequent LPS stimulation. This phenomenon, known as
”endotoxin tolerance” has been well described both in vitro and in vivo [385] and stands in
contrast to ”priming”, which is defined as increased sensitivity to certain stimuli following
prior exposure.
In the course of my investigations, I observed that cells previously treated with siRNA
transfection reagent produced markedly less cytokines in response to poly(I:C) than the
untransfected control cells (e.g. Figures 3.18, 3.20, 3.21). This was not the case for
Pam3CSK and LPS. As poly(I:C) is the synthetic analogue of dsRNA, I hypothesised
that the cells might become tolerant to RNA following prior exposure to siRNA, resulting
in unresponsiveness when subsequently stimulated with poly(I:C).
In order to investigate this hypothesis, adipocytes in a 96-well plate were pre-treated 2
days before stimulation with either poly(I:C) at a concentration of 0.2 - 20 µg/ml, trans-
fection reagent only (liposome), transfection reagent + scrambled siRNA or scrambled
siRNA only. After 48 h, cells were challenged with a single dose of 20 µg/ml poly(I:C)
and stimulated overnight. Supernatant was harvested the following day to measure cy-
tokine levels by ELISA.
Figure 3.22 shows that pretreatment of adipocytes with 0.2 or 2 µg/ml poly(I:C)
resulted in an approximately 30% reduction in poly(I:C)-induced cytokines (compared to
untreated control cells) following the second exposure. Similarly, pretreatment with 100
nM scrambled oligos led to a 50% decrease in cytokine secretion. This indicates that small
doses of RNA (i.e. poly(I:C) or siRNA) may induce tolerance. Conversely, pretreatment
with 20 µg/ml poly(I:C) appears to lead to priming of the cell, causing an approximate
two-fold increase in cytokine production following the second encounter with the ligand.
Strikingly however, the biggest inhibition of cytokine secretion was observed when
cells were pretreated with transfection reagent alone (without addition of siRNA). This
effect of the transfection reagent can be found throughout the results in this chapter. The
transfection reagent I used is based on cationic lipid formulation and although cationic
lipids are now widely used for delivery of molecules into cells, their interaction with cell
components has been largely ignored so far. However, there is accumulating evidence
that cationic lipids are not just inert transporters but do also activate specific cellular
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cascades causing immunomodulatory effects [386] as well as activation of type I IFN and
profound transcriptional effects (Dr. R. Simmonds, unpublished data). It may therefore
well be that these lipids induce a signalling pathway in adipocytes that interferes with
subsequent poly(I:C)-induced cytokine production. However, this does not invalidate the
technique in the case of Pam3CSK4 and LPS signalling. Furthermore, MyD88 siRNA
produced inhibition over and above the transfection reagent alone (Figure 3.18).
Figure 3.22: siRNA transfection reagent and siRNA oligos suppress poly(I:C)-
induced cytokines. In vitro differentiated adipocytes were treated on day -2 as follows:
poly(I:C) at a concentration of 0.2 - 20 µg/ml, transfection reagent only (liposome),
transfection reagent + siRNA, siRNA only. After 48 h, cells were challenged with a single
dose of 20 µg/ml poly(I:C) and stimulated overnight. Supernatant was harvested the
following day to measure cytokine levels by ELISA. Each bar indicates the mean cytokine
production ± SD of triplicates. (n=1)
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3.6 Discussion
Because of the obesity pandemic, a tremendous effort has been made in recent years
to investigate the pleiotropic function of adipocytes. It has been shown that adipocytes
have the potential to release pro-inflammatory cytokines [263] and express TLRs. Batra et
al. [178] provided the first complete TLR expression profile for 3T3-L1 cells and primary
murine adipocytes by demonstrating that murine adipocytes respond to TLR 1 - 9 ligands
whereas TLR expression in the cell line is more restricted. My results in this chapter
(section 3.2) show that primary human in vitro differentiated adipocytes respond to TLR
2, 3 and 4 ligands. Subsequent studies on primary human adipocytes came to similar
findings, although some discrepancies are found among the studies. For instance, a study
by Vitseva et al. [387] reported only the presence of TLR 1, 2 and 4 protein in abdominal
subcutaneous adipose from obese subjects. Nonetheless, my findings were confirmed by
Kopp et al. [388] who showed that human adipocytes respond to TLR 2, 3 and 4 ligands.
The diversity of these different outcomes is probably due to different models employed in
these studies. It was therefore important to examine the expression of TLRs in further
models to clarify the situation. In my model system of in vitro differentiated adipocytes,
the advantage is that it is free of possible contamination due to infiltrated inflammatory
cells that could contribute to the signals obtained from adipocytes.
While the human adipocytes employed in this study did not respond to ligands for TLR
5, 7/8 and 9, Kopp also reported a function for TLR7/8 and TLR9 in inhibiting resistin
secretion even though activation of these receptors had no effect on IL-6 or MCP-1 secre-
tion. However, whilst IL-6 and MCP-1 were induced by TLR 1/2, 3 and 4, TLR2/6 only
stimulated the release of IL-6 with no statistically significant effects on MCP-1 or resistin
[388]. These diverse findings by Kopp et al. make it difficult to interpret their results.
The only consistent finding of that paper was that human adipocytes were completely
unresponsive to stimulation with the TLR5 ligand Flagellin. This finding (together with
my own results) stands in contrast to another study on human adipocytes [389] where
cells responded to TLR 1 - 6 ligands (despite the expression of TLR1 - TLR10 mRNA). A
potential explanation for the difference between Franchini et al. [389] and my results may
be that they used in vitro differentiated adipocytes derived from human bone marrow.
However, although the cells in the bone marrow-derived adipocyte model system also
responded to Flagellin in addition to TLR 2, 3 and 4 ligands, the response to poly(I:C)
and LPS was also found to be strongest, as assessed by upregulation of IL6 mRNA.
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In addition to regulated cytokine secretion, my results also suggest that adipocytes
constitutively release the cytokine IL-6 (and lower levels of IL-8 and MCP-1), highlight-
ing the strong inflammatory potential of these cells. As all experiments were performed
using in vitro cultured adipocytes, the activation of the cells by collagenase isolation or
cell culture media cannot be ruled out. However, to exclude the problem of LPS contam-
ination, all media and reagents were tested for the presence of endotoxin prior to their
use with the limulus amebocyte lysate (LAL) assay and the strictest culturing techniques
employed to ensure that no endotoxin was introduced by other means. Interestingly, a
recent study by Koenen et al. [327] has shown that human adipose tissue incubated in
medium containing 25 mM (4.5 g/L) glucose is characterised by increased gene expression
levels of IL-6, IL-8 and IL-1β compared to tissue that is incubated in medium containing
5 mM (0.9 g/L). Although the actual secretion of these cytokines was not demonstrated
in that study, this result suggests that hyperglycaemic DMEM, which is used as a ”gold”
standard for culturing adipocytes, could be a major trigger behind the basal release of
these cytokines.
When investigating TLR expression at the transcriptional level, I found that human
preadipocytes and adipocytes express the mRNA for all known human TLRs, despite
observing different band intensities. This contrasts with the observation that the cells
only respond to TLR 2, 3 and 4 ligands. A similar observation was made by Franchini
et al. [389], who reported expression of TLR1 -TLR10 mRNA in human bone marrow
derived adipocytes, whereas the cells only responded to TLR 1 - 6 ligands. This difference
may be explained by post-transcriptional or post-translational gene regulation such as
alternative splicing. Alternatively, it is also possible that the receptors are not accessible
to their ligands in cell culture conditions. A third possible explanation may be that the
samples used for RT-PCR might conceivably have been contaminated with genomic DNA
as I did not specifically test for this and it would also be an efficient template for PCR.
However, I think this is unlikely because all samples were treated with DNAase prior to
reverse transcription.
As expected, TLR2 and TLR4 knockdown by siRNA abrogated the cytokine re-
sponse induced by Pam3CSK4 and LPS, respectively. Furthermore, FACS analysis of
preadipocytes revealed high expression of intracellular and extracellular TLR4. However,
TLR2 protein could not be detected which may indicate that this protein is expressed at
a very low level. Indeed, whilst the cytokine response to poly(I:C) and LPS was found
to be statistically significant, IL-6 production following stimulation with Pam3CSK4 and
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MALP-2 was lower (5-10 fold) and did not quite reach statistical significance (Figure 3.7,
page 125). Since TLR2 knockdown could inhibit this stimulated response, but the levels
were already lower, this suggests that the negative FACS result is due to a detection issue
rather than a lack of expression. The apparent detection problem could be solved using
a more sensitive antibody (e.g. an allophycocyanin (APC)-coupled antibody).
My results also seem to suggest that the response to poly(I:C) is mediated via a
receptor other than TLR3. First, I was not able to demonstrate TLR3 protein expression
by FACS analysis and second, TLR3 and TRIF knockdown had no effect on poly(I:C)-
induced cytokines. If poly(I:C) does signal via an alternative route in adipocytes, what
might the alternative be?
In the pre-TLR era, two pathways were described that are activated by dsRNA: The
first pathway depends on the protein kinase R [379] and the other pathway leads to
activation of the RNase L [390]. However, although both pathways are implicated in
anti-viral immunity, they do not result in induction of type I IFN [391]. Although the in-
duction of type I IFN in adipocytes has not been investigated directly, poly(I:C)-induced
IP-10 (which is a target gene of IFN) was used as an indirect readout of type I IFN
induction. Therefore a receptor other than protein kinase R or RNase L is likely to be
involved. Besides TLR3, only the RLRs RIG-I and melanoma differentiation-associated
gene 5 (MDA5) have been shown to lead to dsRNA-dependent IRF activation and pro-
duction of type I IFN [373, 392, 393]. These pathways seem to diverge from the TLR3
pathway only at the initial step of dsRNA recognition: TLR3 recognises dsRNA in-
side intracellular organelles like endosomes, whereas RIG-I and MDA5 sense cytoplasmic
dsRNA. Additionally, some reports have implicated the NLRP3 inflammasome in medi-
ating poly(I:C)-induced cell activation independently of TLR3 [380, 381]. But even if
poly(I:C) leads to induction of a TLR3-independent pathway in adipocytes, there is still
little understanding in the literature on how soluble poly(I:C) could enter the cytosol,
where RIG-I, MDA5 or the NLRP3 inflammasome are located. Since dsRNA is presum-
ably cell-impermeable, poly(I:C) would require to be transported into the cell by a special
transport protein. Although such cell surface transporters for dsRNA have recently been
identified in Caenorhabditis elegans [394], there is still no evidence of a similar transporter
in mammalian cells. Nevertheless, my hypothesis of the existence of a TLR3-independent
pathway in adipocytes is supported by the thesis of A. Lundberg [395], a former PhD stu-
dent in our laboratory. In her experiments, pre-incubation with an anti-TLR3 antibody
only inhibited poly(I:C)-induced IP-10 in dendritic cells and macrophages, whereas no
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reduction in IP-10 could be observed in poly(I:C)-stimulated endothelial cells or synovial
fibroblasts.
In terms of the range of cytokines induced by TLR ligands, it has been observed that
obesity leads to an increase of TNFα expression in adipose tissue of mice [260] and hu-
man [305] leading to the initial assumption that adipocytes are the predominant source
of TNFα in obese adipose. This observation is supported by various studies in murine
cells and the 3T3-L1 cell line, where TNFα secretion by adipocytes is widely observed
[178, 396]. My finding that TNFα secretion by human preadipocytes and adipocytes is
below the detection limit of our ELISA (section 3.2.4) suggests that there are important
differences between human and murine adipocytes. This finding is supported by a recent
study which demonstrated that other cells present in adipose tissue, the so-called stromal
vascular fraction (SVF), can produce substantially more TNFα than adipocytes [234]. In
addition, another study using the arteriovenous balance technique showed that subcuta-
neous adipose tissue does not release measurable amounts of TNFα into the circulation
[5]. However, the observation that obesity leads to macrophage infiltration into the adi-
pose tissue [8, 9] suggests that paracrine effects of TNFα secreted by macrophages may
still have a fundamental role in the induction of insulin resistance in obesity.
In this chapter, I have examined the utilisation of TLR adapter molecules in adipocytes
in great detail. As mentioned already, TLR adapters are seen as potential drugable tar-
gets for the treatment of inflammatory disorders including RA. Since adipose inflamma-
tion may significantly contribute to the development of obesity-associated pathologies, the
understanding of the participation of TLR adapter molecules in inflammation caused by
adipocytes could become important in the future. I thus examined whether knockdown of
MyD88, Mal or TRIF would alter Pam3CSK4, poly(I:C) and LPS-induced cytokine secre-
tion. As expected, MyD88 and Mal knockdown inhibited Pam3CSK4 and LPS-induced
cytokine production, indicating that TLR2 and 4 signalling in adipocytes is mediated
via MyD88 and Mal (Table 3.1, page 146). My data from TRIF knockdown suggest
that TLR4 can additionally signal via TRIF to induce pro-inflammatory cytokines via
late NF-κB activation, whereas TRIF does not seem to be involved in TLR2-induced
cytokine production (as assessed by a requirement of both oligos to produce a consistent
result). These findings are in agreement with the common literature and suggest that
LPS signalling in adipocytes may be similar to immune cells: Binding to TLR4 on the
cell surface could induce cytokines via early-phase activation of NF-κB through the TIR
domain-containing adapters Mal and MyD88 (Figure 3.23). The ligand-receptor complex
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may then be internalised, where it signals via TRIF to activate NF-κB (Figure 3.14, page
135). This would mean internalisation of TLR4, and intracellular TLR4 protein was in-
deed detected by FACS analysis (Figure 3.1, page 115). Strikingly, TRIF knockdown did
not inhibit poly(I:C)-induced cytokines (Table 3.2, page 147). This finding is contrary
to my expectation and suggests that poly(I:C) signals via an alternative route to induce
IP-10. This adds further evidence to my hypothesis that poly(I:C) signals via an alterna-
tive, TLR-independent pathway. Rather unexpectedly, however, I observed a significant
reduction of poly(I:C)-induced IL-6, IL-8 and MCP-1 production after MyD88 knockdown
(Table 3.2, page 147). Later data indicate that these poly(I:C)-induced pro-inflammatory
cytokines may be induced via an autocrine IL-1 feedback (see sections 5.5/5.7 and chapter
6).
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Chapter 4
Effect of TLR ligands on glucose
handling
Based on the findings in chapter 3, I started to focus my attention on the response of
adipocytes to Pam3CSK4, poly(I:C) and LPS. The question now was whether adipocytes
responded to these ligands simply to promote inflammation or whether TLR-induced
signalling might affect their role in regulating glucose homoeostasis. Indeed, the tight
link between inflammation and dysregulated glucose homoeostasis has been established
(see Tables 1.8 - 1.11 in section 1.5). In particular, TLR4-deficient mice are protected
from obesity-induced insulin resistance and diabetes [12, 320, 321, 322]. Furthermore,
a state of insulin resistance has been observed in human endotoxemia [397]. For these
studies and my results in chapter 3, I hypothesised that TLRs may be important metabolic
regulators, and that their activation during an infection or in the obese state may directly
lead to insulin resistance. In adipocytes, in particular, insulin resistance manifests itself
as a reduction in insulin-stimulated glucose uptake and increased lipolysis (see sections
1.1.5/1.2.1 on page number 29-32).
As described in chapter 1, insulin-stimulated glucose uptake in adipocytes is mediated
via the insulin-responsive glucose transporter GLUT4. In the unstimulated state, GLUT4
resides in specialised intracellular vesicles. Insulin signalling leads to the translocation of
GLUT4 storage vesicles to the plasma membrane (see Figure 1.4, page 37). Moreover,
GLUT4 translocation is the essential rate-limiting step in insulin-dependent glucose up-
take and states of insulin resistance are associated with impaired regulation of GLUT4
gene expression and function [80]. In addition to GLUT4, glucose uptake in adipocytes
can also be mediated via GLUT1, which is an insulin-independent glucose transporter
[91].
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Another process regulated by insulin is lipolysis, the hydrolysis of stored triglycerides
into FFAs and glycerol (described in section 1.4.3, page 56). In the fed state, insulin
suppresses adipose tissue lipolysis. Physiologically, in the fasting state, reduced levels of
circulating insulin permit lipolysis in order to mobilise fuel from adipose depots. Patho-
logically, the suppression of lipolysis becomes ineffective in an insulin resistant state,
contributing to dyslipidemia. There have been several publications that lipolysis can be
induced by inflammation through stimulation with TNFα [398]. Interestingly, a recent
paper also provided a role for LPS in promoting lipolysis in mice [399].
In order to investigate my hypothesis, that TLRs may be important metabolic regula-
tors, I investigated glucose homoeostasis in adipocytes after stimulation with Pam3CSK4,
poly(I:C) or LPS. This was assessed in detail by examining the effect of these ligands on
insulin-dependent and -independent glucose uptake, GLUT4 translocation and expres-
sion of GLUT1 and GLUT4. GLUT4 was studied as the predominant insulin-regulated
glucose transporter in adipocytes. In parallel, I investigated GLUT1 as an example of
an insulin-independent transporter which is ubiquitously expressed among different cell
types [91]. A small section at the end of this chapter also describes the impact of TLR
ligands on lipolysis. Due to the well-established role of TNFα in insulin resistance [400],
the cytokine was used as a positive control throughout this chapter.
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4.1 Effect of TLR ligands on insulin-stimulated glu-
cose uptake
4.1.1 Establishing a 3H-2-deoxy-D-glucose (2DOG) uptake as-
say
As the first step, I assessed the effect of TLR activation on the uptake of 3H-2DOG by
in vitro differentiated adipocytes. It has already been observed that prolonged TNFα
treatment inhibits insulin-stimulated 2DOG transport into adipocytes [401]. I therefore
established a glucose uptake assay, using TNFα as a positive control (see section 2.2.7,
page 104). Adipocytes were incubated for 3 or 48 h in control medium or in medium con-
taining 50 ng/ml TNFα. Thereafter, cells were stimulated for 30 min with 200 nM insulin,
followed by addition of 3H-2-DOG. The amount of 3H-2DOG taken up over 10 min was
assessed by liquid scintillation counting. As observed by Hauner et al. [401], TNFα led to
dramatic changes in glucose uptake (Figure 4.1A). In untreated adipocytes, insulin stimu-
lation resulted in an approximately 3-fold increase in glucose uptake. However, when cells
were pre-incubated with TNFα, there was a significant reduction in insulin-stimulated 3H-
2DOG transport (Figure 4.1B). Simultaneously, insulin-independent glucose uptake was
increased (Figure 4.1C). This effect was more pronounced after prolonged incubation (48
h) with TNFα than after short-term stimulation for 3 h.
4.1.2 Changes in glucose uptake following Pam3CSK4, poly(I:C)
and LPS treatment
In order to examine whether TLR ligands might have a similar effect on glucose uptake
as TNFα, cells were incubated in medium containing 1 µg/ml Pam3CSK4, 20 µg/ml
poly(I:C), 10 ng/ml LPS or in control medium. As observed for TNFα, prolonged expo-
sure of adipocytes to poly(I:C) and LPS led to a significant reduction in insulin-stimulated
2DOG uptake (Figure 4.1B) and interestingly, the two ligands also caused a highly signif-
icant elevation in insulin-independent glucose uptake at 48 h (Figure 4.1C). In contrast,
Pam3CSK4 treatment had no effect on insulin-independent nor insulin-stimulated glucose
uptake (Figure 4.1B/C).
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Figure 4.1: (A) Prolonged exposure of adipocytes to poly(I:C) and LPS induces
changes in glucose uptake. This figure shows normalised 3H-2DOG uptake (compared
to untreated, unstimulated control cells) by adipocytes of 1 representative donor (out of
6). Adipocytes were treated for 3 or 48 h with 1 µg/ml Pam3CSK4, 20 µg/ml Poly(I:C),
10 ng/ml LPS or 50 ng/ml TNFα (positive control). 3 h prior to the assay, cells were
starved in KRH buffer and then stimulated for 30 min with 200 nM insulin. 2DOG uptake
was initiated by addition of 3H-labelled 2DOG (final concentration: 100 µM, 1 µCi per
well). Uptake was terminated after 10 min by washing the cells with ice-cold PBS. Cells
were lysed in 1% SDS and radioactivity was measured by liquid scintillation counting.
Each bar represents the mean ± SD of results from triplicates.
160
EFFECT ON GLUCOSE HANDLING
Figure 4.1: (B) Prolonged exposure of adipocytes to poly(I:C) and LPS induces
changes in glucose uptake. This figure shows the fold induction of insulin-stimulated
2DOG uptake by adipocytes of 6 donors. Each line in this figure represents 1 donor. Data
were analysed using a paired, one-tailed student t test (*/**, p < 0.05/0.01)
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Figure 4.1: (C) Prolonged exposure of adipocytes to poly(I:C) and LPS induces
changes in glucose uptake. In vitro differentiated adipocytes were incubated for 3 or
48 h with TNFα (positive control), Pam3CSK4, poly(I:C) or LPS. Amount of glucose
uptake was measured by addition of 3H-2DOG (final concentration: 100 µM, 1 µCi per
well) for 10 min. Thereafter, cells were washed, lysed and glucose uptake was quantified
by liquid scintillation counting. Shown are normalised and pooled data of 6 independent
donors. Data were analysed using a one-way ANOVA with Dunnetts Multiple comparison
(**/***, p < 0.01/0.001 compared to untreated control).
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4.2 Effect of TLR ligands on GLUT4 translocation
The reduction in insulin-stimulated glucose uptake induced by poly(I:C) and LPS (Figure
4.1) could be due to decreased GLUT4 translocation to the plasma membrane. In order
to investigate the effect of inflammation on GLUT4 trafficking, I undertook confocal
microscopy studies in the laboratory of Dr. Jelena Gavrilovic at the University of East
Anglia in Norwich, UK.
4.2.1 The HA-GLUT4-GFP chimera
The initial plan was to detect endogenous GLUT4 with a fluorescence-labelled anti-
GLUT4 antibody and visualise the molecular complex using confocal microscopy. How-
ever, during my search for an adequately specific antibody targeting intracellular GLUT4,
I came across a publication which described the generation of an HA-tagged human
GLUT4 gene with enhanced green fluorescent protein (GFP) at the C-terminus. This
was achieved by inserting an HA-GLUT4 sequence into a GFP-tagged vector [365]. The
chimeric HA-GLUT4-GFP molecule allowed the visualisation of cell-surface localisation,
total expression, and intracellular distribution of GLUT4 in a single cell [365]. Figure 4.2A
shows a schematic illustration of the HA-GLUT4-GFP chimera. I was able to obtain this
plasmid with the kind help of Prof. Jeremy Tavare´ (University of Bristol, UK).
An analytical restriction digest with Kpn I and Hind III which have sites flanking the
insert, gave rise to a band of the expected size (Figure 4.2B). After purification, 1 µg of
plasmid DNA was transfected into 293T and expression of the construct was visualised 30
h following transfection by monitoring GFP fluorescence under UV-microscopy (Figure
4.2C). In parallel to the transfection of 293T cells, human adipocytes were also transfected
with the plasmid. However, neither the construct nor a control GFP vector could be
successfully transfected into primary adipocytes with this method.
4.2.2 Optimisation of plasmid transfection into adipocytes
In an attempt to optimise the transfection method for the delivery of the HA-GLUT4-
GFP plasmid into adipocytes, cells in a 12-well plate were transfected with DNA rang-
ing from 0.2 - 5 µg. In parallel to DNA titration, the following methods were tested:
1) Electroporation (NucleofectorTM System, Amaxa), 2) a liposome-based transfection
reagent (siIMPORTERTM , Upstate), 3) a non-liposomal reagent [FUGENE (Roche; non-
liposomal reagent)] and 4) calcium phosphate transfection (kit obtained from Sigma).
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Figure 4.2: The HA-GLUT4-GFP plasmid. (A) The HA-GLUT4-GFP chimera. An
HA epitope in the first exofacial loop of GLUT4 is exposed to the exterior of the cell
upon GLUT4 translocation and fusion with the plasma membrane. This epitope can be
detected using an anti-HA antibody, followed by immunostaining with a fluorescent sec-
ondary antibody (Alexa Fluor 633nm). The GFP moiety at the C-terminus of GLUT4
allows estimation of total expression levels of the transfected GLUT4 chimera. (B) Re-
striction analysis of the HA-GLUT4-GFP plasmid with restriction enzymes Kpn I and
Hind III. The plasmid was visualised on ethidium bromide-stained 1% agarose gel follow-
ing digestion. 1: digested pDNA, 2: isolated, undigested pDNA. M: molecular weight
marker. (C) 293T cells expressing the HA-GLUT4-GFP plasmid 30 h after transfection
with 1 µg HA-GLUT4-GFP using the siIMPORTERTM Transfection Reagent. Scale bars,
100 µm.
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Electroporation led to a great loss of cell viability and only a few adipocytes re-attached
to the well. The other three methods tested showed no effect on cell viability but pri-
mary adipocytes were found to be completely resistant to plasmid DNA delivery via the
siIMPORTER or FUGENE reagents. However, calcium phosphate transfection led to
incorporation of DNA into cells and GFP expression could be monitored between 30 h -
48 h following transfection. It has to be noted though that the transfection efficiency was
low (< 1% as judged visually).
4.2.3 Quantification of insulin-stimulated translocation of HA-
GLUT4-GFP
Having optimised the method for transfection of the HA-GLUT4-GFP construct as far
as the currently available techniques allowed, I set out to investigate the effect of TLR
ligands on translocation of artificially expressed HA-GLUT4-GFP. In vitro differentiated
adipocytes on cover slips were transfected with the HA-GLUT4-GFP plasmid by calcium
phosphate transfection and incubated for 48 h in medium containing TNFα, Pam3CSK4,
poly(I:C) or LPS. On day 2 post transfection, cells were stimulated with 200 nM insulin
for 30 min and subsequently fixed without permeabilisation. Surface-localised GLUT4
was assessed by the appearance of the HA epitope on the cell surface which was de-
tected indirectly using an anti-HA antibody and a secondary Alexa633-labelled antibody
(red). Total endogenous GLUT4 expression was determined directly by assessing GFP
fluorescence.
As shown in Figure 4.3, insulin stimulation caused a redistribution of HA-GLUT4-
GFP from the cytosol to the cell surface (compare panels C and D), demonstrating that
the cellular response to insulin was functional. Figure 4.4 further demonstrates that pre-
treatment with TNFα or TLR ligands does not prevent translocation of HA-GLUT4-GFP
to the surface following insulin stimulation. Quantitative analysis of one representative
experiment was performed on 3 cells for each condition and showed no effect of TNFα or
TLR ligands on GLUT4 translocation (Figure 4.5). As for TNFα, this observation was in
agreement with an earlier study [345] where TNFα had also no effect on insulin-induced
GLUT4 trafficking to the plasma membrane. In that study, the profound association
between TNFα and insulin resistance was partially attributed to the ability of TNFα
to down-regulate GLUT4 mRNA. I thus raised the question whether poly(I:C) and LPS
may act in a similar way and therefore decided to investigate the effect of TLR ligands
on GLUT4 expression as the next step.
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Figure 4.3: Insulin triggers translocation of GLUT4 to the cell surface. In vitro
differentiated adipocytes were transfected with the HA-GLUT4-GFP plasmid and either
left unstimulated (panels A+C) or stimulated with 200 nM insulin (panels B+D) for 30
min. Non-permeabilised cells were fixed and labelled with anti-HA and Alexa Fluor 633
conjugate to examine HA-GLUT4-GFP located on the cell surface (red; middle panels).
Total expression of the construct was assessed by GFP (green; left panels). Merged images
are shown in the right-hand panels. (A) unstained, unstimulated cells (B) unstained,
insulin-stimulated cells (C) stained, unstimulated control (D) stained, insulin-stimulated
control. Shown is 1 cell per condition of 3 acquired cells. This experiment was performed
once. Scale bars, 20 µm.
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Figure 4.4: Normal GLUT4 translocation following stimulation with TNFα and
TLR ligands. In vitro differentiated adipocytes were transfected with the HA-GLUT4-
GFP plasmid and incubated for 48 h with TNFα or TLR ligands. Thereafter, cells were
stimulated with 200 nM insulin for 30 min. Following stimulation, non-permeabilised
cells were fixed and labelled with anti-HA and Alexa Fluor 633 conjugate to examine
HA-GLUT4-GFP located on the surface (red; middle panels). Total expression of the
construct was assessed by GFP (green; left panels). Merged images are shown in the
right-hand panels. Cells in this figure were treated as follows: (A) 50 ng/ml TNFα (B)
1 µg/ml Pam3CSK4 (C) 20 µg/ml Poly(I:C) (D) 10 ng/ml LPS. Shown is 1 cell per
condition of 3 acquired cells. This experiment was performed once. Scale bars, 20 µm.
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Figure 4.5: TNFα and TLR ligands do not affect GLUT4 translocation. HA-
GLUT4-GFP translocation in human adipocytes was assessed by determining the ratio
of fluorescence intensity (F) of the GFP vs. the 633 nm (HA) channel after stimulation
with 200 nM insulin. For each condition, 25 slices were collected per cell and 3 cells were
acquired per condition. The two control bars represent GLUT4 translocation in untreated
cells (± insulin). Each bar represents the mean ± SD of results from triplicates. Result
of 1 representative experiment is shown.
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4.3 Effect of TLR ligands on GLUT1 and GLUT4
expression
In order to determine whether the poly(I:C)- and LPS-induced changes in glucose uptake
were due to altered expression of glucose transporters, I set out to investigate their effects
on GLUT1 and GLUT4 transcription and protein synthesis. Both glucose transporters
are reportedly expressed in adipocytes [91], although only GLUT4 is responsive to insulin
stimulation whereas GLUT1 functions independently of insulin.
4.3.1 Expression of GLUT1 and GLUT4 during adipogenesis
First, I sought to confirm the expression of the two glucose transporters in my cellular
model system. This was performed by qRT-PCR for GLUT1 and GLUT4 in differen-
tiating adipocytes. The adipocyte-specific marker ADIPOQ (adiponectin) was analysed
simultaneously as a positive control for adipogenesis. As shown in Figure 4.6, expres-
sion of GLUT1 mRNA remained approximately constant during differentiation, whereas
GLUT4 mRNA was completely undetectable in preadipocytes but was induced upon
differentiation.
4.3.2 Investigation of GLUT1 expression following stimulation
with TNFα and TLR ligands
Having confirmed the presence of GLUT1 and GLUT4 mRNA in in vitro differentiated
adipocytes, I next examined the effect of TLR ligands on GLUT1 mRNA expression.
Cells were incubated for 3 h or 48 h in medium containing TNFα (positive control),
Pam3CSK4, poly(I:C), LPS, Flagellin (negative control) or in medium without ligands
(untreated control). As shown in Figure 4.7A, neither Pam3CSK4 nor Flagellin influenced
GLUT1 mRNA, whereas prolonged stimulation with TNFα, poly(I:C) and LPS resulted in
a significant induction of GLUT1 expression. This effect was not significant after short (3
h) incubation with the same ligands. These observations agree with the increase in insulin-
independent 2DOG uptake observed in Figure 4.1. Thus, an enhanced expression of
GLUT1 in the presence of poly(I:C) and LPS may be responsible for the increase in basal
glucose uptake. Indeed, western blotting with anti-GLUT1 antibodies also demonstrated
induction of GLUT1 protein at 48 h of incubation with TNFα, poly(I:C) or LPS whereas
in untreated control cells, GLUT1 was not detected at all (Figure 4.7B).
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Figure 4.7: Poly(I:C) and LPS both upregulate GLUT1. (A) In vitro differentiated
adipocytes were incubated for 3 or 48 h in medium containing 50 ng/ml TNFα (positive
control), 1 µg/ml Pam3CSK4, 20 µg/ml poly(I:C), 10 ng/LPS, 20 ng/ml Flagellin (neg-
ative control) or in medium without ligands (untreated control). The fold change in
GLUT1 expression relative to RPLP0 was monitored and analysis was performed using
the 2−∆∆CT method as described in Methods. Shown are normalised and pooled data of
7-10 independent donors (mean ± SEM). Data were analysed using a one-way ANOVA
with Dunnetts Multiple comparison (*/**, p < 0.05/0.01). (B) In vitro differentiated
adipocytes were incubated for 48 h in medium containing 50 ng/ml TNFα (positive con-
trol), 1 µg/ml Pam3CSK4, 20 µg/ml poly(I:C), 10 ng/LPS, 20 ng/ml Flagellin (negative
control) or in medium without ligands (untreated control). Thereafter, cells were lysed
in 1% triton lysis buffer and western analysis was performed using a mouse monoclonal
antibody specific for GLUT1. The bands were detected at their predicted size of 55 kDa
and 38 kDa, respectively. The figure is representative of 6 independent donors.
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So far, my experiments showed that upregulated GLUT1 expression correlates with
the increase in insulin-independent glucose uptake following poly(I:C) and LPS treatment.
A similar LPS-induced upregulation of GLUT1 is an important factor in the activation
of immune cells such as macrophages [402] or T cells [403]. In order to compare GLUT1
induction in adipocytes to macrophages, I studied the effect of LPS on GLUT1 mRNA
induction in monocyte-derived human macrophages. Figure 4.8 shows that LPS results
in a 15-fold upregulation in GLUT1 expression in macrophages 8 h after stimulation.
This agrees with the previously reported literature that enhanced GLUT1 expression is
important for LPS-induced activation of immune cells by enabling a greater influx of
glucose into the cell (and therefore increased glycolysis during the proliferative stage).
The importance of this finding will be discussed in section 4.6.
GLUT1 in monocyte-derived
human macrophages
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Figure 4.8: Upregulation of GLUT1 mRNA in LPS-stimulated macrophages.
Human monocyte-derived macrophages were stimulated with 10 ng/ml LPS. Cells were
lysed after 2, 8 or 24 h following stimulation. The fold change in GLUT1 expression
relative to RPLP0 was monitored and analysis was performed using the 2−∆∆CT method
as described in Methods. Each dot represents the mean ± Error of 1 donor (n = 1).
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4.3.3 Investigation of GLUT4 expression following stimulation
with TNFα and TLR ligands
As a next step, I examined the effect of TLR ligands on GLUT4 expression. As described
for GLUT1, in vitro differentiated adipocytes were stimulated for 3 or 48 h with TLR
ligands, as well as TNFα. As shown in Figure 4.9A, qRT-PCR analysis revealed signifi-
cantly reduced GLUT4 transcript levels when cells were exposed to TNFα or LPS for 48
h (p < 0.001). In contrast, prolonged exposure to poly(I:C) had no effect on steady state
GLUT4 mRNA levels. However, when GLUT4 protein levels were assessed by western
blotting, this was reduced in adipocytes exposed for 48 h to poly(I:C) and LPS (Figure
4.9B). Taken together, this is in line with the effects of the ligands on in insulin-stimulated
2DOG uptake (Figure 4.1).
These data therefore indicate that LPS mediates suppression of GLUT4 via a tran-
scriptional mechanism whereas in the case of poly(I:C), suppression may be mediated via
a post-transcriptional mechanism and/or via suppression of GLUT4 mRNA at a time-
point earlier than 48 h (Figure 4.9A). In fact, a recent study by Franchini et al. [389] has
demonstrated that GLUT4 mRNA expression is suppressed by poly(I:C) at 24 h following
stimulation (but not at 8 h).
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Figure 4.9: Poly(I:C) and LPS both downregulate GLUT4. (A) In vitro differ-
entiated adipocytes were incubated for 3 or 48 h in medium containing 50 ng/ml TNFα
(positive control), 1 µg/ml Pam3CSK4, 20 µg/ml poly(I:C), 10 ng/LPS, 20 ng/ml Flag-
ellin (negative control) or in medium without ligands (untreated control). The fold change
in GLUT4 expression relative to RPLP0 was monitored and analysis was performed us-
ing the 2−∆∆CT method as described in Methods. Shown are normalised and pooled data
of 8-11 independent donors. Data were analysed using a one-way ANOVA with Dun-
netts Multiple comparison (***, p < 0.001). (B) In vitro differentiated adipocytes were
incubated for 48 h in medium containing 50 ng/ml TNFα (positive control), 1 µg/ml
Pam3CSK4, 20 µg/ml poly(I:C), 10 ng/LPS, 20 ng/ml Flagellin (negative control) or in
medium without ligands (untreated control). Thereafter, cells were lysed in 1% triton
lysis buffer and western analysis was performed using a rabbit polyclonal antibody spe-
cific for GLUT4. The bands were detected at their predicted size of 55 kDa and 38 kDa,
respectively. The figure is representative of 3 independent donors.
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4.3.4 Effect of the differentiation state on LPS-induced changes
GLUT1 and GLUT4 gene expression.
A recent study by Xie et al. [404], which studied the effect of macrophages on 3T3-L1
adipocytes, found that macrophage-induced GLUT1 transcript levels were less upregu-
lated in highly differentiated adipocytes than in early differentiated cells. Because of
reported similarities between macrophages and preadipocytes [341] and my finding of LPS-
induced upregulation of GLUT1 in macrophages (Figure 4.8), I wondered whether the
increase in GLUT1 levels in my in vitro differentiated cultures was due to the preadipocyte
fraction present in these cultures.
A procedure developed by Chung et al. [355] allowed me to study any potential dif-
ference between adipocytes and preadipocytes of the same culture in response to LPS.
This was achieved by carefully separating adipocytes from undifferentiated cells by den-
sity centrifugation (described in section 2.2.5 on page 102). Prior to cell separation,
adipocyte cultures were incubated for 3 or 48 h in medium containing 10 ng/ml LPS or
medium alone. LPS-stimulated, in vitro differentiated adipocytes were then separated
from the undifferentiated cell fraction and mRNA was extracted from both fractions
to analyse GLUT1 and GLUT4 expression (Figure 4.10). As expected, the two frac-
tions expressed different amounts of GLUT1 and GLUT4 mRNA in the unstimulated
state: In the unstimulated preadipocyte fraction (pellet), GLUT1 mRNA was 2-fold
more abundant compared to adipocytes (floaters). At the same time, there was a 77-fold
lower abundance of GLUT4 mRNA. Despite variations in GLUT1 and GLUT4 expres-
sion in the unstimulated state, relative LPS-induced GLUT1 upregulation was similar
between preadipocytes and adipocytes. On the other hand, GLUT4 mRNA was only
downregulated in adipocytes whereas in preadipocytes, LPS caused only minor changes
in GLUT4 expression. This may be due to the fact that GLUT4 expression levels are
already extremely low in preadipocytes. Taken together, this data indicates that LPS-
induced upregulation of GLUT1 mRNA is not due to contamination with undifferentiated
preadipocytes but a genuine manifestation of adipocyte biology.
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Figure 4.10: GLUT1 is similarly induced by LPS in differentiated and non-
differentiated cells. Differentiated adipocytes were separated from undifferentiated cells
to investigate whether the differentiation state has an effect on LPS-induced changes in
GLUT1 and GLUT4 expression. Prior to separation, adipocyte cultures were incubated
for 3 or 48 h in medium containing 10 ng/ml LPS or medium alone. LPS-stimulated
cultures were then separated by density centrifugation into mature adipocytes (Floaters)
and preadipocytes (Pellet). (A) shows GLUT1 and GLUT4 expression expression in
each fraction relative to unseparated (Unsep.) cultures. (B) shows LPS-induced changes
in GLUT1 and GLUT4 expression of each fraction normalised to unstimulated control.
Analysis was performed using the 2−∆∆CT method as described in section 2.2.4.4. Each
bar represents the mean ± Error of triplicates of a single experiment.
176
EFFECT ON GLUCOSE HANDLING
4.4 Effect of TLR ligands on Akt phosphorylation
As described in section 1.2.3 (page 36-39), insulin signalling leads to activation of the
PI3K pathway. Akt is a downstream effector of PI3K and many studies support a role
for Akt in insulin-stimulated glucose uptake [118], although this remains controversial
[405]. The inhibitory effect of TNFα on insulin-stimulated Akt phosphorylation is well
recognised in the literature [400]. In contrast, an effect of TLR stimulation on Akt phos-
phorylation in human adipocytes has not been described so far. Based on my findings
that TLR 3 and 4 activation attenuate insulin-stimulated glucose uptake, I sought to
determine whether TLR activation within adipocytes leads to the inhibition of insulin-
stimulated Akt phosphorylation on its activating serine residue (Ser 473). To determine
the optimal pre-incubation with TLR ligands, I first performed a time-course experiment
where I incubated adipocytes with TNFα for various time periods. On day 14, the cells
were serum-starved in DMEM for 4 h prior to stimulation with 200 nM Insulin for 30
min. The stimulation was terminated by washing the cells 1x with ice cold PBS. Akt
phosphorylation was analysed as described in section 2.2.2 (page 92-97).
As shown in Figure 4.11A, TNFα reduced insulin-stimulated Akt phosphorylation
when it was added to the cell medium 24 h - 48 h prior to the experiment. When
added only 4 h prior to insulin stimulation, it showed no inhibitory effect. I therefore
repeated the experiment, this time by pre-incubating the cells for 48 h with Pam3CSK4,
poly(I:C) and LPS. As expected, TLR 2 ligands such as Pam3CSK4 and MALP-2 did not
inhibit insulin-stimulated Akt phosphorylation (Figure 4.11B). Likewise, pretreatment
with poly(I:C) and LPS had no consistent inhibitory effect on Akt phosphorylation in 3
tested donors (Figure 4.11C). However, as described in section 1.2.3, insulin-stimulated
GLUT4 translocation does not necessarily have to be mediated via Akt, and additional
pathways such as the CAP-Cbl pathway have been described. Given that insulin-induced
GLUT4 translocation to the plasma membrane appears to be normal under the presence
of LPS (Figure 4.5), it might be that the CAP-Cbl pathway could compensate for a
defect in Akt phosphorylation. Figure 4.11 also shows that Akt protein expression is not
downregulated by poly(I:C) and LPS.
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Figure 4.11: No inhibitory effect of TLR ligands on insulin-stimulated Akt-
phosphorylation. (A) Prolonged TNFα exposure inhibits Akt phosphorylation. In
vitro differentiated adipocytes of one donor were treated with TNFα at the time-points
indicated. Cells were stimulated with 200 nM insulin or left unstimulated. Cells were lysed
in 1% triton lysis buffer and western analysis was performed using antibodies specific for
Akt phosphorylated on serine 473 and total Akt. (B) & (C) Cells were incubated with
TNFα and TLR ligands for 48 h. The bands were detected at their predicted size of 75
kDa. One (out of three) donors is shown here.
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4.5 Effect of TLR ligands on lipolysis
In this chapter, I have observed that poly(I:C) and LPS induce profound changes in glucose
handling. I thus addressed the question whether these two ligands might also cause a loss
of stored lipids by stimulating the lipolytic system in adipocytes. To investigate this
question, I decided to measure glycerol concentration in the cell culture medium after
incubating the cells in the presence of TLR ligands. As serum is known to enhance
glycerol release by adipocytes [406], all experiments were performed in medium with
reduced serum content (2.5 - 5% DMEM).
Cells were exposed for 72 h to TNFα (positive control), R848 (negative control),
Pam3CSK4, poly(I:C) or LPS. Glycerol concentration in the cell culture medium was
measured using the Free Glyerol Reagent Kit from Sigma which measures free, endogenous
glycerol. As shown in Figure 4.12, incubation with TNFα and poly(I:C) led to a significant
increase of the glycerol content in the medium (p < 0.01), indicating that these two ligands
stimulate lipolysis. LPS, on the other hand, did not cause a significant glycerol release
into the medium. This may simply indicate that LPS has a little effect on lipolytic
activity compared to the other two ligands, as opposed to its great impact on glucose
uptake. However, a confounding factor for reduced activity of LPS might be that cells
were incubated in medium with reduced serum content. This decreases availability of LBP
[407], which is needed for binding of LPS to the TLR4 co-receptor CD14 and therefore
for LPS-induced signalling. This idea is backed up by the fact that cytokines were also
reduced in this system.
In all experiments throughout this chapter, treatment of cultures with the TNFα or
TLR ligands was not associated with detectable changes in cell morphology (assessed by
microscopy).
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Figure 4.12: Poly(I:C), but not LPS, stimulates lipolysis. In vitro differentiated
adipocytes were incubated for 72 h in the presence of 50 ng/ml TNFα (positive control),
1 µg/ml R848 (negative control), 1 µg/ml Pam3CSK4, 20 µg/ml poly(I:C) or 10 ng/ml
LPS. The degree of lipolysis was determined by glycerol release into the medium. For
each donor, the glycerol release of stimulated cells was normalised to that of unstimulated
control cells. Shown are the pooled data of 3 independent donors. Each bar represents
mean induction of glycerol release ± S.E. (**, p < 0.01 versus control as determined by
one-way ANOVA with Dunnetts multiple comparison.)
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4.6 Discussion
At the beginning of this chapter, I hypothesised that the activation of adipocytes by
Pam3CSK4, poly(I:C) and LPS plays an important role in the regulation of metabolism
(e.g glucose uptake) during inflammation. Several considerations gave rise to this hypoth-
esis: First, TLR4-deficient mice were found to be protected from obesity-induced insulin
resistance and diabetes [12, 320, 321, 322]. Second, it has been reported that endotoxemia
leads to insulin resistance in human [397] and rat [408]. Alterations in glucose metabolism
have also been observed during influenza infection, where one of the most severe compli-
cations is hypoglycaemia. This has been described in influenza-infected animals [409, 410]
as well as influenza-infected children [411]. All these observations indicate that immunity
and metabolism must be tightly linked with each other.
The key finding of this chapter is that stimulation of cultured adipocytes with poly(I:C)
and LPS affects glucose uptake. Insulin-independent glucose uptake increases while the
response to insulin decreases following poly(I:C) and LPS treatment. I therefore specu-
lated that this divergence in glucose uptake might be explained by a differential effect of
inflammation on the translocation and/or expression of GLUT isoforms.
When studying GLUT4 translocation in adipocytes, my preliminary experiments indi-
cated that insulin-stimulated trafficking of GLUT4 to the plasma membrane is not affected
by poly(I:C)- and LPS-induced signalling. This outcome was unexpected, as in skeletal
muscle, insulin resistance seems to result from a defect in the insulin-signalling pathways
that regulate GLUT4 translocation [50]. However, the situation in adipocytes seems less
clear and even if inflammation may lead to proximal insulin signalling defects [412], distal
compensatory mechanisms could still allow for normal GLUT4 translocation. Neverthe-
less, my findings on GLUT4 translocation are in agreement with a study by Stephens et
al. [345], where it was demonstrated that TNFα-treated 3T3-L1 adipocytes had no defect
in insulin-induced GLUT4 translocation. However, TNFα still induced insulin resistance
in these cells, as assessed by reduced levels of GLUT4 (and IRS-1) protein expression.
I therefore investigated the effect of poly(I:C) and LPS on the expression of the GLUT
isoforms GLUT1 and GLUT4. I found significantly altered expression of these two glucose
transporters following poly(I:C) and LPS stimulation, although the effect was completely
opposite: Whilst GLUT1 expression was upregulated after 48 h, GLUT4 expression was
suppressed at the same time. How could this seemingly conflicting finding be explained?
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The generation of an immune response is a highly energy-dependent process. Following
exposure to a pathogen, immune cells must be able to immediately shift from a quiescent
phenotype to a highly active state and proliferation must occur within hours of stimulation
[413]. This demands rapid uptake and utilisation of nutrients such as glucose. It has been
shown that inflammation leads to a significant upregulation of the glucose transporter
GLUT1, which is the primary glucose transporter in immune cells including T cells [403]
and macrophages [402]. Thus, reallocation of glucose from peripheral tissues towards the
immune system is a crucial event in the initiation of an immune response and since PRRs
act at the front-line of detection, it seems plausible that glucose uptake is regulated via
these receptors.
As illustrated in Figure 4.13, I now propose that in a healthy individual, glucose
homoeostasis is regulated by insulin. Any excess glucose in the circulation is rapidly
taken up by cells expressing the insulin-sensitive glucose transporter GLUT4 and most
importantly, have the capacity to store all that energy. In the course of an infection,
however, PRRs (e.g. TLRs) may help to channel the precious metabolic fuel from energy-
storing tissue (e.g. adipocytes) to energy-consuming tissue (e.g. immune cells). Thus,
this beneficial pathway might be subverted in obesity through constant inflammation,
leading to insulin resistance in adipocytes. Therefore, insulin resistance in obesity could
be seen as an ”aberrant” response to a condition that may not have been often present
in human evolution.
The decrease in GLUT4 expression following poly(I:C) or LPS stimulation (Figure 4.9)
and the reduction in insulin-stimulated glucose uptake following administration of TNFα,
poly(I:C) and LPS (Figure 4.1) fit with this hypothesis. Notably, GLUT4 concentrations
are reduced in adipocytes from obese subjects and those with impaired glucose tolerance
or T2DM whereas GLUT4 concentrations are not reduced in skeletal muscle in obese
subjects or patients with T2DM [50].
My hypothesis does not explain why poly(I:C) and LPS induce GLUT1 expression
(Figure 4.7) and, as a consequence, insulin-independent glucose uptake in cultures of in
vitro differentiated adipocytes (Figure 4.1). It has been suggested that the phenotype of
preadipocytes is closer to the macrophage than to the adipocyte profile [341]. I therefore
examined whether the increase in insulin-independent glucose uptake may be attributed
to the fraction of undifferentiated cells (i.e. preadipocytes) in the cell culture system.
However, separation of preadipocytes from adipocytes by density centrifugation showed
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no difference in LPS-induced GLUT1 upregulation between preadipocytes and adipocytes
(Figure 4.10) and therefore this cannot be an explanation.
Previous studies demonstrated that GLUT1 expression levels are affected by stress
conditions such as hyperglycaemia [414], hyperinsulinemia [415], or TNFα [416]. Although
I can only speculate about the mechanism leading to increased GLUT1 expression in
adipocytes, I suggest that the elevation in GLUT1 is responsible for the increased glucose
uptake of adipocytes. This might lead to a vicious cycle operating between GLUT1
content and increased stress in adipocytes. At this point, it is important to highlight
that this is just an in vitro model and that future studies should address this question in
vivo. Although hypoglycaemia in sepsis is an observed metabolic disorder [417] it seems
less clear to what extent individual tissues and organs contribute to this effect [418, 419].
Furthermore, glucose metabolism during viral infection remains a completely unexplored
area. From my results I would expect that sepsis and some viral infections leads to a
massive increase in glucose utilisation by cells populating the lymphoid organs (spleen,
lymph nodes) and a decreased glucose uptake into the liver and adipose (epididymal fat
pads).
Figure 4.13: Hypothetical Model. The data in this chapter indicate that inflammation may
cause a shift in the regulation of glucose homoeostasis: Whilst insulin is the key regulator for
glucose uptake in health, glucose uptake during inflammation might become a PRR-dependent
process. This may ensure that glucose is preferably taken up by cells which have encountered
an antigen (i.e. immune cells). This beneficial may be subverted in obesity through constant
inflammation, resulting in insulin resistance in peripheral tissues including adipose.
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According to my hypothesis (Figure 4.13), the activation of PRRs by PAMPs during
infection helps to allocate energy. In obesity, PRRs in adipocytes might be unintention-
ally activated by endogenous ligands that may not be present or detectable under normal
conditions. So far, I can only speculate about the nature of these endogenous ligands.
A possible trigger was identified in 2001, when Lee et al. [196] observed that saturated
fatty acids (SFAs), whose levels are often elevated in obesity, induce NF-κB activation
via TLR4. This finding of SFAs as alternative, cross-reactive ligands for TLR4 has been
supported by others [320, 420] whilst being questioned at the same time: Schaeﬄer et al.
[421] demonstrated that radiolabelled SFAs do not bind directly to TLR4. Additionally,
Erridge et al. [422] suggested that the stimulatory effect of SFAs on TLR4 was due to
endotoxin contamination of the widely used reagent fatty-acid-free BSA (which is com-
monly used to complex SFAs for use in such experiments). Although it is still controversial
whether SFAs do really bind to TLR4, one can imagine that there are other, probably yet
unidentified endogenous metabolites that may induce inflammation and insulin resistance
in obesity via TLR3 or TLR4, respectively.
Another candidate for obesity-induced low-grade inflammation via PRRs might be
the ligands themselves. Animal studies [423, 424] and human evidence [425] suggest that
sub-clinical endotoxemia (caused by low to moderately elevated LPS) may be involved
in obesity-induced insulin resistance. LPS is thought to derive from the death of gram-
negative bacteria in the gut, from where it can migrate into intestinal capillaries by a
TLR4-dependent pathway [426]. The composition of the gut microbiota can be modulated
by the diet: a high-fat diet encourages the growth of gram-negative bacteria and augments
LPS plasma levels [423]. On the other hand, modulating the gut microbiota through
antibiotics has been shown to improve glucose tolerance in DIO insulin-resistant mice
[427].
An emerging and intuitive question of this chapter is why glucose uptake is changed
in response to poly(I:C) and LPS but not in response to Pam3CSK4. In the previous
chapter, I showed that human adipocytes did have a small response to stimulation with
Pam3CSK4 and MALP-2, although the induction in cytokine secretion did not reach
statistical significance such as it did for poly(I:C) or LPS (Figure 3.7, page 125). This
leads me to speculate that Pam3CSK4 may not be potent enough to induce the metabolic
changes observed by poly(I:C) and LPS. This may be due to decreased expression of
TLR2 compared to the other receptors. Another possibility might be that TLR2 plays no
role in metabolic regulation in the human system. In mouse, however, TLR2 was recently
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found to play a role in insulin-stimulated glucose transport [428] and interestingly, my
own data in chapter 3 indicate that murine adipocytes respond stronger to Pam3CSK4
and MALP-2 than their human counterparts (Figure 3.7).
In order to further investigate the link between inflammation and insulin resistance, I
examined whether TLR activation inhibits Akt phosphorylation. Most (if not all) studies
support a role for Akt in mediating insulin-stimulated GLUT4 translocation. I hypothe-
sised that TLR activation within adipocytes induces insulin resistance by inhibiting the
phosphorylation of Akt. However, whilst TNFα consistently decreased the phosphoryla-
tion of Akt, no such effect was found after poly(I:C) and LPS ligand treatment. This is
in contrast to the glucose uptake studies I performed where both LPS and poly(I:C) were
inhibitory within the same time frame. In this context, it is important to note that Akt
phosphorylation might not be a good readout for insulin resistance. Several models of in-
sulin resistance have shown that the induction of insulin resistance is not associated with
a change in Akt phosphorylation [429, 430, 431, 432]. Explanations of my data could be
that Akt is not essential in the insulin-induced GLUT4 translocation cascade or insulin-
stimulated glucose uptake could be mediated by other kinases not tested. As reviewed in
Manning and Cantley [433], there are three Akt isoforms (Akt1, Akt2, Akt3) which can
have distinct cellular functions. Of these isoforms, only Akt2 appears to be required for
insulin-stimulated glucose GLUT4 translocation in adipocytes [118]. However, the anti-
body used in this study detected all three Akt isoforms when phosphorylated at Ser473.
Therefore, an inhibitory effect of poly(I:C) or LPS on Akt2 phosphorylation might have
been undetectable due to strong Akt1 and Akt3 phosphorylation.
Because of the well established role of TNFα in inducing insulin resistance, I used this
cytokine as a positive control throughout this chapter. By doing this I confirmed previ-
ous reports that TNFα treatment significantly changes glucose uptake by suppression of
GLUT4 expression and leads to increased lipolysis. This raises of course the possibility
that insulin resistance might not only be directly induced by TLR activation in adipocytes
(as my data indicate). TLR stimulation of primary human macrophages leads to strong
TNFα secretion and it is well established that macrophages infiltrate the adipose tissue
in obesity [8, 9]. It is therefore plausible that macrophage-derived TNFα may act on
adipocytes in a paracrine manner causing insulin resistance. This theory is supported
by the observation that mice lacking TNFα are protected from obesity-induced insulin
resistance [314]. Furthermore, TNFR1-deficient mice are protected from diet-induced
obesity and have lower levels of insulin and leptin in their circulation [434]. However,
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although macrophages are seen as the main producers of TNFα, it is questionable how
much they contribute to TNFα-induced insulin resistance. On one hand, lethally irra-
diated Tnf −/− mice reconstituted with bone marrow from Tnf −/− mice (Tnf −/−→KO
bone marrow chimera) have enhanced insulin sensitivity compared to Tnf +/+→KO bone
marrow chimera, implicating that macrophage-derived TNFα does play a role in mediat-
ing insulin resistance. On the other hand, Tnf −/−→WT mice are not protected against
insulin resistance when compared with Tnf +/+→WT, suggesting that TNFα does not
uniquely have to be secreted by cells of the haematopoietic system [435]. It is, however,
undisputed that data obtained from mouse models cannot be directly applied to human
physiology, especially since murine adipocytes make TNF and human adipocytes do not.
Administration of a TNFα neutralising antibody to improve insulin sensitivity in obese
human subjects with T2DM has led to inconsistent results. Whilst Ofei et al. [333] re-
ported no effect of TNFα blocking on insulin resistance, a recent study by Stanley et
al. [336] shows that long-term administration of the TNFα blocking antibody etanercept
improves fasting glucose levels in patients with the metabolic syndrome. Nevertheless,
if TNFα secreted by adipose tissue resident macrophages affects adipocytes only in a
paracrine manner, systemic TNFα blocking antibodies may not be able to block the ac-
tivity of endogenous TNFα in adipose tissue [400].
In conclusion, my findings in this chapter demonstrate profound effects of poly(I:C)-
and LPS-induced inflammation on metabolic functions of cultured human adipocytes.
Prolonged exposure of adipocytes to poly(I:C) and LPS significantly changed glucose
uptake which could at least partly be explained by changes in GLUT1 and 4 expression.
In addition to its disturbance of carbohydrate metabolism, poly(I:C) potently stimulated
lipolysis. The combination of these effects may contribute to the development of insulin
resistance in obesity.
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Candidate mechanisms for
immune-regulated glucose handling
by primary human adipocytes
In this chapter I will describe several approaches I used to investigate the mechanism
underlying the changes in glucose handling mediated by poly(I:C) and LPS. As the changes
in glucose uptake are only significant after prolonged incubation with the ligands at 48 h
but not at 3 h, I investigated in this chapter whether glucose metabolism may be regulated
in an indirect manner via a secondary mediator such as a cytokine that accumulates in
the medium during the stimulatory period. This cytokine may signal back to the cells
in a autocrine or paracrine manner, leading to the observed metabolic changes. On the
following pages, this hypothesis will be referred to as the ”cytokine hypothesis”.
Various cytokines have already been linked to the development of insulin resistance
and T2DM, including TNFα [305] and IL-6 [436]. Whilst the ability of TNFα to mediate
insulin resistance is well established, the role of IL-6 remains controversial. Plasma levels
of both cytokines positively correlate with adiposity [5, 305]. This stands in contrast to
the insulin-sensitising, adipocyte-specific hormone adiponectin, whose secretion in obesity
is paradoxically decreased [281]. More recently, interest has grown into the role of the IL-1
family of cytokines and one of its prominent members IL-1β. IL-1β has been known for
a long time to be involved in the pathogenesis of T1D through its toxic effects on β cells
on the pancreas [437]. More recently, it has also been implicated in T2DM, as treatment
of T2DM patients with IL-1 receptor antagonist (IL-1Ra) improved glycemic control and
β cell function [337].
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In order to identify potential candidate cytokines that may be responsible for poly(I:C)-
and LPS-induced changes in glucose uptake, I undertook a proteomic approach: Primary
cultures of human in vitro differentiated adipocytes were stimulated with Pam3CSK4,
poly(I:C) and LPS to assess their cytokine secretion profile with a commercially avail-
able array technique. This led to identification of various cytokines which are candidates
for mediating the metabolic effects observed in the previous chapter and some of these
candidates have been further investigated.
5.1 Testing the cytokine hypothesis and kinetics of
inflammation-induced changes in glucose uptake
In order to test the cytokine hypothesis, I reasoned that conditioned media from poly(I:C)-
stimulated cells would be able to recapitulate glucose handling findings at the shorter 3
h timepoint, since the putative mediator would already be present in a sufficient con-
centration. This could not be done with LPS since the cells have to be incubated in a
serum-free buffer prior to the insulin-stimulated 2DOG uptake assay and TLR4 requires
the presence of the serum component LBP to function [212]. Therefore, in vitro differ-
entiated adipocytes were incubated for 3 h in supernatant obtained from cells that had
been previously stimulated with 20 µg/ml poly(I:C) over night. As shown in Figure 5.1A,
the transfer of supernatant led to profound effects in glucose uptake. In untreated control
cells, insulin increased glucose uptake by a factor of 2.12 ± 0.18 (mean ± SD), whereas
in cells pre-incubated with the supernatant, insulin-stimulated glucose uptake was only
elevated by a factor of 1.29 ± 0.18. Insulin-independent (basal) glucose uptake was ele-
vated by a factor of 1.78 ± 0.19. In contrast to the observations described in the previous
chapter, the effect was already observed after 3 h, thereby indicating that this may result
from factors transferred in the supernatant.
Next, I studied the kinetics of poly(I:C)- and LPS-induced changes in glucose uptake
in more detail by only looking at the changes in basal glucose uptake. Stimulation of
in vitro differentiated adipocytes with TNFα, poly(I:C) and LPS resulted in a time-
dependent increase in insulin-independent glucose uptake, suggesting that this effect may
be mediated via accumulation of a secreted factor, and therefore providing more support
for the cytokine hypothesis.
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Figure 5.1: Further evidence for the cytokine hypothesis. In vitro differentiated
adipocytes of one donor were stimulated in triplicates in KRH buffer containing 20 µg/ml
poly(I:C). 24 h after onset of the stimulation, the culture supernatant was removed from
each well. The supernatant was pooled and transferred to unstimulated cells of the same
donor, where it was left on for 3 h before performing an insulin-stimulated 2DOG uptake
assay. Each bar represents the mean ± SD of results from triplicates. The numbers
above the bars represent fold induction in insulin-stimulated 3H uptake (compared to the
unstimulated control). (B) The kinetics of the increase in insulin-independent glucose
uptake were investigated in in vitro differentiated adipocytes isolated from one donor.
Cells were incubated with 50 ng/ml TNFα, 20 µg/ml poly(I:C) or 10 ng/ml LPS for
various time-points. Each bar represents the mean ± SD of results from triplicates.
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5.2 Investigating a potential role of IL-6, IL-8 and
type I IFN on insulin-stimulated glucose uptake
As a further step, I decided to investigate the effect of ”obvious” candidates such as IL-6
and IL-8 on glucose uptake, since I knew that these cytokines are secreted in large quan-
tities following poly(I:C) and LPS stimulation. Additionally, stimulation with poly(I:C)
results in production of IP-10 which may be a secondary effect to induction of type I IFN.
Whilst IL-6 has already been implicated in whole body insulin resistance [436] (albeit the
data are still controversial), a role for IL-8 has so far not been demonstrated. Similarly,
a potential role for IFNα/β in mediating insulin resistance has only been poorly inves-
tigated, although a study has shown that IFN therapy induces insulin resistance in the
peripheral tissues of hepatitis C patients [438]. It therefore seemed possible that these
cytokines could be involved in the regulation of glucose uptake in adipocytes and therefore
a potential role was investigated by performing a 2DOG uptake assay.
In vitro differentiated adipocytes were incubated with 50 ng/ml of each cytokine to be
tested, or 50 ng/ml of TNFα as a positive control. As observed previously, TNFα treat-
ment led to a decrease in insulin-stimulated 2DOG uptake whereas insulin-independent
2DOG uptake was enhanced (Figure 5.2). However, treatment with IL-6, IL-8 or IFNα/β
did not have any apparent effect on 2DOG uptake. Therefore, it seems unlikely that these
cytokines are mediating the poly(I:C)- and LPS-induced metabolic changes, although fur-
ther investigations testing the ability of IFN to induce IP-10 and proving the functionality
of IL-6/IL-8 receptors on adipocytes were not performed.
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Figure 5.2: Administration of recombinant human IL-6, IL-8 and type I IFN
has no effect on glucose uptake. In vitro differentiated adipocytes were treated for
48 h with 50 ng/ml of IL-6, IL-8, IFNα, IFN β or TNFα (positive control). 3 h prior
to the assay, cells were starved in KRH buffer and then stimulated for 30 min with 200
nM insulin. Glucose uptake was initiated by addition of 3H-2DOG (final concentration:
100 µM, 1 µCi per well). Uptake was terminated after 10 min by washing the cells
with ice-cold PBS. Cells were lysed in 1% SDS and radioactivity was measured by liquid
scintillation counting. Each bar represents the mean ± SD of results from triplicates.
Data shown are from one representative donor.
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5.3 Proteomic array to identify novel candidates that
may regulate glucose uptake in adipocytes
Since none of the candidate cytokines examined in section 5.2 exerted a measurable effect
on glucose uptake in adipocytes, I undertook a proteomic approach as described in section
2.2.6 (page 103) to identify novel candidates.
5.3.1 Cytokine profiling of LPS-stimulated human adipocytes
A commercially available membrane-based human cytokine antibody array was used for
simultaneous detection of 120 different cytokines following LPS-stimulation of human
adipocytes (Figure 5.3). In vitro differentiated cells were incubated in medium contain-
ing LPS or medium alone for 48 h. I then confirmed that the cells showed the expected
biological behaviour by assaying glucose uptake after 48 h. Relative cytokine levels were
determined by chemiluminescence detection followed by densitometry analysis. Figure 5.4
shows the relative intensity of each tested cytokine, thereby demonstrating that even in
the unstimulated state, in vitro differentiated adipocytes secrete a large array of different
cytokines and chemokines. Particularly noteworthy is the basal release of the following
proteins: the insulin-sensitising hormone adiponectin, the angiogenesis-promoting pro-
teins angiogenin and angiopoietin-2, the death receptor Fas (also known as CD95), the
neutrophil chemoattractant growth regulated oncogene (GRO), IL-6, the appetite- and
metabolism-controlling hormone leptin, MCP-1, the macrophage migration inhibitory fac-
tor (MIF), osteoprotegerin (OPG; an osteoclastogenesis inhibitory factor) and the tissue
inhibitors of metalloproteinases 1 and 2 (TIMP1/TIMP2). As observed previously (sec-
tion 3.2.4, page 122), TNFα was not released by human adipocytes. In contrast, the
soluble TNF receptor (sTNFRI/II) which can modulate the effects of TNFα by acting as
an antagonist was detected.
When adipocytes were stimulated with LPS, the level of GRO, IL-6, MCP-1 and the
macrophage inflammatory protein-1α/β (MIP-1α/β) increased markedly (Figure 5.5).
Some cytokines also appeared de novo following LPS stimulation. This included the
neutrophil-activating protein-78 (ENA-78; also known as CXCL5), the glucocorticoid in-
duced tumour necrosis factor receptor family related gene (GITR; also known as TN-
FRSF18), GRO-α, IL-5, IL-8 and regulated upon activation normal T-cell expressed, and
presumably secreted (RANTES). Of particular note, IL-1 was not induced by LPS in this
donor (discussed later in 5.7).
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Figure 5.3: Human cytokine antibody array. Membrane-based human cytokine an-
tibody arrays from Raybiotech were used to detect cytokines secreted by in vitro dif-
ferentiated human adipocytes stimulated with 10 ng/ml LPS or control media for 48 h.
The relative cytokine level was determined by chemiluminescence detection followed by
densitometry analysis according to the manufacturer’s instruction (section 2.2.6). Pos-
itive controls were located at the upper left-hand corner (four spots) and at the lower
right-hand corner (two spots) in each membrane. Some of the detected cytokines are
highlighted in the figure as an example. Two different membranes were purchased (A
and B) which allowed simultaneous detection of 120 different cytokines. Abbreviations:
Granulocyte chemotactic peptide-2 (GCP-2), glucocorticoid induced tumour necrosis fac-
tor receptor family related gene (GITR), growth regulated oncogene (GRO), epithelial
neutrophil-activating protein-78 (ENA-78), monocyte chemoattractant protein 1 (MCP-
1), macrophage inflammatory protein-1 (MIP-1), osteoprotegerin (Ost.), regulated upon
activation normal T-cell expressed, and presumably secreted (RANTES), tissue inhibitor
of metalloproteinase-1/2 (TIMP-1/2).
193
CHAPTER 5
F
ig
u
re
5.
4:
H
u
m
a
n
cy
to
k
in
e
a
n
ti
b
o
d
y
a
rr
a
y
-
R
e
la
ti
v
e
in
te
n
si
ty
o
f
cy
to
k
in
e
s
T
h
is
fi
gu
re
sh
ow
s
th
e
re
la
ti
ve
in
te
n
si
ty
of
cy
to
k
in
es
d
et
ec
te
d
in
th
e
m
ed
iu
m
of
ce
ll
s
st
im
u
la
te
d
w
it
h
10
n
g/
m
l
L
P
S
fo
r
48
h
(a
rb
it
ra
ry
sc
al
e)
.
T
h
e
ar
ra
y
w
as
p
er
fo
rm
ed
an
d
an
al
y
se
d
as
d
es
cr
ib
ed
in
se
ct
io
n
2.
2.
6.
194
CANDIDATE MECHANISMS
F
ig
u
re
5.
5:
H
u
m
a
n
cy
to
k
in
e
a
n
ti
b
o
d
y
a
rr
a
y
-
F
o
ld
in
d
u
ct
io
n
o
f
cy
to
k
in
e
s.
T
h
is
fi
gu
re
sh
ow
s
th
e
fo
ld
in
d
u
ct
io
n
of
cy
to
k
in
es
af
te
r
st
im
u
la
ti
on
w
it
h
10
n
g/
m
l
L
P
S
.
T
h
e
ar
ra
y
w
as
p
er
fo
rm
ed
an
d
an
al
y
se
d
as
d
es
cr
ib
ed
in
se
ct
io
n
2.
2.
6.
195
CHAPTER 5
5.3.2 Secretion profile of adipocytes stimulated with Pam3CSK4,
poly(I:C) and LPS
In addition to the cytokine array, I also performed a human adipokine antibody array
which allowed simultaneous detection of 62 different adipokines, some of which are also
found on the cytokine array. This array was performed using adipocytes from a different
donor to that in section 5.3.1 and cells were stimulated with Pam3CSK4, poly(I:C) and
LPS (Figure 5.6). As for the cytokine array, relative protein levels were determined by
chemiluminescence detection followed by densitometry analysis. Figure 5.7 shows the
relative intensity of each tested adipokine. In agreement with the cytokine array (Figure
5.4), unstimulated control cells from this donor were also found to release adiponectin, Fas
(CD95), IL-6, leptin, MCP-1, OPG, as well as TIMP-1 and -2. In addition, this array also
detected basal release of Angiogenin-2 (Ang-2), plasminogen activator inhibitor-1 (PAI-1)
and serum amyloid A (SAA), factors which were not present on the cytokine array. The
basal release of a few proteins differed slightly from the adipokine array: Whilst PARC
(pulmonary activation regulated chemokine) and SDF-1 (stromal cell-derived factor 1)
were not detected in the cytokine array, their basal release was detected in the adipokine
array. Also, unstimulated cells of this donor secreted IL-8 and MIP-1β (which were not
released by cells of the other donor in the basal state). This results highlights variation
between the primary cells of different donors.
Stimulation with Pam3CSK4, poly(I:C) and LPS led to upregulation of various pro-
teins (Figure 5.8). As observed in the previous donor, ENA-78 was secreted by LPS-
stimulated cells (see Figure 5.8 and Figure 5.11). Interestingly, ENA-78 was also induced
by poly(I:C) whereas stimulation with Pam3CSK4 had no effect on its expression.
Importantly, IL-1-α/β was secreted in this donor following stimulation with poly(I:C)
and LPS (and Pam3CSK4 to a smaller extent). Other cytokines which were also found
to be induced or upregulated upon stimulation with Pam3CSK4, poly(I:C) and/or LPS
include: IL-6, IL-8, IP-10, MCP-1, MCP-3, PDGF-BB (platelet-derived growth factor-
BB) and RANTES. Of note, poly(I:C) stimulation suppressed secretion of Ang-2 and
leptin and curiously, insulin secretion appeared to be upregulated following poly(I:C)
stimulation. Possible explanations for this are discussed in section 5.7.
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Figure 5.6: Human adipokine antibody array. Membrane-based human adipokine
antibody arrays were purchased for simultaneous detection of 62 human adipokines se-
creted by in vitro differentiated human adipocytes stimulated with 1 µg/ml Pam3CSK4,
20 µg/ml poly(I:C) or 10 ng/ml LPS or control media for 48 h. The relative adipokine
level was determined by chemiluminescence detection followed by densitometry analy-
sis. Positive controls were located at the upper left-hand corner (four spots) and at the
lower right-hand corner (two spots) in each membrane. Some of the detected adipokines
are highlighted in the figure as an example. Abbreviations: Angiogenin-2 (Ang2), ep-
ithelial neutrophil-activating protein-78 (ENA-78), monocyte chemoattractant protein
1/3 (MCP-1/3), macrophage inflammatory protein-1 (MIP-1), osteoprotegerin (OPG),
platelet-derived growth factor (PDGF-BB), regulated upon activation normal T-cell ex-
pressed, and presumably secreted (RANTES), serum amyloid A (SAA), stromal cell-
derived factor 1 (SDF1), tissue inhibitor of metalloproteinase-1/2 (TIMP-1/2), soluble
tumour necrosis factor receptor 2/1 (sTNFR2/1).
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Figure 5.7: Human adipokine antibody array - Relative intensity of adipokines.
This figure shows the relative intensity of cytokines detected in the medium of stimulated
and unstimulated cells (arbitrary scale). The cells were stimulated with either 1 µg/ml
Pam3CSK4, 20 µg/ml poly(I:C) or 10 ng/ml LPS for 48 h. The array was performed and
analysed as described in section 2.2.6.
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Figure 5.8: Human adipokine antibody array - Fold induction of adipokines.
This figure shows the fold induction of cytokines detected in the medium of cells stimulated
with 1 µg/ml Pam3CSK4, 20 µg/ml poly(I:C) or 10 ng/ml LPS for 48 h. The array was
performed and analysed as described in section 2.2.6.
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5.3.3 Selection of candidates
Detailed analysis of the adipokine and cytokine array allowed me to compile a list of
candidates that may be responsible for changes in glucose uptake as predicted by the
cytokine hypothesis. I rated these candidates based on their fold induction and focused
on cytokines/adipokines with a fold induction of ≥ 5. This led to a selection of candidates
which are summarised in Figure 5.9. Figures 5.10 and 5.11 give an overview of the fold
induction of some interesting candidates and also show IL-6, IL-8 and MCP-1 as a com-
parison. Adiponectin, whose secretion level was relatively unaffected by LPS stimulation,
is shown in Figures 5.10 because of its great importance as a insulin sensitising mediator.
Figure 5.9: Overview of candidates from the adipokine and cytokine array.
Candidates were selected based on their fold upregulation by a factor of ≥ 5.
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5.4 Investigating a potential role for ENA-78 in reg-
ulating glucose uptake
ENA-78, also known as chemokine CXC ligand 5 (CXCL5), was first identified as a
product of epithelial cells after stimulation with IL-1β or TNFα [439]. Interestingly, this
protein has been previously shown to be upregulated in abdominal subcutaneous adipose
tissue samples obtained from obese subjects (compared to lean samples) [440]. In a recent
study, ENA-78 was found to have a crucial role in linking obesity to insulin resistance
in mice [441]. However, that study described macrophages to be the primary source of
this chemokine. Since both antibody arrays have shown induction of ENA-78 secretion
by adipocytes following stimulation with poly(I:C) and LPS (Figures 5.10 and 5.11), I
speculated that this chemokine might potentially regulate poly(I:C)- and LPS-induced
glucose uptake in adipocytes.
In order to confirm and quantify the results of the cytokine arrays, cultures of in
vitro differentiated human adipocytes were stimulated with Pam3CSK4, poly(I:C) and
LPS, and levels of ENA-78 in the cell culture medium were determined at 24 h following
stimulation. Stimulation with all ligands resulted in a dose-dependent secretion of ENA-78
into the medium (Figure 5.12A). Adipocytes were found to secrete low basal levels of ENA-
78, similar to IL-6, IL-8 and MCP-1 (Figure 5.12A). The results obtained were similar to
the results of the adipokine array (Figure 5.11): Stimulation with Pam3CSK4 for 24 h led
to a 11±4.6-fold upregulation of ENA-78 (adipokine array: 4-fold upregulation) (Figure
5.12B). Poly(I:C) stimulation resulted in a 67±20-fold upregulation (adipokine array: 121-
fold upregulation) and LPS stimulation induced ENA-78 by a factor of 76±26 (adipokine
array: 134). However, although ENA-78 was confirmed to be strongly upregulated by
poly(I:C) and LPS, administration of recombinant ENA-78 to adipocyte cultures did not
affect glucose uptake (Figure 5.12C) or the expression of the glucose transporters GLUT
1 or GLUT4 (Figure 5.12D). This may indicate that ENA-78, despite being produced in
locally inflamed adipose tissue [441], may exert its insulin resistance-inducing action in
other tissues such as muscle or liver. However, similarly to section 5.2, it is not known
for sure whether the ENA-78 receptor is expressed by these cells or if this recombinant
material is able to activate it.
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Figure 5.12: ENA-78 has no effect on glucose handling but is strongly induced
following stimulation with poly(I:C) and LPS. (A) In vitro differentiated adipocytes
were stimulated with various doses of Pam3CSK4, poly(I:C) and LPS. Culture super-
natant were harvested after 24 h to assay production of ENA-78 by ELISA. Each bar
represents the mean ± SD of results from triplicates. The experiment was repeated with
cells from 3 different donors with consistent result. (B) Cells were stimulated for 24 h
in the presence of medium alone or medium containing 1 µg/ml Pam3CSK4, 20 µg/ml
poly(I:C) or 10 ng/ml LPS. Culture supernatant were harvested to assay production of
ENA-78 by ELISA. The data shown are pooled from 3 independent donors and represent
the fold induction of ENA-78 secretion (mean ± SEM). For each donor, the calculated
mean of ENA-78 secretion was normalised to the mean of the unstimulated cell frac-
tion. (C) Normalised 3H-2DOG uptake by adipocytes of 1 representative donor (out of
3). Adipocytes were treated for 48 h with 50 ng/ml ENA-78. 3 h prior to the assay,
cells were starved in KRH buffer and then stimulated for 30 min with 200 nM insulin.
Glucose uptake was initiated by addition of 3H-2DOG (final concentration: 100 µM, 1
µCi per well). Uptake was terminated after 10 min by washing the cells with ice-cold
PBS. Cells were lysed in 1% SDS and radioactivity was measured by liquid scintillation
counting. Each bar represents the mean ± SD of results from triplicates. (D) Differen-
tiated adipocytes of one donor were incubated for 48 h in medium containing 50 ng/ml
TNFα (positive control), 50 ng/ml ENA-78 or in medium alone (untreated control). Cells
were lysed in 1% triton lysis buffer and western analysis was performed using antibodies
targeting GLUT1 and GLUT4. Note: intervening lanes between TNFα and ENA-78 have
been removed in this blot.
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5.5 Investigating a potential role for IL-1 in regulat-
ing glucose uptake
As shown in Figure 5.11, stimulation with poly(I:C) and LPS led to an approximate 100-
fold induction of IL-1β whereas IL-1α was upregulated by a factor of 29.5 [for poly(I:C)]
or 3.4 (for LPS), respectively. This finding, although not being supported by the cytokine
array, made IL-1 therefore an important candidate for the cytokine hypothesis. IL-1 has
been the subject of intense investigation recently and has not only caught the attention
of academical researchers but also of the pharmaceutical industry [351]. Whilst the toxic
effects of IL-1 on β cells has long been linked to the development of T1DM [437], recent
studies have underscored its potential role in the pathology of insulin resistance and
T2DM in human [337] and rodents [338, 339]. However, unlike TNFα, far less is known
about how IL-1 might cause insulin resistance [442]. With this in mind, my results of the
adipokine array promoted me to explore the role of IL-1 in cultured human adipocytes.
5.5.1 Influence of Poly(I:C) and LPS on IL-1β
In order to verify the results of the adipokine array, the supernatant of poly(I:C)- and
LPS-stimulated in vitro differentiated adipocytes was analysed by ELISA for secretion of
IL-1β. However, despite the fact that this assay is used routinely in the lab, the level of
IL-1β protein in the cell culture supernatant was below the detection limit of 50 pg/ml.
I therefore examined the level of IL1B mRNA in stimulated adipocytes (Figure 5.13A).
In cells treated with poly(I:C), IL1B mRNA was induced at 2 h post stimulation, and
a maximal effect was observed after 16 h with a 11.3±2.9-fold induction. Compared
to poly(I:C), LPS affected IL1B transcription more rapidly and strongly: mRNA was
induced at 1 h post stimulation and reached its maximum at 4 h with a mean fold induction
of 47.7±3.4. Hence, there was potentially a discrepancy between IL1B mRNA induction
and secretion of mature IL-1β. This may be explained by one of the various control
mechanisms that regulate IL-1β release. In addition to conventional gene regulatory
mechanisms (e.g. transcription and translation), IL-1β processing and release is tightly
regulated by an intracellular protein complex termed the inflammasome [160]. Human
IL-1β is synthesised as a 31 kDa inactive precursor (see Figure 1.5 on page 44). To gain
activity, the precursor must be cleaved by caspase-1 between Asp116 and Ala117 to yield
a 17 kDa mature form [165, 443]. In contrast to human monocytes, human macrophages
are reportedly unable to release IL-1β solely by TLR ligand stimulation [444], despite
transcriptional activation and translational de-repression occurring. Nonetheless, a recent
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study has shown the presence of the mature forms of IL-1β in cell lysates of LPS-stimulated
macrophages [444], suggesting that mature IL-1β is produced but not secreted by the cell.
In order to examine whether human adipocytes behave similarly to human macrophages,
macrophages and in vitro differentiated adipocytes were stimulated with LPS over a time-
course and subjected to western blotting for detection of mature IL-1β. The antibody I
used allowed specific detection of the 17 kDa processed form of IL-1β but not the precur-
sor form. Whereas macrophages cleaved IL-1β as expected 2 to 4 h after stimulation, this
could not be detected in lysates of adipocytes (5.13B). This suggests that adipocytes do
not cleave IL-1β at the timepoints investigated, but more experiments with finer dissection
of different timepoints will be needed to allow for any firm conclusion.
5.5.2 Effect of IL-1 on secretion of other cytokines and regula-
tion of glucose handling
Since I was unable to detect IL-1β in adipocytes by ELISA or western blotting, I won-
dered whether the cells are responding to extremely low IL-1 concentrations. Thus, I
investigated the sensitivity of adipocytes to IL-1 by stimulating cells with a dose titration
of recombinant human IL-1α (0.001 - 10 ng/ml; Figure 5.14). I used the IL-1α subtype
for practical reasons as this was already available in the laboratory. Both subtypes re-
portedly signal via the IL-1 type 1 receptor, leading to activation of the NF-κB pathway
[442]. As shown in Figure 5.14B/C, IL-1 stimulation led to a strong dose-dependent se-
cretion of IL-6, IL-8 and MCP-1, and to a moderate induction of IP-10. IL-1-induced
secretion of IP-10 has so far been reported for human umbilical vein endothelial cells and
astrocytes but not for monocytes [445, 446]. Importantly, IL-1 proved to be extremely
potent since 10−2 ng/ml (10 pg/ml) was sufficient to induce cytokine production by the
cells. Hence, IL-1 seems to act at concentrations that are below the detection limit of
our ELISA, suggesting that the adipokine array may have been more sensitive than the
other detection methods used. It is therefore plausible that IL-1 is produced at a very
low concentration by poly(I:C)/LPS-stimulated adipocytes, a concentration which may
be sufficient to induce a biological response but not high enough to be picked up by the
cytokine array and IL-1 ELISA.
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Figure 5.13: Poly(I:C) and LPS induce IL1B mRNA. (A) In vitro differentiated
adipocytes in a 12-well plate were stimulated with 20 µg/ml poly(I:C) or 10 ng/ml LPS.
Normalised relative amount of IL1B mRNA expression was determined by qRT-PCR in
3 independent donors. For each donor, the mRNA level detected in unstimulated cells
was normalised against RPLP0 and attributed a value of 1. IL1B transcript levels of
stimulated cells was expressed relative to unstimulated cells. Shown is the mean fold
upregulation ± SEM of the mean ratio of IL1B to RPLP0 (3 pooled donors). Time
points post stimulation are indicated on the x axis. (B) In vitro differentiated adipocytes
(left) and monocyte-derived human macrophages (right) were stimulated in a 24-well
plate with 10 ng/ml LPS at time-points indicated. Cells were lysed in 1% triton to ex-
tract cytoplasmic proteins. Proteins were separated by SDS-PAGE, transferred to PVDF
membranes, and probed with an antibody for the 17 kDa processed form of IL-1β (which
does not recognise the uncleaved precursor of IL-1β). Blots shown are representative for
2 (adipocytes) and 1 (macrophages) donors.
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Figure 5.14: IL-1 stimulates production of pro-inflammatory cytokines at low
concentrations. (A) Primary in vitro differentiated adipocytes were stimulated with 10
ng/ml IL-1α. Culture supernatant were harvested after 24 h to assay cytokine production
by ELISA. The data shown are pooled from 6 independent donors and represent the mean
± SEM. (B) & (C) Cells were stimulated with various doses of IL-1α. Culture supernatant
were harvested after 48 h to assay cytokine production by ELISA. Each bar represents
the mean ± SD of results from triplicates.
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When examining the ability to modulate glucose handling, I found that IL-1 regulates
insulin-dependent and -independent glucose uptake at the tested concentrations of 0.1
and 10 ng/ml (Figure 5.15A). Insulin-independent glucose uptake was enhanced in a
dose-dependent manner by a factor of 2.1±0.1 and 3.1±0.8, respectively. At the same
time, insulin-stimulated glucose uptake was reduced from a factor of 2.31 (control) to a
factor of 1.19 and 1.09, respectively. Therefore, glucose uptake by IL-1-treated cells shows
the same pattern as glucose uptake by cells that have been stimulated with poly(I:C) and
LPS. Analysis of GLUT1 protein expression at various doses of IL-1 revealed consistent
induction, which required only 10 pg/ml of IL-1, with a strong induction occurring at a
range between 100 pg/ml - 10 ng/ml (Figure 5.15B). As already shown for poly(I:C) and
LPS in section 4.1.2, the decrease in insulin-stimulated glucose uptake was mirrored by a
decrease in GLUT4 mRNA (Figure 5.15C), whereas the increase in insulin-independent
glucose uptake and GLUT1 protein accorded with enhanced GLUT1 mRNA. Hence, IL-
1-induced changes in glucose uptake may be caused by the same mechanism as that of
cells treated with poly(I:C) and LPS.
5.5.3 Inhibition of IL-1-dependent adipocyte effects by IL-1Ra
(anakinra)
Binding of IL-1 to its receptor is blocked by IL-1Ra, which is a 152-amino acid, non-
glycosylated protein originally isolated from monocytes [447]. Commercially produced
recombinant mature IL-1Ra is known as anakinra, which binds to IL-1 receptors without
inducing a cellular response, thereby antagonising competitively the inflammatory effects
of IL-1α and IL-1β [448]. In order to investigate the effect of anakinra, I first tested
its ability to block IL-1 signalling in human preadipocytes. Human preadipocytes were
incubated for 6 h with 1 or 10 ng/ml of IL-1 in the presence or absence of 50 µg/ml
anakinra. As shown in Figure 5.16, anakinra completely blocked IL-1-induced cytokine
production, thereby confirming its functionality.
Having confirmed that the anakinra is functional, I tested its effect on poly(I:C)-
induced dysregulation of glucose uptake. To this end, in vitro differentiated human
adipocytes were incubated for 48 h with poly(I:C) in the presence or absence of 10 or 50
µg/ml anakinra. Anakinra was added 1 h prior to incubation with poly(I:C). As shown
in Figure 5.17A, anakinra partially restored glucose uptake by reducing the poly(I:C)-
dependent increase in basal glucose uptake and moderately increasing insulin-stimulated
glucose uptake. This result was in line with a substantial reduction in poly(I:C)-induced
209
CHAPTER 5
Figure 5.15: IL-1 can regulate glucose handling. (A) In vitro differentiated
adipocytes were treated for 48 h with 0.1 or 10 ng/ml IL-1α. 3 h prior to the assay,
cells were starved in KRH buffer and then stimulated for 30 min with 200 nM insulin.
Glucose uptake was initiated by addition of 3H-2DOG (final concentration: 100 µM, 1
µCi per well). Uptake was terminated after 10 min by washing the cells with ice-cold
PBS. Cells were lysed in 1% SDS and radioactivity was measured by liquid scintillation
counting. Each bar represents the mean ± SD of results from triplicates. Data shown are
from 1 representative donor (n=2). (B) In vitro differentiated adipocytes were incubated
for 48 h in medium containing different concentrations of IL-1α or medium alone. There-
after, cells were lysed in 1% triton lysis buffer and analysis was performed using a mouse
monoclonal antibody specific for GLUT1. The figure is representative of 4 independent
donors. (C) In vitro differentiated adipocytes were incubated for 3 or 48 h in medium con-
taining 50 ng/ml TNFα, 10 ng/ml IL-1α or in medium without ligands (control). The fold
change in GLUT1 and GLUT4 expression relative to RPLP0 was monitored and analysis
was performed using the 2−∆∆CT method as described in Methods. Shown are normalised
and pooled data of 3 independent donors (mean ± SEM). Data were analysed using a
one-way ANOVA with Dunnetts Multiple comparison (*/**/***, p < 0.05/0.01/0.001).
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Figure 5.17: Anakinra partially restores poly(I:C)-induced changes in glucose
uptake. (A) In vitro differentiated adipocytes were treated for 48 h with 20 µg/ml
poly(I:C) in the presence or absence of 10 or 50 µg/ml anakinra. For each assay, anakinra
was added 1 h prior to stimulation with poly(I:C). On day 2, cells were starved for 3 h in
KRH buffer and then stimulated for 30 min with 200 nM insulin (grey & black bars) or
left unstimulated (white bars). Glucose uptake was initiated by addition of 3H-labelled
2-DOG (final concentration: 100 µM, 1 µCi per well). Uptake was terminated after 10
min by washing the cells with ice-cold PBS. Cells were lysed in 1% SDS and radioactivity
was measured by liquid scintillation counting. Shown are the pooled data of 3 (left) or 2
(right) independent donors. Results of each donor were normalised before pooling. Each
bar represents the mean ± SEM. For each experiment shown in (A), the supernatant of
the cells was analysed on day 2 for reduction of poly(I:C)-induced cytokines following
administration of 10 or 50 µg/ml of anakinra (panel B). Shown are the pooled data of 3
(grey) or 2 (black) different donors.
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cytokines following administration of 10 or 50 µg/ml anakinra (Figure 5.17B). Here, the
effect of anakinra is expressed in terms of the % reduction compared to the effect of
poly(I:C) alone. The inhibition of poly(I:C)-induced cytokines appeared to be dependent
on the different doses of anakinra. Although the pooled data of the glucose uptake as-
say (Figure 5.17A) do not indicate a dose-dependent effect of anakinra, the data of each
donor did show a dose-dependent effect when analysed individually. Therefore, poly(I:C)-
induced IL-1 might play a role in dysregulation of glucose uptake in adipocytes.
5.6 Investigating the effect of adiponectin on glucose
handling
The results of the cytokine and adipokine array have shown that the level of the insulin-
sensitising hormone adiponectin is only slightly decreased following poly(I:C) and LPS-
induced stimulation (Figure 5.10 and 5.11). However, as this adipokine is currently highly
topical in the literature and a study in mouse macrophages demonstrated that it in-
hibits TLR-mediated NF-κB activation [449], I wondered whether small modulation in
adiponectin levels could influence LPS-mediated disregulation of glucose uptake.
In vitro differentiated human adipocytes of one donor were exposed to LPS for 48 h
with and without 10 µg/ml additional recombinant adiponectin and response to insulin
was assessed by performing a 2DOG uptake assay. On day 2, an insulin-stimulated glucose
uptake assay was performed on the cells. Whilst LPS treatment alone reduced insulin-
stimulated glucose uptake as expected, administration of adiponectin led to a moderate
increase in insulin-stimulated glucose uptake (+ 13%) but no affect on basal glucose uptake
(Figure 5.18A). Therefore, adiponectin has the potential to upregulate insulin-stimulated
glucose uptake, albeit the increase is not completely convincing. The effect of poly(I:C)
and LPS on adiponectin expression levels was further investigated at various time-points
in another donor, by relative quantification of ADIPOQ mRNA in stimulated cells. Whilst
poly(I:C) stimulation resulted in minor upregulation of ADIPOQ, LPS treatment caused
a small decrease in mRNA expression around 4 h following stimulation.
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Figure 5.18: Recombinant human adiponectin only moderately restores dys-
regulated glucose uptake in adipocytes. (A) In vitro differentiated adipocytes were
treated for 48 h with 10 ng/ml LPS (left) or a combination of 10 ng/ml LPS + 10 µg/ml
adiponectin (right). 3 h prior to the assay, cells were starved in KRH buffer and then
stimulated for 30 min with 200 nM insulin. Glucose uptake was initiated by addition of
3H-labelled 2-DOG (final concentration: 100 µM, 1 µCi per well). Uptake was terminated
after 10 min by washing the cells with ice-cold PBS. Cells were lysed in 1% SDS and ra-
dioactivity was measured by liquid scintillation counting. Each bar represents the mean
± SD of results from triplicates. Data shown are from 1 donor. (B) In vitro differentiated
adipocytes were stimulated with 20 µg/ml poly(I:C) or 10 ng/ml LPS. Normalised rela-
tive amount of adiponectin mRNA expression was determined by qRT-PCR in 1 donor.
For each donor, the mRNA level detected in unstimulated cells was normalised against
RPLP0 and attributed a value of 1. ADIPOQ transcript levels of stimulated cells was
expressed relative to unstimulated cells. Shown is the mean fold upregulation ± SEM of
the mean ratio of ADIPOQ to RPLP0. Time points post stimulation are indicated on
the x axis.
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5.7 Discussion
This chapter is built around my hypothesis that the poly(I:C)- and LPS-induced changes
in glucose uptake in adipocytes may be mediated via cytokines produced by the cells
themselves. Indeed, these adipocyte-derived secreted factors, commonly summarised un-
der the term ”adipokines”, are currently one of the main focuses in the literature and
the central topic of many recent reviews [346, 450, 451, 452]. The list of newly discov-
ered adipokines is growing rapidly and the current literature suggests that many of these
adipokines are involved in the pathogenesis of insulin resistance and diabetes.
Given that the magnitude of immune-mediated regulation of glucose uptake appeared
to be correlated with the duration the ligands were left on the cells (Figure 5.1), it
seemed plausible that adipokines may play an important role. I therefore tested the effect
of IL-6 and IL-8 on glucose uptake, as I have shown that these cytokines are secreted by
adipocytes upon stimulation with poly(I:C) and LPS. However, whereas TNFα had clearly
an effect on 2DOG uptake, these cytokines appeared to have no effect (Figure 5.2). As
already mentioned, the data for IL-6 in mediating insulin resistance in adipocytes remain
conflicting. Whilst some studies have demonstrated that IL-6 promotes insulin resistance
in 3T3-L1 [453], others have challenged these data by showing that IL-6 enhanced glucose
uptake in 3T3-L1 adipocytes [454].
I next sought to identify novel adipokines that may act as potential regulators of
metabolic function. To this end, I carried out cytokine and adipokine profiling of factors
secreted by primary cultures of human differentiated subcutaneous adipocytes (section
5.3). I have found that adipocytes are a major source of several molecules regulating
inflammation (IL-1, IL-5, IL-6, GITR, MIF) and a few factors that regulate cell death
and cellular growth (Fas, SAA, angiopoietin, PDGF-BB). Of note, there was a remarkable
number of molecules involved in chemotaxis (ENA-78, GRO, IL-8, IP-10, MCP-1, MCP-
3, MIP-1, PARC, RANTES, SDF-1). All these factors might play a major role in the
enhanced recruitment of immune cells into adipose tissue in obesity.
Many of the adipokines detected in the arrays have recently been described to be re-
leased from adipocytes or whole adipose tissue. These include MIF [455], osteoprotegerin
[456], PAI-1 [457], PARC [458], PDGF-BB [458], RANTES [459], SAA [460], and TIMP1
& TIMP2 [440, 461]. Klimcakova et al. [461] have shown that angiogenin, whose secre-
tion was slightly suppressed by poly(I:C), is expressed by both adipocytes and the SVF in
subcutaneous adipose. Angiopoietin-2, whose secretion level remained unaffected in the
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cytokine array, has been shown in one study to be upregulated in adipose of obese sub-
jects compared to lean [440]. Fas, a factor also detected in the supernatant of adipocytes,
is reportedly upregulated in adipocytes of common genetic and diet-induced mouse mod-
els of obesity and insulin resistance, as well as in adipose of obese and type 2 diabetic
patients [462]. Furthermore, Fas activation in 3T3-L1 adipocytes has been shown to de-
crease insulin-stimulated glucose uptake [463]. However, its expression was not markedly
affected by stimulation with poly(I:C) and LPS in this model system, therefore excluding
this molecule as a candidate. GRO and MIP-1α/β, whose expression was found to be
upregulated by LPS in the cytokine array, have recently been shown to be secreted by hu-
man visceral differentiated adipocytes [464]. MIF, which was detected in both arrays, has
already been shown to be spontaneously released by human preadipocytes and adipocytes
[455]. In contrast to a former study, which observed increased expression of leptin mRNA
in subcutaneous adipose tissue of LPS-treated hamsters [465], leptin levels remained rel-
atively unchanged following administration of LPS (Figure 5.4, 5.7). This once more
highlights important differences between human and rodent. Paradoxically, leptin pro-
duction was decreased following poly(I:C) stimulation. This finding may deserve further
investigation in the future.
The cytokine array led to detection of two potentially novel adipokines which have
previously not been brought into association with obesity or adipocytes. The first protein
is GITR (also known as TNFRSF18) which was originally identified in T cells [466]. As
shown in Figure 5.10, LPS stimulation of adipocytes resulted in a 7.7-fold upregulation
of GITR secretion. The other prospective new adipokine emerging from that array is
IL-5, which was secreted de novo in response to LPS by a factor of 13.2. IL-5, typically
produced by TH2 cells, has long been associated with the cause of several allergic diseases
such as asthma [467]. To my knowledge, I am here the first to demonstrate that it may
also be released by human adipocytes and although it has not (yet) been implicated in
obesity, it might play a potential role behind the link of obesity and asthma [35, 468].
There are some notable parallels between my results of the protein arrays and a pre-
vious study, that has measured cytokine levels in lysates of whole subcutaneous adipose
tissue in lean versus obese subjects [440]. Of the 120 different cytokines tested in that
study, 28 were found to be significantly upregulated in obesity. 17 of these were also se-
creted by adipocytes in my culture system and with the exception of TIMP1 and TIMP2,
the expression of all mutual cytokines was affected by stimulation with poly(I:C) or LPS.
When combining my results with that study, some cytokines appear to be particularly
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induced by obesity and poly(I:C)/LPS-stimulation. These are: ENA-78, MIP-1α/β, Os-
teoprotegerin, RANTES and IL-1 (although the latter was not detected in the first donor).
All these factors appear to promote inflammation in obesity, with the exception of osteo-
protegrin, which is thought to serve a protective function in adipose against inflammation
[456].
At the time of conducting the cytokine profiling, a study emerged that described the
secretion profile of in vitro differentiated adipocytes isolated from visceral human adipose
tissue [464]. Despite some known depot-specific differences in gene expression between
visceral and subcutaneous adipose [469], it is still not clear to what extent the expression of
adipokines is influenced by adipose tissue localisation. It was therefore highly interesting
to compare my results from subcutaneous adipocytes to the cytokine profile of visceral
adipocytes. As Bassols et al. [464] also stimulated the cells with LPS, using the same
concentration (10 ng/ml) as I did, it allowed for a direct comparison between the two
systems. When comparing my results with that study, it became apparent that in terms
of adipokines, the differences between adipocytes from visceral and subcutaneous depots
may be smaller than expected. LPS stimulation led to a notable upregulation of IL-6, IL-
8, GRO, MCP-1 and MIP-1α/β secretion in both visceral and subcutaneous adipocytes.
Similar to my system, the secretion level of the insulin-sensitising hormone adiponectin
remained unaffected by LPS stimulation. Similarly, TNFα and IP-10 was not released by
either unstimulated or LPS-stimulated visceral adipocytes (which is in agreement with
my cytokine array). The visceral adipocytes of the described study seem to differ only
in two factors from their subcutaneous counterparts: Whilst LPS stimulation did not
have an effect on the production of MIF or leptin in subcutaneous adipocytes, Bassols et
al. [464] showed a moderate increase in MIF release in visceral adipocytes and the same
time a decrease in leptin levels following stimulation with LPS. This comparison suggests
that in terms of cytokines, adipocytes from subcutaneous depots may secrete a similar
range to visceral adipocytes. However, as the antibody arrays only allowed for relative
quantification, this comparison provides no information as to what degree the individual
tissue depots contribute to the pro-inflammatory milieu in obesity.
Stimulation with poly(I:C) unexpectedly led to a detection of insulin (Figure 5.7).
Since it is not likely that adipocytes are producing insulin, the array has possibly picked
up a protein similar to insulin. The antibody pair on this array detect both the pro-
and mature form of insulin and there is a considerable amount of homology among pro-
insulin, IGF-I and IGF-II. As there was no signal for IGF-I on the array, it is possible
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that the array picked up IGF-II or maybe even a similar protein not yet characterised.
An alternative explanation could be that the insulin might have derived from FCS in the
cell culture medium, which is known to contain insulin, however this was not investigated
further.
The neutrophil activating chemokine ENA-78 was found to be strongly induced follow-
ing poly(I:C) and LPS stimulation in both arrays. Although this chemokine has previously
been shown to be secreted by whole human adipose tissue [440], its production has been
attributed to the macrophage fraction within the adipose tissue [346, 441]. To my knowl-
edge, I am here the first to demonstrate that adipocytes can release a large amount of this
protein in response to poly(I:C) or LPS (Figure 5.12). Considering that this factor has
recently been linked to insulin resistance in mice [441] and its gene polymorphism appears
to be associated with diabetes in an Iranian population [470], I decided to examine the
potential function of ENA-78 on glucose uptake in human adipocytes. Although the secre-
tion of ENA-78 following TLR ligand stimulation could be re-confirmed by ELISA, I found
no regulatory effect of recombinant ENA-78 on glucose handling in human adipocytes. As
suggested by Chavey et al [441], this could indicate that adipose-tissue-derived ENA-78
mediates its negative function on insulin signalling in distant muscle cells, where insulin-
stimulated glucose uptake was significantly decreased following administration of recom-
binant ENA-78. Alternatively, the recombinant form of ENA-78 used in my experiments
may not have been bioactive and this requires further investigation.
Although the data of the cytokine and adipokine array indicated only slight attenu-
ation of adiponectin secretion following poly(I:C) and LPS treatment (Figures 5.10 and
5.11), the effect of adiponectin on glucose uptake was studied further due to the impor-
tance of adiponectin as an insulin-sensitising hormone. A time-course for poly(I:C) and
LPS showed that adiponectin mRNA levels were only moderately modified. Similarly,
administration of recombinant adiponectin to LPS-stimulated cells led to a small but
potentially real effect. However, further repeats would be needed to definitely to rule
adiponectin out as a candidate for changes in glucose uptake following administration of
poly(I:C) and LPS. These data, in conjunction with the study of Bassols et al. [464],
indicate that inflammatory signalling in adipocytes does not affect expression or secretion
of adiponectin by adipocytes.
There is currently a growing body of literature that T2DM has an inflammatory
dimension which is mediated via IL-1β. Elevated circulating IL-1β has been described as
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a risk factor for T2DM in humans [309] and adipose of obese, insulin-resistant individuals
expresses higher levels of IL-1β than adipose of obese, metabolically healthy individuals
[310]. Importantly, a clinical trial by Larsen et al. [337] has shown that blocking IL-1β
signalling by IL-1Ra improves fasting plasma glucose levels and β cell secretory funtion
in obese patients with T2DM. This concept has also been validated in the mouse: IL-
1Ra prevented diabetes in mice fed a HFD by improving β-cell survival and function
[338]. Hence, there is a large interest for identifying the major players responsible for
IL-1β production in obesity, both cells and cell components. A minor breakthrough
has been published this year in Nature Medicine where the authors provide evidence for
the involvement of the NLRP3 inflammasome in insulin resistance and T2DM of obese
individuals [326].
In the context of diabetes, IL-1 has so far mainly been studied for its effect on pan-
creatic β cells. However, only a small number of studies have investigated its effect on
adipocytes. He et al. [471] have shown that IL-1α inhibits insulin signalling in 3T3-L1 by
IRS-1 phosphorylation on Ser307, Ser612, and Ser636. The same time, IL-1β was shown
to inhibit insulin-induced phosphorylation of the insulin receptor β subunit, IRS-1, and
Akt and the extracellular regulated kinase 1 and 2 in murine and human adipocytes [472].
Moreover, IRS-1 expression seems to be downregulated by IL-1β in adipocytes [473]. Of
note, a recent study has shown that differentiation of human adipocytes induces expres-
sion of caspase-1, which processes IL-1β from an inactive precursor into the active form
[318].
Given the potential importance of IL-1 in T2DM, it was therefore exciting to find
that poly(I:C) and LPS stimulation caused an upregulation in IL-1 production, especially
of the IL-1β subtype (Figure 5.11). The fact that IL-1 was not detected in one out of
two investigated donors suggests that IL-1 may be induced in extremely low quantities
and therefore may be hard to detect. In another model of in vitro differentiated human
adipocytes, IL-1β also was detected in cell lysates after stimulating the cells for 24 h with
1 µg/ml LPS and 25 µg/ml poly(I:C) [389]. However, the concentration of IL-1β was only
between 10 - 20 pg/ml for both ligands. This range is below the detection limit of our
ELISA.
The discovery of potential IL-1 release by adipocytes motivated me to investigate
its effect on glucose uptake. My findings on IL-1, as shown in Figure 5.15, add to the
growing evidence of IL-1-mediated metabolic dysfunction. Furthermore, these data also
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add to the previous chapter, where I have discussed the tight link between immunity and
metabolism. Metabolic effects of IL-1 have in fact been known for a long time [474]. Whilst
low levels of IL-1β appear to have a positive physiological effect in healthy individuals
by stimulating pancreatic β cell proliferation and secretion of insulin, high concentrations
of IL-1β negatively affect β cell function and mediate glucotoxicity [164]. My data here
demonstrate that concentrations of 0.1 or 10 ng/ml of IL-1 dysregulate glucose uptake
in adipocytes and also the glucose transporter system. IL-1 upregulates GLUT1 mRNA
and protein, whereas GLUT4 mRNA is suppressed following IL-1 administration. The
latter finding is in contrast to a study by Lagathu et al. [472], where GLUT4 mRNA
was only slightly affected by IL-1 treatment. However, the experiment in that study was
performed with differentiating 3T3-F442A and differentiated 3T3-L1 murine adipocytes
and not with primary human adipocytes.
The effect of anakinra on poly(I:C)-induced inflammation and -dysregulated glucose
uptake seems promising and deserves further investigation. Whilst administration of
anakinra has led to a moderate but clear improvement in insulin-stimulated glucose up-
take, its inhibition of poly(I:C)-induced cytokines was striking (Figure 5.17). Based on
these results, I decided to enhance the number of donors for poly(I:C) and also investi-
gate the effect of anakinra on LPS-induced changes in glucose uptake. Another batch of
anakinra was obtained, which inexplicably did not lead to the same results. This batch
will soon be tested by other members of our laboratory in different cell culture systems.
As yet, however, I cannot draw an ultimate conclusion as to whether anakinra really
reverses potential IL-1-mediated effects on glucose uptake.
So is IL-1 the ultimate candidate I was looking for? Considering my results, IL-1 has
certainly a great potential to regulate glucose uptake in adipocytes. However, the relative
success of anakinra treatment and the detection of IL-1α and β in the cytokine array do
not allow for the ultimate conclusion that IL-1 is the central mediator I was after. To fur-
ther support my hypothesis that poly(I:C)- and LPS-induced changes in glucose uptake
may be mediated via IL-1, it would be worthwhile to continue these experiments with
adipocytes derived from IL-1-deficient mice. In addition, future studies will have to fur-
ther dissect the poly(I:C)- and LPS-induced signalling pathways in adipocytes, especially
with regard to potential inflammasome activation. Although human adipocytes report-
edly express caspase-1 [318] the precise mechanisms leading to its activation in human
adipocyes have not been investigated. Also, I have not succeeded in detecting mature
IL-1β in lysate or supernatant of human adipocytes by western blotting. This problem
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might eventually be overcome by trying a different technique. A recent study for instance
has demonstrated caspase-1 activity in lysates of primary human adipocytes by using a
caspase-1 fluorometric kit (Biovision) [327]. However, that study does not provide any
evidence that mature IL-1β can effectively be secreted by human adipocytes and therefore
this will still need to be verified.
It may be noteworthy to mention that IL-1β is differently regulated between var-
ious myeloid cell populations [475]. Whilst human monocytes release active IL-1β in
response to TLR stimulation alone [444], stimulation of TLR2 or TLR4 has no effect on
IL-1β release in THP-1 cells [476] or primary human macrophages [444] in the absence
of ATP. Nevertheless, despite the relatively ineffective activation of caspase-1 by LPS in
macrophages, western blots of cell lysates revealed the intracellular presence of mature
form of IL-1β, suggesting that the release of mature IL-1β is due to a defect in its secretion
[444]. Whilst I could confirm this finding for human macrophages (Figure 5.13), I did not
detect mature IL-1β in lysates of adipocytes at the time-points investigated.
Altogether, my findings in this chapter suggest that subcutaneous adipocytes con-
tribute to the pro-inflammatory milieu associated with obesity and dysregulated glucose
handling, as they continuously release a wide range of cytokines and have the ability to
upregulate even more factors in response to poly(I:C) & LPS. This accords with other
studies that demonstrate the release of pro-inflammatory cytokines by adipocytes that
predict T2DM [54]. Further studies are now needed to define the role of each adipokine in
the pathogenesis of insulin resistance. Furthermore, the role of IL-1 in adipocytes deserves
further attention.
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Concluding Discussion
As outlined at the beginning of this thesis (section 1.1.5 and 1.5), many factors and
cell types are believed to contribute to insulin resistance and T2DM in obesity. Certainly,
T2DM does not occur as long as pancreatic β cells are still able to cope with the increased
demand for insulin during the initial period of insulin resistance. Furthermore, it is now
well acknowledged that macrophages infiltrate adipose tissue in the obese state [8, 9] and
the potential contribution of T cells to peripheral insulin resistance is gaining increasing
attention [10, 11, 303]. Nonetheless, the process described above would not occur without
dramatic morphological changes in adipose tissue characterised by adipocyte hypertrophy
and hyperplasia [55]. Thus, adipocytes are at the centre of obesity-induced pathologies
and their ability to produce several pro-inflammatory cytokines and adipokines suggests
that these cells may significantly contribute to inflammation and dysfunction of other
tissues, including the liver and skeletal muscle [477] as well as the pancreas [46, 478].
This thesis has therefore been entirely devoted to the investigation of the inflammatory
potential of adipocytes, with the aim to add another piece to the complex puzzle of the
multifaceted disorder T2DM.
Several questions described in section 1.6 have shaped this thesis. As stated at the
beginning, the major goal was to investigate TLR expression in adipocytes as a potential
link between immunity and metabolism. The discovery that FFAs [12] (in particular SFAs
[196]) can provoke inflammation via TLR4 has shown that endogenous metabolites po-
tentially communicate with the immune system via TLRs. Moreover, endogenous ligands
released from necrotic cells such as mRNA [188] and dsRNA [479] have been proposed
as ligands for TLR3 and RIG-I or MDA5, respectively. Given the association between
TLRs and insulin resistance [12], it should be mentioned that TLRs have already been
implicated in several inflammatory/autoimmune disorders including T1DM [480, 481],
atherosclerosis [482], RA [483], systemic lupus erythematosis [484] and Crohn’s disease
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[485]. However, although the potential involvement of TLRs in human disease is becoming
more established, the current understanding is still based on research using TLR knockout
mice and immortalised cell lines. As important as these studies are for our basic under-
standing on TLR function, it is evident that the insights arising from these studies may
not be directly applied to human physiology. Hence, the first objective of this study was
to evaluate the response of human adipocytes to TLR ligands, as only murine adipocytes
were known to express functional TLRs at the time I started my PhD investigation [178].
In chapter 3, I show that adipocytes significantly respond to the TLR ligands poly(I:C)
and LPS and also show a distinctive, although not statistically significant, response to
the TLR2 ligands Pam3CSK4 and MALP-2 (Figure 3.7, page 125). Having identified the
response to TLR ligands in human adipocytes, I went on to examine TLR adapter usage
in adipocytes and to my knowledge, this is the first report on TLR adapter utilisation in
adipocytes (described in section 3.4).
My data in the third chapter, combined with the observation that TLR4-deficient
mice are protected from obesity-induced insulin resistance [12], directed me to the hy-
pothesis that inflammatory signalling in adipocytes may contribute to the development of
insulin resistance in obesity. This was investigated in chapter 4, where my main finding
demonstrates that insulin-dependent and -independent glucose uptake is changed follow-
ing stimulation with the ligands poly(I:C) and LPS but not with Pam3CSK4 (Figure
4.1A/B/C, page 160 - 162). As the changes in glucose uptake increased with time, I
hypothesised that this effect might be mediated via an intermediate molecule such as a
cytokine, that accumulates in the medium and changes adipocyte function through an au-
tocrine or paracrine feedback mechanism. Potential candidates were therefore identified
by performing a cytokine and adipokine array as described in chapter 5. Although there is
no firm evidence yet for the ”ultimate” candidate leading to poly(I:C)- and LPS-induced
insulin resistance, the data in chapter 5 demonstrate that the cytokine IL-1, whose mes-
sage and protein levels are induced following stimulation with both ligands (Figures 5.11
and 5.13), has the ability to induce remarkable changes in glucose uptake (Figure 5.15,
page 210) and works at extremely low concentrations. These observations strengthen
the concept of IL-1 as a central mediator of insulin resistance in adipose tissue. Indeed,
although it has been shown that IL-1 impairs β cell function [486] and these effects are
reversed by administration of the IL-1R antagonist anakinra in vitro [486] and in vivo
[337, 338, 339], the potential effects of IL-1 on adipocyte dysfunction has not been well
investigated. In a recent study, Koenen et al. [327] have now demonstrated that IL1B
mRNA and pro-IL-1β protein is induced in primary human adipocytes under hypergly-
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caemic conditions (such as those employed in this project). Furthermore, primary human
adipocytes have been shown to express NLRP3 protein [327], and NLRP3 and Casp1
expression in adipose tissue correlates with body weight [318, 326, 327] (see Table 1.10 on
page 64). Hence, it is possible that the elevated levels of IL-1β observed in obesity stem
from activated adipocytes which might therefore impair their own function.
Although my data show that in vitro differentiated adipocytes are highly responsive
to poly(I:C), a major pattern throughout this thesis is that poly(I:C)-induced NF-κB-
dependent cytokines are induced with delayed kinetics compared to LPS-induced NF-κB-
dependent cytokines. Whilst the induction of IL6 and IL1B mRNA peaks between 1 - 4
h following LPS stimulation, the maximal induction following poly(I:C) is observed much
later at 16 h (see Figure 3.5, page 121 and Figure 5.13, page 207). Furthermore, LPS-
dependent IκBα degradation was observed 30 min after stimulation whereas poly(I:C)-
induced IκBα degradation was not observed even after 4 h of stimulation (Figure 3.5, page
121). In contrast, poly(I:C) induces IP10 mRNA much earlier at 2 h post stimulation
(Figure 3.4, page 119). This suggests that poly(I:C) follows biphasic kinetics characterised
by initial activation of the type I IFN pathway (assessed by induction of IP10 mRNA) and
later activation of the NF-κB pathway (assessed by induction of IL6 and IL1B mRNA).
Despite the late induction of IL6 and IL1B mRNA, IL-6, IL-8 and MCP-1 protein se-
cretion was observed at 6 h following poly(I:C) stimulation (Figure 3.3, page 118). This
may indicate that this initial production is regulated through post-transcriptional events
such as alternative splicing, processing or mRNA stability. Indeed, pre-synthesised IL6
and IL1B transcripts were detected in unstimulated cells and as discussed in section 3.6,
adipocytes constitutively release basal levels of IL-6.
Whilst my results in the third chapter support the expected finding that TLR4 is the
main receptor for LPS in human adipocytes, I could not find the same strength of evidence
that poly(I:C) signals via TLR3. This is discussed in detail in section 3.6. Furthermore,
the observation that MyD88 knockdown leads to a significant reduction in IL-6, IL-8 and
MCP-1 in response to poly(I:C) (Table 3.2, page 147) initially seemed difficult to explain.
Nonetheless, my further findings of IL-1 as a strong inducer of IL-6, IL-8 and MCP-1 in
adipocytes (section 5.5) might provide an explanation for that observation. As shown in
Figure 5.14 (page 208), IL-1 induced the secretion of IL-6, IL-8 and MCP-1 (and low levels
of IP-10) even at low concentrations. It is thus plausible that even low level induction of
IL-1 following stimulation with poly(I:C) promotes production of these cytokines, thereby
greatly amplifying the response. This would lead to a vicious cycle of inflammation with
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IL-1 functioning as a master regulator. As described in section 3.4.2, IL-1 signals via
the adapter MyD88 [169] and my data in Figure 3.19 (page 142) demonstrate that IL-1
induced cytokines are significantly reduced following MyD88 knockdown. Hence, if IL-1
is induced following poly(I:C) stimulation, MyD88 knockdown would therefore not only
inhibit LPS-induced cytokines, but also poly(I:C)-induced cytokines via IL-1R signalling,
even if poly(I:C) may initially signal via a TLR-independent pathway.
According the scenario outlined above, one might expect that IL1B mRNA is induced
prior to the induction of other cytokines. However, poly(I:C)-triggered IL1B mRNA was
upregulated around the same time as poly(I:C)-induced upregulation of IL6 mRNA. This
might be explained by induction of IL-1α, which was not investigated in detail in this the-
sis. However it was found to be induced ∼ 30-fold by poly(I:C) in the adipokine array (see
Figure 5.11 on page 202). Since IL-1 release is mainly controlled through processing of
pro-IL-1β by an inflammasome-dependent protease (e.g. caspase-1, Figure 1.5), it might
also be that poly(I:C) signals via cytoplasmic RLRs (e.g. RIG-I, MDA5) to induce type
I IFN/IP-10 and pro-IL-1β processing via caspase-1. Small amounts of IL-1β may then
act back onto the cell to induce the transcription of IL-6, IL-8 and MCP-1 as well as its
own transcription to amplify the signal. Indeed, the ability of IL-1 to induce itself is well
documented in the literature [474] and the idea of a vicious activation cycle is a central
concept of auto-inflammatory diseases [487]. Recent evidence now is overturning old ideas
that ”naked” extracellular dsRNA is not transported across the plasma membrane. Trans-
fection of dsRNA has been shown not to be required to induce a response by cytoplasmic
RLRs [373, 392]. For instance, Gitlin et al. [392] have shown that MDA5, not TLR3,
is the dominant receptor mediating the response to ”naked”, extracellular poly(I:C) in
bone marrow-derived dendritic cells and macrophages. This concept was also demon-
strated in a study by Kanneganti et al. [380], where the stimulation of primary murine
macrophages with ”naked” poly(I:C) induced IL-1β via a NF-κB-independent, NLRP3-
dependent mechanism. Whilst incubation of wild-type macrophages with poly(I:C) in-
duced IL-1β secretion, this response was abolished in NLRP3-deficient cells. In contrast,
NLRP3-deficient macrophages still responded to poly(I:C) by secretion of TNFα and IL-
6, a response which was abrogated in TLR3-deficient macrophages. Notably, Poeck et al.
[488] recently demonstrated that stimulation of mouse bone marrow-derived dendritic cells
with the encephalomyocarditis virus and 5’-triphosphate RNA (which signal via MDA5
and RIG-I, respectively) induces the simultaneous production of type I IFN and IL-1β.
At least in the case of RIG-I, IL-1β production appeared not to be secondary to type I
IFN: bone marrow-derived dendritic cells from Irf3−/−Irf7−/− did not produce type I IFN
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in response to 5’-triphosphate RNA whilst IL-1β secretion was unaffected. As for MDA5,
the dependence of IL-1β on type I IFN secretion was not investigated. Finally, Stienstra
et al. [318] have provided evidence that caspase-1 is induced during differentiation in pri-
mary human adipocytes and hyperglycaemic culturing conditions, such as those employed
in this study, are known to contribute to its activation [327].
So what might be the poly(I:C) equivalent in obesity? As I will discuss below, obesity-
induced adipocyte hypertrophy has been suggested to lead to cell necrosis [489], and
nucleic acids released from necrotic cells have been proposed as potential ligands for
PRRs, including TLR3 and RIG-I/MDA5 [479]. Since poly(I:C), the synthetic analog of
dsRNA, can not only activate TLR3 [187], but also MDA5 [392, 490] and the NLRP3
inflammasome [380, 381], it is plausible that nucleic acids released by necrotic adipocytes
might follow the same route as poly(I:C), leading to the same adverse outcome as observed
in my in vitro experiments. However it has to be added that the stimulation of PRRs by
endogenous nucleic acids released from dying cells is still more speculation than a proven
concept so far.
In 2006, Shi et al. [12] published the ground-breaking discovery that TLR4-deficient
mice are protected from insulin resistance and T2DM when placed on a HFD. This finding
was the first suggestion that TLRs could be one of the links between obesity, inflamma-
tion and T2DM. In this thesis I have therefore explored the question of TLRs as central
coordinators of immunity and metabolism. Although my studies have concentrated on
exploring the function of TLRs in adipocytes, it is important to bear in mind that other
metabolically important cells including pancreatic β cells [479] and hepatocytes [175] also
express TLRs as well as other PRRs. Interestingly, TLR 2, 3, and 4 are strongly expressed
in murine pancreatic islets and this also seems to be the case in human, although TLR3
appears to be stronger expressed than TLR2 or TLR4 in human islets [491]. This further
strengthens the potential of PRRs to act as a fundamental bridge between immunity and
metabolism. Intriguingly, this apparent bridge between the two systems seems to have
been conserved throughout evolution. Whilst mammals require two different cell types
for nutrient metabolism and innate immunity (i.e. adipocytes and cells from the myeloid
lineage), the fat body in Drosophila is responsible for both immune and metabolic func-
tion: It is not only the primary organ for lipid storage, but also central for mediating the
humoral defence by secreting a battery of antimicrobial peptides in response to infections
[177]. Notably, activation of the toll pathway in Drosophila inhibits insulin signalling
activity, resulting in decreased triglyceride storage and larval growth [492]. This finding
227
CHAPTER 6
has led the authors to propose that communication between these two regulatory systems
evolved to divert energy in times of need from systemic growth to the acute requirement
of combating infection.
In section 4.6 I proposed that inflammatory signals may cause profound changes in
glucose handling (see Figure 4.13, page 183). This could ensure that glucose can be pri-
marily consumed by activated (immune) cells that have encountered an antigen. Since
immune cells lack glycogen stores, they are dependent on the rapid supply of extracellular
glucose in order to become activated or maintain their effector status [413]. Again, this
immunometabolic regulation appears to be mediated via PRRs which seem to be crucial
for linking these two seemingly distinct systems. Nonetheless, the beneficial mechanism
of PRR-regulated glucose handling may lead to an ”aberrant” response in obesity where
chronic, local adipose tissue inflammation is observed. Histological analysis of adipose tis-
sue of obese humans and mice has revealed that ATMs are not randomly distributed within
the tissue. Much rather, they seem to be aggregated in so-called crown-like structures
[489], which contain up to 15 ATMs surrounding individual adipocytes. These crown-
like structures are believed to represent sites of adipocyte necrosis as a consequence of
adipocyte hypertrophy [489]. In addition to the already discussed potential ligands for
adipocyte activation via PRRs in obesity (e.g. SFAs, gut-derived LPS; see section 4.6),
another likely scenario might therefore be that DAMPs released from necrotic adipocytes
(e.g. RNA) activate the surrounding adipocytes through PRRs, resulting in cytokine pro-
duction and subsequent recruitment of immune cells. In such a scenario, PRR expression
by adipocytes could be seen as a evolutionary relic from the fly. As obesity is an entirely
new challenge to human evolution, there may not have been any selective pressure against
the expression of PRRs by adipocytes.
In a recent study, Ricardo-Gonzalez et al. [493] have refined the hypothesis of insulin
resistance as an adaptive strategy to reallocate nutrients. As discussed in section 1.5.1,
obesity and insulin resistance is associated with an increased ratio of TH1 : TH2 cells and it
has therefore been proposed that strategies which increase the number of TH2 cells might
be of therapeutic promise in insulin resistance and T2DM [11]. While IFNγ-secreting
TH1 cells are important for combating viral infections, the immune response to parasitic
helminths is directed by anti-inflammatory IL-4-secreting TH2 cells, whose differentiation
is largely dependent on the transcription factor STAT6. As infections with helminths tend
to be chronic, Ricardo-Gonzalez et al. hypothesised that the response to parasites might
be anabolic and asked whether the IL-4/STAT6 immune axis, which controls immunity
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to parasites, may also control nutrient metabolism and insulin sensitivity. Analysis of
STAT6 expression showed that this transcription factor is expressed in the murine liver
and adipose tissue (but not in muscle). Remarkably, Stat6−/− mice are resistant to diet-
induced obesity but develop insulin resistance and glucose intolerance on a HFD despite
being lean. Furthermore, mice on a HFD receiving intraperitoneal injections of IL-4 are
protected from weight gain and display improved glucose homoeostasis [493]. Hence, in
contrast to TLR4 signalling which leads to insulin resistance, activation of IL-4/STAT6
signalling improves insulin sensitivity, therefore indicating that the interaction between
the immune system and metabolism is likely to be even more complex and fine-tuned
than shown in this thesis.
The view of insulin resistance as an evolutionary conserved strategy to reallocate nu-
trients during microbial infection raises several questions. For instance, in chapter 4 of
this thesis it was observed that stimulation of adipocytes with poly(I:C) and LPS leads
not only to a decrease in insulin-dependent glucose uptake but also to a simultaneous
increase in basal/insulin-independent glucose uptake (Figure 4.1A/B/C, page 160 - 162).
Whilst the decrease in insulin-dependent glucose uptake was associated with a reduction
in GLUT4 expression, the increase in insulin-independent glucose uptake was reflected
by simultaneous upregulation of GLUT1. Nonetheless, the increase in basal glucose up-
take and GLUT1 expression was rather unexpected and seems to contradict the idea
of nutrient reallocation during infection. Inflammation-induced upregulation of GLUT1
expression in adipocytes has so far only been reported in 3T3-L1 cells under the influ-
ence of TNFα [416] or during treatment with conditioned medium from LPS-activated
macrophages [494]. As observed by Lumeng et al. [494], exposure of 3T3-L1 adipocytes to
macrophage-conditioned medium resulted in significantly increased basal glucose uptake
and decreased insulin-stimulated glucose uptake. As found in my study, this correlated
with an increase in GLUT1 and a decrease in GLUT4 [494]. Although reports on GLUT1
in obesity have been rare, some studies have observed increased GLUT1 expression and
basal glucose uptake in adipocytes isolated from DIO mice [495] and obese Zucker rats
[496], and this finding was associated with a decrease in insulin responsiveness. This in-
dicates that the observations I made in vitro could be a physiologically ”real” finding and
not an artefact of the in vitro culture system. Furthermore, these observations, together
with my own data, suggest that inflammatory conditions decrease insulin sensitivity of
adipocytes despite an increase in total glucose utilisation. It is questionable, however,
whether insulin insensitivity in vitro (as assessed by downregulation of GLUT4 and a
decreased response to insulin) really contributes to insulin resistance in vivo. As pro-
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posed in section 4.6, it would therefore be interesting to examine glucose consumption by
individual tissues during inflammation in an in vivo model. Interestingly, whilst adipose-
specific depletion or overexpression of GLUT4 has profound effects on insulin resistance
in the mouse [135, 143], GLUT1 (but not GLUT4) polymorphism has been suggested to
contribute to susceptibility to T2DM in some human populations [497]. On the other
hand, downregulation of GLUT4 in human adipose tissue in obesity and T2DM has been
well documented [50], whereas the role of GLUT1 in human obesity remains completely
unexplored.
Remarkably, upregulation of GLUT1 in response to LPS has been observed in other
cell types, in particular immune cells such as murine peritoneal macrophages [402]. Fur-
thermore, various studies have shown that regulation of glucose uptake and expression of
GLUT1 are critical for T cell function [403, 413, 498]. Jacobs et al. [498] for instance
have demonstrated that T cell receptor stimulation leads to upregulation of GLUT1 ex-
pression, and the regulation of T cell glucose uptake via GLUT1 was found to be critical
since low glucose prevented appropriate T cell responses. Moreover, transgenic GLUT1
overexpression augmented T cell activation by increasing T cell size and cytokine produc-
tion, thereby further delineating a vital role for glucose and glucose uptake in immunity
[498]. However, as beneficial as this mechanism may be for mounting an immune response,
there may also be some potential drawbacks: As mentioned in section 4.6, hypoglycaemia
is observed during sepsis [417] and influenza infection [409, 410, 411]. This seems to be
due to increases in whole-body glucose utilisation despite marked peripheral insulin re-
sistance which initially leads to hyperglycaemia (reviewed in [499]). Interestingly, from
the perspective of my findings related to IL-1β, a study by Oguri et al. [500] revealed
an important role for this cytokine in mice in LPS-induced hypoglycaemia. LPS led to
hypoglycaemia in mice deficient in either IL-1α or IL-1β but not in mice deficient in
both cytokines, suggesting mutual compensation. Indeed, when IL-1 was administered
directly to mice, this also induced hypoglycaemia directly and the minimum effective dose
of IL-1α or IL-1β was about 3 orders of magnitudes less than that of TNFα [500]. Hence,
IL-1 appears to be central for regulating glucose handling not only in adipocytes but also
systemically [500]. It would be interesting to investigate whether IL-1α/β-deficient mice
might be protected from hypoglycaemia in influenza and other viral infections. Further-
more, the contribution of GLUT1 to systemic hypoglycaemia during infection remains to
be investigated.
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My findings in chapter 5 highlight the inflammatory potential of subcutaneous adipocytes
and suggest that these cells may contribute to the pro-inflammatory milieu associated with
obesity and dysregulated glucose handling. Notably, the generation of an inducible ”fat-
less” model system, the FAT-ATTAC mouse (fat apoptosis through targeted activation of
caspase 8) by Pajvani et al. [501] has shown that the septic response to LPS is dramat-
ically reduced in the absence of adipocytes, further underlining the detrimental role of
adipocytes in inflammation. Possibly, adipocyte-derived factors may not only feed back
to adipocytes to dysregulate glucose handling but may also act systemically, having pro-
found effects on pancreatic β cells and muscle tissue and therefore influence metabolism
even globally. In fact, the remarkable ability of adipocytes to crosstalk with various tis-
sues such as pancreatic β cells and myocytes via adipokines has been well described and
has led to the terms adipoinsular axis [274] and the adipocyte-myocyte axis [502]. The
adipoinsular axis was originally described by Kieffer and Habener [274] as a hormonal
feedback loop between adipocytes and β cells which can interact with each other via the
two hormones leptin and insulin. In the meantime, it has become evident that addi-
tional adipocyte-derived factors, including IL-6 and SFA, also play an important role in
the pathogenesis of β cell dysfunction (reviewed in Zhao et al. [478]). Moreover, IL-1β
appears to be one of the key culprits in β cell dysfunction in the progression of T2DM
[46, 337]. Since the expression of IL1B mRNA in adipose tissue of morbidly obese patients
correlates with the degree of insulin resistance [310], it is likely that adipose-derived IL-1β
contributes to the β cell secretory dysfunction in the progress of T2DM. As shown by the
adipokine and cytokine arrays performed in this study, the range of factors secreted by
human adipocytes is immense (see section 5.3 on page 192 - 200). Surely, the impact of
many of these adipose-derived adipokines and cytokines on the function of other tissues
is only about to be revealed.
There are several experiments I would conduct if time permitted. First, I would investi-
gate which receptor or signalling pathway could be responsible for mediating the response
to poly(I:C) in adipocytes. As discussed in section 3.6, it is plausible that poly(I:C) may
signal via a receptor other than TLR3. It would thus be worthwhile to investigate a po-
tential involvement of MDA5 or RIG-I in poly(I:C)-mediated signal transduction. It first
has to be examined whether these receptors are expressed in human adipocytes as this
has not yet been investigated, although other cell types including human β cells have been
found to express these receptors under inflammatory conditions [479, 503]. It would then
have to be examined whether extracellular poly(I:C) can activate these cytosolic receptors
or whether this requires transfection of poly(I:C). Finally, the participation of these re-
231
CHAPTER 6
ceptors in poly(I:C)-mediated signal transduction would be assessed by knockdown using
a siRNA delivery method that does not influence poly(I:C)-induced cytokines.
Another question is whether IL-1 can be confirmed as the central mediator linking
poly(I:C)- and LPS-induced inflammatory signalling to changes in glucose handling. It has
recently been shown that differentiation of primary human adipocytes induces expression
of caspase-1 [318]. Furthermore, there seems to be a direct correlation between obesity
and the expression of NLRP3 and IL-1β in both humans and mice [326]. However, the
potential ability of adipocytes to secrete IL-1α or IL-1β still needs to be evaluated. As
yet, I have not succeed in detecting mature IL-1β in lysate or supernatant by western.
However, the activity of caspase-1 could be measured by a caspase-1 activity assay as
described in Koenen et al. [327] and Stienstra et al. [318] or by western blotting for
activated caspase-1 (p20) as described in Vandanmagsar et al. [326]. As discussed in
section 5.7, the effect of anakinra on poly(I:C)-induced inflammation and -dysregulated
glucose handling deserves further investigation. Furthermore, it has to be tested whether
anakinra might have a similar effect on LPS-induced changes in glucose handling. Since
LPS leads to immediate induction of the NF-κB pathway, I would expect that LPS-
induced IL-6, IL-8 and MCP-1 production is not affected by administration of anakinra,
whereas LPS-induced dysregulation of glucose uptake might still be reversed. Finally, the
potential role of IL-1 in glucose handling should be further investigated by performing
the glucose uptake with adipocytes derived from IL-1α/β-deficient mice. I speculate that
incubation of adipocytes derived from these mice do not alter their glucose uptake in
response to poly(I:C) and LPS.
Finally, I would investigate whether the changes in glucose handling are solely due
to upregulation of GLUT1 and suppression of GLUT4. Since the data in chapter 4 sug-
gest that poly(I:C) and LPS lead to an increase in insulin-independent glucose uptake in
adipocytes via upregulation of GLUT1 (Figure 4.7, page 171) and a decrease in insulin-
sensitive glucose uptake via suppression of GLUT4 (Figure 4.9, page 174) I would try to
confirm this idea by performing GLUT4 knockdown and simultaneous overexpression of
GLUT1. GLUT4 knockdown could be performed using siRNA oligos targeting GLUT4,
whereas GLUT1 overexpression could be achieved by adenoviral overexpression. Prelim-
inary experiments during my first year of the PhD have shown that adipocytes can be
infected with the adenovirus.
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The studies presented in this thesis lead me to conclude that human adipocytes
have the ability to strongly respond to poly(I:C) and LPS by production of several pro-
inflammatory cytokines, therefore demonstrating that adipocytes may be an important
source of obesity-induced inflammation. Moreover, chronic exposure to these two lig-
ands leads to profound alterations in glucose handling, characterised by a decrease in
insulin-stimulated glucose uptake and an increase in basal or insulin-independent glucose
uptake. These changes can at least partly be attributed to alterations in the glucose trans-
porter system, i.e. enhanced expression of GLUT1 combined with decreased expression of
GLUT4. Hence, the results presented here provide answers to the first two questions that
were initially raised (see section 1.6, page 74), which were aimed to identify the range of
TLRs expressed by human adipocytes and addressed the role of these receptors in glucose
handling.
Although the candidate mechanisms responsible for immune-regulated glucose han-
dling have not been completely revealed, my data provide evidence that IL-1 stimulation
has similar effects on glucose handling and the glucose transporter system as poly(I:C) and
LPS. Thus, IL-1, which was found to be induced by poly(I:C) and LPS, could be a central
contributor to these changes. Lastly, we should not forget that the effects outlined above
were also induced by TNFα, which was used as a positive control for insulin resistance
throughout this thesis. Although TNFα itself is not secreted by human adipocytes, the
potential role of ATM-derived TNFα on glucose handling should not be underestimated.
Altogether, my data add to the growing understanding of how the immune system
and metabolism are linked to each other by providing a role for PRRs as fundamental
coordinators of glucose handling and insulin sensitivity. In contrast to other reports based
on mouse models or the murine 3T3-L1 adipocyte cell line, I performed all experiments
with in vitro differentiated human adipocytes, therefore providing completely new insights
into human adipocyte physiology.
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Appendix 1: Additional reagents
Reagent Manufacturer
Western blotting reagents
Full range Rainbow molecular Amersham Biosciences, Little Chalfront, UK
weight marker RPN800
PVDF transfer membrane Perkin Elmer, Boston, MA, USA
ECLTM detection reagent Amersham Biosciences, Little Chalfront, UK
Re-Blot Recycling kit Chemicon International, CA, USA
Molecular biology reagents
QIAamp RNA Blood Mini Kit Qiagen, Hilden, GER
RNeasy Lipid Tissue Mini Kit Qiagen, Maryland, USA
Turbo DNase Ambion, Austin, TX
Reverse Transcriptase Promega, Madison, USA
Taq DNA Polymerase Invitrogen, Paisley, UK
SYBR Green II Molecular probes, Oregon, USA
One step qRT-PCR MasterMix Eurogentec, San Diego, USA
DNA Hyperladders Bioline, London, UK
Ethidium bromide Sigma, Dorset, UK
[3H]-2-deoxy-D-glucose uptake
Bovine Serum Albumin Sigma, Poole, UK
(fatty acid free)
Sodium Pyruvate Sigma, Poole, UK
2-deoxy-D-glucose Sigma, Poole, UK
3H 2-deoxy-D-glucose (1 mCi/ml) Perkin Elmer, Boston, USA
Human recombinant insulin Sigma, Poole, UK
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Appendix 2: Alphabetical List of
Abbreviations
Abbreviation Denotation
2DOG 2-deoxy-D-glucose
Ang-2 Angiogenin-2
AP-1 activator protein 1
APS ammonium persulfate
ARP acidic ribosomal protein
ASC apoptosis-associated speck-like protein containing a CARD
ATM adipose-tissue-resident macrophages
ATP adenosine-5’-triphosphate
◦C degree celsius
BAT brown adipose tissue
BMI body mass index
BSA bovine serum albumin
CAP Cbl associated protein
CARD caspase recruitment domain
Cbl Casitas b-lineage lymphoma
C/EBP CCAAT enhancer binding protein
CRP C-reactive ptrotein
DAMPs danger-associated molecular patterns
DIO diet-induced obese
DMEM Dulbecco’s modified eagle medium
EDTA ethylenediaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
ENA-78 epithelial neutrophil-activating protein-78
ER endoplasmic reticulum
ERK extracellular signalregulated kinase
FABP4 fatty acid binding protein 4
FACS fluorescence-activated cell sorting
FCS foetal calf serum
FFAs free fatty acids
FITC fluorescent isothiocyanate
237
APPENDIX 2: ALPHABETICAL LIST OF ABBREVIATIONS
FTO fat mass and obesity-associated gene
g gram or gravity
GAPDH glyceraldehyde-3P-dehydrogenase
GCP-2 granulocyte chemotactic peptide-2
GDM gestational diabetes mellitus
GFP green fluorescent protein
GITR glucocorticoid induced tumor necrosis factor receptor fam-
ily related gene
GLUT glucose transporter
GRO growth regulated oncogene
h hours
H+ proton
HA hemagglutinin
HBSS hanks balanced salt solution
HFD high fat diet
HMW high molecular weight
HRP horse radish peroxidase
HUGO human genome organization
IDF international diabetes federation
IFN interferon
IGF insulin-like growth factor
IκB nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor
IKK IκB kinase
IL interleukin
IL-1Ra interleukin 1 receptor antagonist
IP-10 interferon inducible protein
IR insulin receptor
IRAK IL-1R-associated kinase
IRF interferon regulatory factor
IRS insulin receptor substrate
JNK c-Jun N-terminal kinase
K+ potassium
KIR Kennedy Institute of Rheumatology
KRH Krebs-Ringer-HEPES
L liter
LAL limulus amebocyte lysate
LAP latency-associated peptide
LBP LPS-binding protein
LPG2 laboratory of genetics and physiology-2
LPS lipopolysaccharide
LRRs leucine-rich repeats
M mol/liter
µg microgram
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µl microliter
µM micromolar
mg milligram
min minutes
ml milliliter
Mal MyD88 adapter like
MALP-2 Macrophage-activating lipopeptide-2
MAMPs microbe associated molecular patterns
MAPK mitogen activated protein kinase
MCP-1 monocyte chemoattractant protein 1
MC4R melanocortin-4 receptor
M-CSF macrophage colony stimulating factor
MD-2 myeloid differentiation factor 2
MDA5 melanoma differentiation-associated gene 5
MIP-1 macrophage inflammatory protein-1
mTOR mammalian target of rapamycin
MyD88 myeloid differentiation primary response gene 88
Na+ sodium
NACHT domain present in neuronal apoptosis inhibitory protein
(NAIP), CIITA, HET-E and TP1
NALP3 NACHT, LRR and PYD domains-containing protein 3
(now called NLRP3)
NBD nucleotide-binding domain
NCEP-ATPIII national cholesterol education program - adult treatment
panel III
NCI normalised cytokine induciton
N.D. not defined
NEMO NF-κB essential modulator
NF-κB nuclear factor kappa-light-chain-enhancer of activated B
cells
NLR nucleotide-binding domain, leucine-rich repeatcontaining
NLRP3 NLR family, pyrin domain containing 3 (formerly known
as NALP3)
nm nanometer
n.s. not significant
nt nucleotide
OD optical density
OPG osteoprotegerin
Ost. osteoprotegerin
Pam3CSK4 Pam3CysSerLys4
PAGE polyacrylamide gel electrophoresis
PAMP pathogen associated molecular patterns
PARC pulmonary activation regulated chemokine
PBS phosphate-buffered saline
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PCR polymerase chain reaction
PDGF-BB platelet-derived growth factor-BB
PDK1 phosphoinositide-dependent protein kinase 1
PH pleckstrin-homology
PI3K phosphoinositide 3-kinase
PIP2 phosphatidylinositol (4,5)-bisphosphate
PIP3 phosphatidylinositol (3,4,5)-triphosphate
PKB protein kinase B
PKC protein kinase C
poly(I:C) polyinosinic-polycytidylic acid
PPAR peroxisome proliferator-activated receptor
PRR pattern recognition receptor
PSA penicillin, streptomycin and amphotericin
PTB phosphotyrosine-binding
PVDF polyvinylidene fluoride
PYD pyrin domain
qRT-PCR quantitative reverse transcriptase polymerase chain reac-
tion
RA rheumatoid arthritis
RANTES regulated upon activation normal T-cell expressed, and
presumably secreted
RBP4 retinol-binding protein-4
RIG-I retinoic-acid-inducible protein I
RISC RNA-induced silencing complex
RLR RIG-I-like receptor
RNAi RNA interference
ROS reactive oxygen species
RPLP0 large ribosomal protein P0
RT room temperature
RT-PCR reverse transcriptase polymerase chain reaction
S serine
SAA serum amyloid A
SARM sterile α and HEAT-armadillo motifs
SC subcutaneous
Scr scrambled
SD standard deviation
SDF-1 stromal cell-derived factor 1
SDS sodium dodecyl sulfate
SEM standard error of mean
Ser serine
SFAs saturated fatty acids
SGLT Sodium-dependent glucose co-transporter
siRNA small interfering RNA
SLC2A gene symbol for facilitative GLUT transporter
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STAT signal transducer and activator of transcription
sTNFR soluble tumour necrosis factor receptor
SV stromal vascular
SVF stromal vascular fraction
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
TAK1 transforming growth factor-β-activated protein kinase 1
TBK1 TANK-binding kinase-1
TBS tris buffered saline
TEMED tetramethylethylenediamine
TH T helper cell
Thr threonine
TICAM TIR-containing adapter molecule
TIMP tissue inhibitor of metalloproteinase
TIR toll/IL-1R domain
TIRAP TIR-domain containing adapter protein
TLR toll-like receptor
TMB tetramethylbenzidine
TNF tumour necrosis factor
TRAF tumour-necrosis factor-receptor-associated factor
TRAM TRIF-related adapter molecule
TREG regulatory T cell
TRIF TIR domain-containing adapter inducing interferon β
TXNIP thioredoxin-interacting protein
TZD thiazolidinedione
Tyr tyrosine
UCP-1 uncoupling protein 1
V volt
WAT white adipose tissue
WHO world health organisation
WT wild-type
Y tyrosine
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